

DOCUMENT MADE AVAILABLE UNDER THE PATENT COOPERATION TREATY (PCT)

International application number:	PCT/EP2016/082662
International filing date:	23 December 2016 (23.12.2016)
Document type:	Certified copy of priority document
Document details:	Country/Office: EP
	Number: 16176025.1
	Filing date: 23 June 2016 (23.06.2016)
Date of receipt at the International Bureau:	31 January 2017 (31.01.2017)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)

Bescheinigung

Die angehefteten Unterlagen stimmen mit der als ursprünglich eingereicht geltenden Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

Certificate

The attached documents are exact copies of the text in which the European patent application described on the following page is deemed to have been filed.

Attestation

Les documents joints à la présente attestation sont conformes au texte, considéré comme initialement déposé, de la demande de brevet européen qui est spécifiée à la page suivante.

Patentanmeldung Nr.

Patent application No.

Demande de brevet n°

16176025.1 / EP16176025

The organization code and number of your priority application, to be used for filing abroad under the Paris Convention, is EP16176025.

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.



V. Joseph

Anmeldung Nr:
Application no.: 16176025.1
Demande no :

Anmeldetag:
Date of filing: 23.06.16
Date de dépôt :

Anmelder / Applicant(s) / Demandeur(s):

Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 Boulevard Marius Vivier Merle
69003 Lyon/FR

Bezeichnung der Erfindung / Title of the invention / Titre de l'invention:

(Falls die Bezeichnung der Erfindung nicht angegeben ist, oder falls die Anmeldung in einer Nicht-Amtssprache des EPA eingereicht wurde, siehe Beschreibung bezüglich ursprünglicher Bezeichnung.

If no title is shown, or if the application has been filed in a non-EPO language, please refer to the description for the original title.

Si aucun titre n'est indiqué, ou si la demande a été déposée dans une langue autre qu'une langue officielle de l'OEB, se référer à la description pour le titre original.)

VIRUS PURIFICATION

In Anspruch genommene Priorität(en) / Priority(Priorities) claimed / Priorité(s) revendiquée(s)

Staat/Tag/Aktenzeichen / State/Date/File no. / Pays/Date/Numéro de dépôt:

Am Anmeldetag benannte Vertragsstaaten / Contracting States designated at date of filing / Etats contractants désignées lors du dépôt:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO RS SE SI SK SM TR

VIRUS PURIFICATION

FIELD OF INVENTION

The disclosure relates to methods for the purification of viruses for use in vaccines
5 and in particular relates to an improved sucrose gradient process step allowing the separation of impurities such as protamine sulphate.

The disclosure also relates to Zika virus vaccines and compositions and methods for producing said vaccines and administering the vaccines to subjects for the generation of an anti-Zika virus immune response.

BACKGROUND OF THE INVENTION

Adverse responses to protamine sulfate have been known for many years. Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug.

15 Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may experience life-threatening reactions and fatal anaphylaxis upon receiving large doses of protamine intravenously. Severe reactions to intravenous protamine can occur in the absence of local or systemic allergic reactions to subcutaneous injection of protamine-containing insulin. Although there is no clear evidence for hypersensitivity
20 reactions of protamine sulphate linked to vaccination, vaccines containing protamine impurities have a precaution and contraindication warning in their labels stating that a serious allergic reaction after a previous dose of such a protamine containing vaccine (e.g. IXIARO®, see CDC site <http://www.cdc.gov/japaneseencephalitis/vaccine/>) is a contraindication to further doses. Thus elimination of said impurity is a medical request for
25 an improved safety profile. On the other hand protamine sulphate is an excellent tool (and often better than other tools such as benzonase) to purify crude harvests of viruses grown on cell substrates.

In 2007, Zika virus was detected for the first time outside of the endemic regions of Asia and Africa since its discovery in a Rhesus monkey in Uganda in 1947. Since then, the
30 virus has caused a large epidemic in French Polynesia, spreading through islands in the Pacific and into South and Central America by 2015 (WHO “Zika Situation Report” February 5, 2016). Evidence suggests that in addition to being transmitted by *Aedes* species

mosquitos, other vectors may exist, and the virus may be transmitted by blood transfusion, transplacentally, and through sexual transmission (WHO Zika Virus Fact Sheet, Feb. 2016). Though the symptoms of Zika virus infection include mild fever, rash, and conjunctivitis, there is a likely correlation between infection and neurological disorders, including Guillain-
5 Barré syndrome and microcephaly in fetuses/neonates subsequent to infection during pregnancy. There is currently no specific treatment or vaccine for Zika virus and the only preventative measurements involve control of the mosquito vector. Zika virus presents a substantial public health threat due to the wide circulation of the *Aedes* mosquito, multiple routes of transmission, and potentially severe neurological effects of infection.

10

SUMMARY OF THE INVENTION

During the course of virus purification, it was observed that addition of protamine sulfate to a virus harvest produced on a cell substrate removed not only contaminating DNA
15 derived from host cells, as expected, but surprisingly also virtually eliminated immature and otherwise non-infectious virus particles from the preparation. This finding provided a streamlined, gentle, reproducible and broadly-applicable process for obtaining highly-purified infectious virus particles for applications such as vaccine preparation. In addition, it was surprisingly found that said protamine sulfate can very efficiently be separated from the virus
20 fraction allowing for a safer vaccine produced at high yields.

Disclosed herein are virus vaccines and compositions comprising an inactivated virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said virus vaccines for the prevention of virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of
25 being exposed to virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated virus particle, wherein the virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide
30 pure compositions largely void of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided for Zika virus and Chikungunya virus.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are not intended to be drawn to scale. The figures are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing, alignments were performed with the multi alignment package Jalview (Waterhouse et al., 2009, Bioinformatics 25 (9) 1189-1191). In the drawings:

Figure 1: Average distance tree (by % identity, nt), complete genomes.

Figure 2: Neighbor joining tree (by % identity, nt), complete genomes.

Figure 3: Pairwise alignment-Jalview (% identity, nt), complete genomes.

Figure 4: Average distance tree (by % identity, aa), E-protein.

Figure 5: Neighbor joining tree (by % identity, aa), E-protein.

Figure 6: Pairwise alignment-Jalview (% identity, aa), E-protein.

Figure 7: Alignment (blue shading: % identity, aa), E-protein.

Figure 8a: Overview of an efficient Zika virus purification process.

Figure 8b: Overview of an efficient inactivation step.

Figure 9: SEC-HPLC of individual 30x concentrated Zika harvest prior PS treatment

Figure 10: SEC-HPLC of individual 30x concentrated Zika harvest post PS treatment

Figure 11: Preparation of the sucrose gradient.

Figure 12: Representative SDS-PAGE from the sucrose gradient harvest of a Zika purification is shown.

Figure 13: Schematic separation of Virus (ChikV as an example) and PS/HPC using the optimized 3-layer sucrose gradient centrifugation process.

Figure 14: Correlation between JEV Antigen content in NIV analysed by ELISA and SEC-HPLC (Dionex Ultimate 3000, Superose 6 column).

Figure 15: A silver-stained SDS-PAGE gel showing the protein content of the virus preparation following different steps of the process of the invention (defined in the table next to the figure). The SGC purified pool consisting of SGC fractions F7-F11 is shown in lane 12.

Figure 16: The SEC area (mAU*min; right axis) and TCID₅₀ results (log TCID₅₀/mL; left axis) of ChikV production harvests before and after PS treatment is shown. The grey portions of the bars indicate large losses in SEC area following PS treatment, but no corresponding change in the total number of infectious particles (indicated by black portions of the bars) (A); SEC profile of virus preparation before and after PS addition, showing a complete removal of large size virus aggregates by PS treatment as well as a reduction in host cell proteins (HCP) and LMW impurities (B).

Figure 17: Relative amounts of ChikV particles and other components by SEC-HPLC analysis at the different steps of the process of the invention including, from top to bottom: crude harvest (a) are shown; 10X concentrated harvest; diafiltrated harvest; PS treated material; CC700-treated material and SGC purified pool.

Figure 18: Comparison of different sucrose gradients (a: gradient 1: 50%, 10% sucrose, b gradient 2: 50%, 35%, 10% sucrose, c: gradient 3: 50%, 25%, 10% sucrose, d: gradient 4: 50%, 35%, 15%, 10% sucrose) with ChikV particles.

Figure 19: Comparison of two different ZikaV harvest schedules.

Figure 20: SEC-HPLC elution profile of ZikaV NIV. Data were processed on Dionex Ultimate 3000 / Superose 6 Increase column.

Figure 21: SEC-MALLS analysis of inactivated ZikaV.

Figure 22: Cumulative particle size distribution of Zika NIV.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are virus vaccines and compositions comprising an inactivated virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said virus vaccines for the prevention of virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of

being exposed to virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated virus particle, wherein the virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide pure compositions largely void of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided for Zika virus and Chikungunya virus.

Disclosed herein are downstream processes for purifying virus particles from a crude preparation. The downstream process can be applied to either a virus which has not adapted for propagation on a particular cell substrate or for a partial / fully cell substrate adapted virus particle.

Aspects of the invention provide processes for the purification of infectious virus particles comprising the steps of (a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate; (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising a protamine salt, preferably a protamine sulphate, to obtain a virus preparation (b); and further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation to obtain a virus preparation (c) comprising the infectious virus particles.

In some embodiments, the concentration of protamine sulphate in step (b) is about 1 to 10 mg/ml, more preferably about 1 to 5 mg/ml, more preferably about 1 to 2 mg/ml. In one embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/mL. In one embodiment, the concentration of protamine sulphate is 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml. In a preferred embodiment, the concentration of protamine sulphate in step (b) is about 1.6 mg/ml (for e.g. Chikungunya) or about 2 mg/ml (for e.g. Zika).

In some embodiments, the residual host cell DNA of the virus preparation (c) is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL. In a preferred embodiment, the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL. In some embodiments, the residual host cell protein of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual

host cell protein of the virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual non-infectious virus particles of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual non-infectious virus particles of the virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual protamine is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL, more preferably is below the detection limit in particular below the detection limit in the final drug substance.

In some embodiments, the crude harvest (a) comprising the virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b). In some embodiments, the one or more pre-purification step(s) comprises digesting host cell genomic DNA in the crude harvest (a) comprising the virus particles and impurities by enzymatic treatment. In some embodiments, the one or more pre-purification step(s) comprises filtration, ultrafiltration, concentration, buffer exchange and/or diafiltration. In some embodiments, the one or more pre-purification steps is filtration using a filter having a pore size equal to or less than 1 µm. In some embodiments, the filter has a pore size equal to or less than 0.2 µm. In a preferred embodiment, the filter has a pore size of 0.2 µm. In some embodiments, the concentration and/or ultra/diafiltration and/or buffer exchange is performed by tangential flow filtration (TFF). In some embodiments, ultra/diafiltration of the crude harvest (a) comprising the virus particles and impurities is performed using a hollow fiber membrane having a cut-off of equal to or less than 300 kDa. In a preferred embodiment, the hollow fiber membrane has a cut-off of 100 kDa.

In some embodiments, the virus particle is a live virus, a chimeric virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In a further step, the virus particles of the invention may be optionally inactivated. In some embodiments, the virus particle is an attenuated form of the virus particle. For example, the virus may have reduced infectivity, virulence, and/or replication in a host, as compared to a wild-type virus. In some embodiments, the virus is a mutated or modified virus, for example the nucleic acid of the virus may contain at least one mutation relative to the wild-type virus. In some embodiments, the virus is a recombinant live virus, meaning a virus that is generated recombinantly and may contain nucleic acid from different sources.

In some embodiments, the virus particle is a live virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In some embodiments, the virus belongs to a virus family selected from the group consisting of Paramyxoviridae, Orthomyxoviridae, Flaviviridae, Filoviridae, Arenaviridae, Rhabdoviridae, and Coronaviridae. In some
 5 embodiments, the virus belongs to a virus family selected from the group consisting of
 Togaviridae (being live or inactivated), such as alphaviruses, or Flaviviridae (being live or
 inactivated). In some embodiments, the virus is a virus of the family Flaviviridae, i.e. a
 flavivirus. In other embodiments, the virus is a Zika virus or Yellow Fever virus. In
 preferred embodiments, the virus is a Zika virus. In a most preferred embodiment, the Zika
 10 virus is a Zika virus from the Asian lineage.

In some embodiments, the relative reduction of impurity of the final virus preparation relative to the liquid medium (a) comprising the virus particles and impurities is in a range from 60 to 95%. In some embodiments, the residual impurity of the final virus preparation is less than 1%.

15 In some embodiments, the filtration of step in (b)(ii) of claim 1 is performed using a filter having a pore size equal to or greater than 1 μm . In some embodiments, the filter has a pore size equal to or greater than 0.2 μm . In a preferred embodiment, the filter has a pore size of 0.2 μm .

In some embodiments, the virus is propagated in a cell line selected from the group
 20 consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a
 HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6
 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a
 diploid avian cell line. In some embodiments, said cell line is a duck cell line. In some
 embodiments, said cell line is a diploid avian cell line. In some embodiments, said cell line is
 25 EB66 cell line. In a preferred embodiment, said cell line is a Vero cell line.

Aspects of the invention provide a use of any of the processes described herein for manufacturing a composition for immunization against a viral infection. In a preferred embodiment, the composition is a vaccine. In one embodiment, the composition or vaccine is directed against Chikungunya virus. In one embodiment, the composition or vaccine is
 30 directed against a flavivirus. In one embodiment, the composition or vaccine is directed
 against Yellow Fever virus. In one embodiment, the composition or vaccine is directed
 against Zika virus such as e.g. a Zika virus of the Asian lineage.

Other aspects provide compositions comprising the virus particles obtainable by any of the processes described herein for treating and/or preventing a viral infection. In one embodiment, the viral infection is caused by Chikungunya virus. In one embodiment, the viral infection is caused by a flavivirus. In one embodiment, the viral infection is caused by Yellow Fever virus. In one embodiment, the viral infection is caused by Zika virus such as e.g. a Zika virus of the Asian lineage.

Furthermore, disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering the Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus.

Zika virus is a flavivirus closely related to Dengue virus and is similarly transmitted by the *Aedes* species mosquito, although other arthropod vectors for Zika virus are possible. Since it was first isolated from a Rhesus monkey in the Zika forest of Uganda in 1947, there were very few reported incidents of human infection, especially outside of the endemic regions of Africa and Asia until a large outbreak in French Polynesia in 2007 (Haddow *et al. PLoS Neglected Tropical Diseases* (2012) 6(2), Malone *et al. PLoS Neglected Tropical Diseases* (2016) 10(3),). The virus has since spread through islands of the Pacific, including Oceania, and into South and Central America (WHO “Zika Situation Report” February 5, 2016).

In addition to being spread by the bite of an infected mosquito, evidence also suggests transmission may occur between individuals, such as from the blood of an infected individual, *in utero*/transplacental transmission from an infected mother to the fetus, sexual transmission between sexual partners, and possibly by other local transmission routes. There is a possible association between Zika virus infection during pregnancy and microcephaly in the fetus/neonate. Microcephaly is a rare condition in which a baby’s head circumference is significantly less than expected based on the average for their age, sex, and ethnicity. This is a result of the brain failing to undergo proper embryonic development, and in 90% of cases is associated with mental retardation (Rocha *et al. (2016) Bull World Health Organ* 8 Feb. 2016).

There is a probable association between individuals having had a prior Zika virus infection and the incidence of Guillain-Barré syndrome, a neurological disorder in which the

individual's immune system destroys the myelin sheath surrounding axons of the peripheral nervous system (WHO "Zika Situation Report" February 5, 2016).

No specific treatments or vaccines for Zika virus currently exist, and the only measures at this time to prevent infection are through vector control and avoiding travel to regions experiencing outbreaks.

Described herein are Zika virus vaccines and compositions comprising inactivated Zika virus that provide a safe method for generating an immune response to Zika virus, including virus-neutralizing antibodies, that may help prevent against Zika virus infection.

Any strain of Zika virus may be used in the methods and compositions described herein. In some embodiments, the Zika virus is an isolate from an infected subject during a Zika virus outbreak. In some embodiments, the Zika virus is a strain isolated from Africa or from the African virus lineage. In some embodiments, the Zika virus is a strain isolated from Asia or from the Asian lineage (includes also strains from French Polynesia). In some embodiments, the Zika virus is a strain isolated from the Americas (South America, Central America, or North America), such as a Suriname Zika virus strain. In some embodiments, the Zika virus has a RNA genome corresponding (but not limited) to the DNA sequence provided by GenBank Accession No. AY632535.2, KU321639.1, KU497555.1, KU501215.1, KU509998.1, KU527068.1, KU681081.3, KU681082.3, KU707826.1, KU744693.1, or LC002520.1 or RNA genome disclosed partially or fully herein (SEQ ID NO: 2 to 69).

In some embodiments, the attenuated form of ChikV is derived from the LR2006-OPY1 ChikV infectious clone (La Reunion isolate). In some embodiments, the attenuated form of ChikV is the $\Delta 5nsP3$ mutant as described by Hallengård et al. (Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 mice (2014) Journal of Virology 88(5):2858–2866) or an immunogenic variant thereof. The immunogenic variant of the $\Delta 5nsP3$ ChikV mutant is herein defined as having at least 80% sequence identity to the nucleotide sequence of the $\Delta 5nsP3$ mutant sequence, especially at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% sequence identity.

In some embodiments, the process of the invention results in an enrichment of infectious virus particles from the crude harvest comprising infectious virus particles and non-infectious virus particles and other virus products such that the enrichment of the

infectious virus particles is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, preferably at least 80%, especially 85% relative to the total virus particle content of the crude harvest (a) comprising the virus particles and impurities.

In some embodiments, the residual impurity of the final virus preparation with respect to all impurities in the crude harvest is less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, preferably less than 5% as determined by SEC-HPLC (Size Exclusion Chromatography – HPLC).

Another aspect of this invention is the realization that by using an approach of a type of vaccine (i.e. the Japanese Encephalitis Vaccine (JEV) with tradename IXIARO®, see Srivastava A.K. et al., 2001, Vaccine 19, 4557-4565, WO99/11762) which the regulatory agencies have seen and licensed before, it may be possible to very quickly develop a Zika or Chikungunya vaccine and provide it to the subjects in need as soon as possible. The industrial process as disclosed for IXIARO®, providing a very effective vaccine against JEV, had to be complemented by further inventions disclosed herein in order to provide a more efficient (higher yield) and safer (less or no protamine sulphate with its allergic potential) Zika vaccine compared to the available JEV vaccine. A particular innovation of the herein disclosed vaccines are their avoidance of any protamine salt (SEQ ID NO: 1) in the final drug substance by introducing an improved sucrose gradient. Said sucrose gradient not only allowed the separation of protamine sulphate but also allowed for a very effective inactivation by formaldehyde and resulted in the case of Zika with over 90% yield with the improved process disclosed herein vs about 35% yield with the published JEV process, see experimental part for comparison).

Aspects of the disclosure relate to methods of producing a virus in Vero tissue culture cells. Vero cells are a commonly used tissue culture cell line derived from the kidney of an African green monkey. The Vero cells used in the methods described herein are the VERO (WHO) cell line, obtained from the Health Protection Agency general cell collection under catalogue number 88020401.

Vero cells can be grown to confluent monolayers, for example in tissue culture flasks; in suspension (on microcarriers), for example in roller bottles; or in any other cell culture system for viral production. In some embodiments, the Vero cells are grown in a bioreactor for viral production. For plaque assays or plaque reduction neutralization test (PRNT), Vero cells are grown in monolayers in tissue culture flasks, dishes, or wells of a plate. To infect

the Vero cells with the virus, the culture medium is inoculated with virus and the cells are incubated with the virus for a period of time. The cells may be washed after inoculation to remove any virus that did not adsorb to the cells in a given amount of time.

The methods provided herein involve passaging the virus in Vero cells. As used herein, the terms “passage” or “passaging” refer to infecting a population of Vero cells with virus and subsequently inoculating a second population of Vero cells with virus produced by infection of the first Vero cell population. In some embodiments, a portion of the culture medium from the infected Vero cells (containing virus that was released from the infected cells) is used to inoculate a second population of Vero cells. This is referred to as one passage or one round of passaging. The passaging may be performed serially, for example, a portion of the culture medium from the infected second population of Vero cells is used to inoculate a third population of Vero cells, and so on. In some embodiments, virus obtained from a single plaque is used to inoculate another population of cells.

In some embodiments, the virus is passaged in Vero cells several times, such as at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 times. In some embodiments, the virus is passaged in Vero cells at least 4 times or 5 times. In some embodiments, the virus is passaged in Vero cells at least 30 times. It is important that the virus population, i.e. the virus sequences, stays as much as possible constant over said passaging. If adaption of the virus occurs (i.e. appearance of mutated viruses in the original virus population), it is preferred that said passages are not used in the context of manufacturing of said virus, e.g. for Zika it was found that up to passage 3 and culturing to day 7 can be used without major shifts in virus population, i.e. introduction of virus population with mutations. However this observation need to be done for each virus strain and may be different.

In some embodiments, the Vero cells are incubated for at least 2 days after inoculation with the virus at e.g. a typical 0,01 MOI (multiplicity of infection), to allow for viral production, prior to passaging. In some embodiments, the Vero cells are incubated for at least 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 days e.g. at least 7 days after inoculation with the virus prior to passaging. The number of days the Vero cells are incubated after viral inoculation may depend on factors such as the multiplicity of infection used to inoculate the cells and the viral titer desired in the culture medium. Serial passaging of the virus in Vero cells may result in generation of a Vero cell adapted virus strain.

The culture medium from the infected Vero cells may be harvested (collected) to obtain the virus. In some embodiments, the culture medium is harvested from infected Vero cells and is replaced with fresh culture medium, which is then harvested after another period of time. In some embodiments, the culture medium harvested from infected Vero cells is pooled from independent Vero cell cultures and/or from independent days. Harvesting can be repeated up to 4 times by 7 or 9 days post infection, for example, and result in a high yield of virus per unit cell culture. In order to minimize the adoption of Zika virus strain to Vero cells, it was found that Vero cell could be incubated for at least 7 days, more preferably 5 days, prior to passaging and subsequently supernatants could be harvested at days 2, 3, 5 and 7 or 2, 3, and 5 (see also experimental part). The harvested culture medium can be stored at +4°C prior to purification of the virus from the culture medium up to 2 weeks.

In some embodiments, debris from infected and lysed Vero cells may be removed from the harvested culture medium, referred to as a “clarification” of the culture medium. The harvested culture medium may be clarified by common methods known in the art, such as low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45 µm. The harvested culture medium can be stored at +4°C prior to concentration.

To concentrate the titer of the virus in the harvested culture medium, it may be subjected to concentration by any method known in the art. For example, the harvested culture medium may be concentrated by methods including, without limitation, ultrafiltration, ultracentrifugation, centrifugal concentrator, vacuum centrifugation, and lyophilization. In some embodiments, the harvested culture medium is concentrated by ultrafiltration and the retentate containing the Zika virus is collected. In some embodiments, the harvested culture medium is concentrated by precipitation in which polyethylene glycol (PEG) 8000 is dissolved in the culture medium (up to 10%) and the precipitate is dissolved in a buffer, for example phosphate-buffered saline (PBS, pH 7.0).

The harvested culture medium may be precipitated to produce a virus supernatant. In some embodiments, the harvested culture medium is precipitated to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. In some embodiments, the harvested culture medium is concentrated prior to precipitation. In some embodiments, the harvested culture medium is precipitated by adding protamine sulfate (e.g. SEQ ID NO: 1) to the harvested culture medium and incubating the mixture, for

example at +4°C or on ice. In some embodiments, the harvested culture medium is treated with benzonase to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. However, it was found that the treatment with protamine sulfate is preferred (see experimental part). In some embodiments, the precipitated culture medium is centrifuged to collect precipitated material and the supernatant containing the virus, referred to as a “virus supernatant,” is collected.

The virus supernatant may be further purified after precipitation, for example density gradient ultracentrifugation. In some embodiments, the virus supernatant is further purified by sucrose gradient. Fractions may be collected from the sucrose gradients and assayed for presence of the virus. Methods for assaying for virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as Western blotting and ELISA's. The fractions containing virus may be pooled based on titer of the virus and level of other impurities. The level or amount of impurities present in the virus supernatant can be estimated by testing for Vero cell DNA, virus aggregates and/or Vero cell protein (see experimental part). A particular embodiment of the invention is the improved sucrose gradient that allows for an efficient protamine separation as shown in experimental part. It was surprisingly found that addition of a 10% sucrose virus containing fraction to a simple three layer sucrose density gradient (e.g. a gradient comprising a 15% (w/w) sucrose solution, a 35% (w/w) sucrose solution, and a 50% (w/w) sucrose solution) was able to efficiently separate protamine sulphate without much loss of virus. Thus a particularly preferred embodiment of the invention is the use of a sucrose density gradient that is able to efficiently separate protamine sulphate, wherein said sucrose density gradient is used in the purification of virus such as the viruses described herein, e.g. a Zika virus, Yellow Fever virus or Chikungunya virus.

To achieve a safe vaccine or composition for the administration to subjects, the virus supernatant may be inactivated (see experimental part for Zika virus). As used herein, the terms “inactivated” and “optimally inactivated” may be used interchangeably and refer to a process (or its result) by which the virus is rendered unable to infect a host cell (non-infectious), but that does not affect or substantially affect the antigenicity of the virus, for example, the immunogenic antigens exposed on the surface of the virus are able to stimulate an immune response in a subject (*e.g.*, antigen-specific antibodies). By “does not affect or substantially affect the antigenicity of the virus” is meant that the inactivated virus retains at

least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even essentially 100% of the antigenicity of a virus that is not subjected to inactivation.

A variety of methods are known in the art for inactivating viruses. In some
5 embodiments, the virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

In some embodiments, the inactivating is by chemical inactivation and involves contacting the virus with one or more chemical inactivation agent for a period of time under conditions such that the virus is inactivated but the antigenic epitopes are substantially intact.
10 In some embodiments, the virus is inactivated for a period of time that is longer than is required to completely inactivate the virus. In some embodiments, the virus supernatant is inactivated for the number of days required to inactivate the virus plus at least one additional day. Samples of the virus supernatant may be taken at one or more times throughout the inactivation process and assessed for viral viability (infectivity) by any method known in the
15 art, such as by infecting a monolayer of host cells (*i.e.*, plaque assay). Using such a procedure, the period of time that is required to completely inactivate the virus can be determined, and a longer period of time is selected to ensure complete inactivation.

In some embodiments, the virus is contacted with a chemical inactivation agent for between 1 day and 50 days, between 2 days and 40 days, between 2 days and 30 days,
20 between 2 days and 20 days, between 2 days and 10 days, between 3 days and 9 days, between 4 days and 8 days, between 5 days and 7 days, between 2 days and 5 days, or between 5 and 10 days. In some embodiments, the virus is contacted with one or more chemical inactivation agents for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days,
25 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, or at least 50 days.

In some embodiments, the chemical inactivation is performed at about +5°C, +10°C,
30 +15°C, +20°C, +25°C, +30°C, +35°C, +40°C, or about +45°C. In some embodiments, the chemical inactivation is performed at about +4°C. In some embodiments, the chemical inactivation is performed at about +22°C.

Any chemical inactivation agent known in the art may be suitable for inactivating the virus in the methods described herein. It will be appreciated by one of skill in the art that factors such as the chemical inactivation agent and the temperature at which inactivation is performed may affect the length of time (number of days) required to completely inactivate the virus. Examples of chemical inactivation agents include, without limitation, formaldehyde, enzymes, β -propiolactone, ethanol, trifluoroacetic acid, acetonitrile, bleach, urea, guanidine hydrochloride, tri-n-butyl phosphate, ethylene-imine or a derivatives thereof, and organic solvents such as Tween, Triton, sodium deoxycholate, and sulphohetain. A preferred inactivation is the inactivation with formaldehyde at 22°C +/-2°C for about 10 days.

In some embodiments, the inactivating agent is neutralized after chemical inactivation of the virus. In some embodiments, the inactivating agent is formaldehyde and is neutralized after chemical inactivation using sodium thiosulphate or sodium metabisulfite.

In some embodiments, the virus is inactivated by thermal inactivation. In some embodiments, the thermal inactivation involves exposing the virus to heat, such as dry heat or vapor heat, for a period of time. In some embodiments, the thermal inactivation involves exposing the virus to temperatures of about +40°C, +45°C, +50°C, +55°C, +60°C, +65°C, +70°C, +75°C, +80°C, +85°C, +90°C, +95°C, or about +100°C. In some embodiments, the virus is exposed to heat for at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, about 96 hours, or longer. A preferred thermal inactivation involves exposing the virus to temperatures of about +56°C for 60 minutes.

In some embodiments, the virus is inactivated by exposing the virus to acidic or alkaline conditions for a period of time such that the virus is completely inactivated. The pH of a virus preparation may be adjusted to a desired pH, for example by the addition of an acid, a base, or a buffer with a particular pH to the virus preparation. In some embodiments, the virus is inactivated at an acidic pH of about 2, 2.5, 3, 3.5, 4, 4.5, 5 or about 5.5. In other embodiments, the virus is inactivated at an alkaline pH of about 8, 8.5, 9, 9.5, 10, or about 10.5.

In some embodiments, the virus is inactivated using UV inactivation. UV inactivation involves exposing the virus to energy-rich radiation, such as UV-A, UV-B, or UV-C light for a period of time.

It will be appreciated that any two or more methods of inactivation may be combined and performed concurrently or serially.

The inactivated virus may be subsequently dialyzed to remove any undesired material, including the inactivating agent and any neutralizing agent, and/or to replace the buffer with a buffer that is pharmaceutically acceptable for administration to subjects. In some embodiments, the inactivated virus is dialyzed with PBS. In addition or alternatively, the inactivated virus may be filtered, such as sterile filtered, through a 0.22 μm filter.

It is believed that the herein described improved process (comprising the PS treatment in combination with the optimized sucrose gradient) is applicable and efficient to any virus purification and in particular efficient for any RNA type virus (such as the herein described Zika and Chikungunya and yellow fever viruses) of similar size (i.e. about 50 to 100 nm). Furthermore, it is believed that the combination of the PS treatment with the optimized sucrose gradient (allowing for a complete (or almost complete) separation of PS provides a very efficient virus purification in the very high range, e.g. above 70%, more preferably 75%, 80% or 90%, even more preferably 95%. It is believed that the complete reduction of PS in the virus fraction through the process of the invention allows a very efficient inactivation with almost no or very low viral loss e.g. below 30%, more preferably less than 25%, 20% or 10% loss, even more preferably less than 15% loss.

Any of the methods or uses described herein may be for the prevention of a virus infection in a subject. As used herein, the terms “prevent,” and “preventing,” include the administration of a virus vaccine or composition to a subject to reduce, or delay the onset of the manifestation of clinical or subclinical symptoms, complications, pathologies or biochemical indicia of a disease or infection, or to reduce or inhibit the spread/transmission of the virus. As used herein, antigen(s), such as an inactivated virus, that is administered to a subject prophylactically (e.g., prior to infection) may be referred to as a vaccine.

Zika Vaccine

As described herein Zika virus may cause any of a variety of symptoms upon infection of a subject, and is generally characterized by mild fever; rash (exanthema) on face, neck trunk, upper arms; headache; sensitivity to light; non-inflammatory joint pain; conjunctivitis; lack of appetite; diarrhea; abdominal pain; and/or dizziness. Zika virus infection during pregnancy is likely associated with microcephaly in the fetus/neonate. There

is also a probable association between the onset of Guillain-Barré syndrome or symptoms thereof. Diagnosis of Zika virus infection in subjects exposed to Zika virus or suspected of being exposed to Zika virus involves detecting the presence of virus-specific antibodies and/or molecular testing, such as PCR or real-time PCR detection of Zika virus.

5 Provided herein are methods for administering a dose of a therapeutically effective amount of a Zika virus vaccine to a subject in need thereof. In some embodiments, the subject is a mammalian subject, such as a human, non-human primate, rodent, rabbit, sheep, dog, cat, horse, or cow. In some embodiments, the subject is a mouse. In some
10 embodiments, the subject is a human subject, such as a child, an adult, or an elderly adult. In some embodiments, the subject is a female subject. In some embodiments, the subject is pregnant or planning on becoming pregnant. In some embodiments, the subject is at risk of being exposed to Zika virus. In some embodiments, the subject is living in or traveling to an area where Zika virus is present or is thought to be present. In some embodiments, the subject is living in or traveling to an area that is experiencing a Zika virus infection outbreak.
15 In some embodiments, the subject is living in or traveling to an area where an arthropod vector capable of transmitting the Zika virus vector is present or is thought to be present.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject in a therapeutically effective amount or a dose of a therapeutically effective amount. As used herein, a “therapeutically effective amount” of vaccine is any amount that
20 results in a desired response or outcome in a subject, such as those described herein, including but not limited to prevention of infection, an immune response or an enhanced immune response to Zika virus, or prevention or reduction of symptoms associated with Zika disease.

In some embodiments, the therapeutically effective amount of a Zika virus vaccine or
25 composition described herein is an amount sufficient to generate antigen-specific antibodies (*e.g.*, anti-Zika virus antibodies). In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 70% probability. In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 75%, 80%, 85% 90%, 95%, 96%, 97%, 98%, or at least 99% probability. Whether a subject has been
30 seroconverted can be assessed by any method known in the art, such as obtaining a serum sample from the subject and performing an assay to detect anti-Zika virus antibodies. In some embodiments, a subject is seroconverted if a serum sample from the subject contains an

amount of anti-Zika virus antibodies that surpasses a threshold or predetermined baseline. A subject is generally considered seroconverted if there is at least a 4-fold increase in anti-Zika virus antibodies (*i.e.*, anti-Zika E protein IgG antibodies) present in a serum sample from the subject as compared to a serum sample previously taken from the same subject.

5 In some embodiments, seroconversion of a subject is assessed by performing a plaque reduction neutralization test (PRNT). Briefly, PRNT is used to determine the serum titer required to reduce the number of Zika virus plaques by 50% (PRNT50) as compared to a control serum/antibody. The PRNT50 may be carried out using monolayers of Vero cells or any other cell type/line that can be infected with Zika virus. Sera from subjects are diluted
10 and incubated with live, non-inactivated Zika virus. The serum/virus mixture may be applied to the Vero cells and incubated for a period of time. Plaques formed on the Vero cell monolayers are counted and compared to the number of plaques formed by the Zika virus in the absence of serum or a control antibody. A threshold of neutralizing antibodies of 1:10 dilution of serum in a PRNT50 is generally accepted as evidence of protection (Hombach *et al.* Vaccine (2005) 23:5205-5211).
15

In some embodiments, the Zika virus may be formulated for administration in a composition, such as a pharmaceutical composition. The term “pharmaceutical composition” as used herein means a product that results from the mixing or combining of at least one active ingredient, such as an inactivated Zika virus, and one or more inactive ingredients,
20 which may include one or more pharmaceutically acceptable excipient.

Pharmaceutical compositions of the invention, including vaccines, can be prepared in accordance with methods well known and routinely practiced in the art (see *e.g.*, Remington: The Science and Practice of Pharmacy, Mack Publishing Co. 20th ed. 2000; and Ingredients of Vaccines – Fact Sheet from the Centers for Disease Control and Prevention, *e.g.*, adjuvants
25 and enhancers such as alum to help the vaccine improve its work, preservatives and stabilizers to help the vaccine remain unchanged (*e.g.*, albumin, phenols, glycine)). Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically a therapeutically effective dose of the inactivated Zika virus preparation is employed in the pharmaceutical composition of the invention. The inactivated Zika virus is formulated into
30 pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (*e.g.*, the prophylactic response).

Dosages of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired pharmaceutical response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors.

A physician, veterinarian or other trained practitioner, can start doses of the inactivated Zika virus vaccine employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect (*e.g.*, production of anti-Zika virus antibodies) is achieved. In general, effective doses of the compositions of the present invention, for the prophylactic treatment of groups of people as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and the titer of anti-Zika virus antibodies desired. Dosages need to be titrated to optimize safety and efficacy. In some embodiments, the dosing regimen entails subcutaneous or intramuscular administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 7. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 14. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 28. In some embodiments, the inactivated Zika virus is administered to the subject once.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject with, prior to, or after administration of one or more adjuvants. An adjuvant is a molecule that enhances a response in a subject, such as an immune response, to an antigen or other molecule. In some embodiments, an adjuvant may stabilize an antigen or other molecule. Determining whether a Zika virus vaccine or compositions thereof are administered with an adjuvant depends on various factors (*e.g.*, type and extent of response

desired) and will be evident to one of skill in the art. In some embodiments, administering any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may enhance the production of virus neutralizing (anti-Zika virus) antibodies. In some embodiments, a subject that is administered any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may only require a single administration of the Zika virus vaccine or composition to be seroconverted (produce a level of anti-Zika virus antibodies). Examples of adjuvants may include, without limitation, aluminium salt (aluminium hydroxide or aluminium phosphate), calcium phosphate hydroxide, paraffin oil, killed bacteria, bacterial toxins, toxoids, subunits of bacteria, squalene, thimerosal, detergents, IL-1, IL-2, IL-12, 2-component adjuvants, such as 2-component adjuvants containing an antibacterial peptide and a TLR9 agonist (*e.g.*, IC31®), and combinations such as Freund's complete adjuvant and Freund's incomplete adjuvant. In some embodiments, the Zika virus vaccines or compositions is administered with aluminium hydroxide. In some embodiments, the inactivated Zika virus vaccine or composition is administered with aluminium phosphate salt. A preferred aluminium salt is the aluminium hydroxide with reduced Cu content, *e.g.* lower than 1,25ppb based on the weight of the Zika composition, an adjuvant described in detail in WO 2013/083726 or Schlegl et al., Vaccine 33 (2015) 5989-5996.

In some embodiments, the adjuvant is comprised of two components. In some embodiments, the 2-component adjuvant comprises an antibacterial peptide and a TLR9 agonist. In some embodiments, the antibacterial peptide is provided by the amino acid sequence KLKL₅KLK (SEQ ID NO: 70). In some embodiments, the TLR9 agonist is a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN). In some embodiments, the I-ODN comprises the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 69). In some embodiments, the adjuvant is IC31®. In some embodiments, the adjuvant is in nanoparticle form (See, *e.g.*, US Patent No. 8,765,148 B2, incorporated by reference in its entirety). In some embodiments, the adjuvant is IC31®, *i.e.* KLKL₅KLK (SEQ ID NO: 71) and the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 72), in combination with an aluminium salt such as aluminium hydroxide.

The Zika virus vaccines or compositions described herein may be administered to a subject concomitantly with one or more vaccine to another infectious agent, such as another infectious agent is that present or thought to be present in the same geographic area as Zika

virus. In some embodiments, the other infectious agent is one that the subject is also at risk of being in contact with. In some embodiments, the other infectious agent is transmitted by the same arthropod vector as Zika virus. In some embodiments, the other infectious agent is Japanese Encephalitis virus, Yellow Fever virus, Dengue virus and/or Chikungunya virus.

5 Also within the scope of the present disclosure are kits for use in prophylactically administering to a subject, for example to prevent or reduce the severity of Zika virus infection. Such kits can include one or more containers comprising a composition containing inactivated Zika virus, such as an inactivated Zika virus vaccine. In some embodiments, the kit may further include one or more additional containing comprising a second composition,
10 such as a second vaccine. In some embodiments, the second vaccine is a vaccine for another arbovirus. In some embodiments, the second vaccine is a Dengue virus vaccine and/or a Chikungunya virus vaccine.

In some embodiments, the kit can comprise instructions for use in accordance with any of the methods described herein. The included instructions can comprise a description of
15 administration of the composition containing inactivated Zika virus to prevent, delay the onset, or reduce the severity of Zika virus infection. The kit may further comprise a description of selecting a subject suitable for administration based on identifying whether that subject is at risk for exposure to Zika virus or contracting a Zika virus infection. In still other embodiments, the instructions comprise a description of administering a composition
20 containing inactivated Zika virus to a subject at risk of exposure to Zika virus or contracting Zika virus infection.

The instructions relating to the use of the composition containing inactivated Zika virus generally include information as to the dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages
25 (*e.g.*, multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (*e.g.*, a paper sheet included in the kit), but machine readable instructions are also acceptable.

The kits of the present disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, and the like. Also
30 contemplated are packages for use in combination with a specific device, such as a syringe or an infusion device. The container may have a sterile access port, for example the container

may be a vial having a stopper pierceable by a hypodermic injection needle. At least one active agent in the composition is an inactivated Zika virus, as described herein.

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, virology, cell or tissue culture, genetics and protein and nucleic chemistry described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.

The present invention is further illustrated by the following examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference, in particular for the teaching that is referenced hereinabove. However, the citation of any reference is not intended to be an admission that the reference is prior art.

SEQUENCES

The amino acid sequence of a typical form of protamine is provided by SEQ ID NO: 1: PRRRRSSSRP VRRRRRPRVS RRRRRRGGRR RR.

Provided below are examples of nucleic acid sequences of the genomes of Zika viruses that may be used in the methods, compositions, and/or vaccines described herein.

5 KU321639.1 Zika virus strain ZikaSPH2015, Brazil, complete genome (SEQ ID NO: 2)

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
 ACAGGTTTTATTTGGATTGTGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGG
 AGGATTCCGGATTGTCAATATGCTAAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGAA
 GAGGCTGCCAGCCGGAATTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCCTT
 10 TTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAGTGGGGAAAA
 AAGAGGCTATGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
 GCTAGGAAGGAGAAGAAGAGACGGGGCGCAGATACTAGTGTCGGAATTGTTGGCCTCCTGCTGAC
 CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
 ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
 15 ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
 CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
 AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCCATTCCACTAGGAAGCT
 GCAAACGCGGTCGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
 ATTGGATATTCAGGAACCCCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
 20 CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGT
 GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATATTGTCT
 TGGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
 ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
 GGCTTCGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
 25 ATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
 AGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
 GAATCTGGAGTACCGGATAATGCTGTCAAGTTTATGGCTCCCAGCACAGTGGGATGATCGTTAATGA
 CACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
 GAAGCCACCCTGGGGGGTTTGGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
 30 TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGAC
 ATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAACCTCCACACTGGAACAACAAGAAGCACT
 GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCTGTTCTTAGGGAGTCAAGAAGGAG
 CAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
 TCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCCTTG
 35 TGTACCGCAGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGGA
 GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAA
 CTCTGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
 AGATGATGCTGGAACCTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGTAAGCCACTGTGAG
 40 AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTGGATCAGTTGGAGGCGCTC
 TCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAA
 TGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGCTGAAACACAAAAGATG
 GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGCTCTGCT
 TGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
 45 ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAA
 CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
 CGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTCAGAGCAGCAAAAGACAAA
 50 TAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAAGA
 GCTTTCTTGTGGAGGATCATGGGTTCTGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAAG
 ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACA
 GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGGCCATCTG

ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
 GTGATCTGATCATACCCAAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACA
 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGC
 ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 5 CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCACTGTCTGTTCCGGGCTA
 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACAGAAAGCAACTTAGTAAG
 GTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCT
 GCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 10 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGCTTTTTGCAAACTGCGATCTCCGCTTGGAAAGGCGACCTGAT
 GGTCTCATCAATGGTTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCCTGGCCCCGGGGCACACTGCTTGTGGCGTGG
 15 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAAGTTACCATTTGTTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTGCGCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTGCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 20 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCTTTGCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 25 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAGTTCAGGATCTCCAATC
 30 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATCACCAAGGGAGGAGGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAAGTGTCTTAGACTTGATCCTGGAGCTGGGAAAACAGGAGAGTGT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACAGG
 GTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 35 AATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTACAGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGATTATTCTGGAA
 40 AAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCA
 AGAGTGGGACTTTGTCTGTGACAACTGACATTTAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGTCATACTTGATGGCGAGAGAGTCAATTCTGGCTGGAC
 CCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGCGCATAGGCAGGAATCCCAACAAA
 45 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 TGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 TTTGTGGAAGTCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 50 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGG
 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCTTACAAAGCCGCG
 GCGGCCCAATTGCCGAGACCCTAGAGACCATATGCTTTTGGGGTTGCTGGGAAACAGTCTCGCTG
 55 GGAATCTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCTATT
 GTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC

CAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 CTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGCGA
 5 TGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCC
 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGC
 10 CGTCTCCAGCGCCATACTGTTCGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGGCCCTGATCACAG
 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTCTACAGCCACTTCAC
 TGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 15 AGAAGAGGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCAGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAAGTGAAAGG
 ATACACAAAAGGAGGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 20 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCAG
 CACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGA
 25 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAG
 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGGCCCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTCAAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 30 GGGTGCCAGACCCCCAAGAAGGTACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAG
 AGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGC
 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAGAGAGACCCACCTGAGAGGAGAGTGCCA
 GAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGAAAGGCCAAG
 35 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCT
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATACCAACCAA
 ATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGT
 40 AAAGGTCTTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTTCGAGACAAGACCAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGGAGGCTGAGGAAGTCCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGA
 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 45 AGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACTGGGAAGAAGTTCCG
 TTTTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 CACCAAGATGAACTGATTGGCCGGGCCCGCGTCTCTCCAGGGGGCGGGATGGAGCATCCGGGAGAC
 TGCTTGCTAGCAAAATCATATGCGCAAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTG
 50 GTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGT
 GGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTACGAAATGGACAGACATTCCCTAT
 TTGGGAAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGC
 TGAGAACATTAAAAACACAGTCAACATGGTGGCAGGATCATAGGTGATGAAGAAAAAGTACATGG
 ACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTGAAGCAC
 55 CAATCTTAATGTTGTACAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGACGCTGTGACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAAGAAGC
 CATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGCGCAGG

ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGA

KU497555.1 Zika virus isolate Brazil-ZKV2015, Brazil, complete genome (SEQ ID NO: 3)

5 CCAATCTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGG
TTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGAT
TCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGAAGAGG
CTGCCAGCCGGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTTG
10 AGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAAGA
GGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCCA
GGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTCCGAATCGTTGGCCTCCTGCTGACCACA
GCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGC
TGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTTATATACAGATCATGGATCT
15 TGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGAACCAG
ATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCACAAAA
AAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCATTCCACTAGGAAGCTGCAA
ACGCGGTGCGAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTG
GATATTCAAGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAAC
20 GAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGTGCAT
AGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGA
ACATGGGGGTTGTGTCAACGTAATGGCAGAGGACAAACCGACTGTGCGACATAGAGCTGGTTACAA
CAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCT
TCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGT
25 CTGCAAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTTGGCAAAGGGAGCC
TGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCGGGAAGAGCATCCAGCCAGAGAAT
CTGGAGTACCGGATAATGCTGTCAGTTCATGGCTCCAGCACAGTGGGATGATCGTTAATGACACA
GGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAG
CCACCCTGGGGGGTTTTGGAAGCTTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAG
30 ATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGACATTC
CATTACCTTGGCACGCTGGGGCAGACACCGGAACTCCACACTGGAACAACAAAGAAGCACTGGTA
GAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGACTCAAGAAGGAGCAGT
TCACACGGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTG
GCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTA
35 CCGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTA
CAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCT
GACCCCACTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTAAGA
TGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCTATAGGAGTCGGGGAGAAGAAG
ATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGAAAAGCATTTGAAGCCACTGTGAGAGG
40 TGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCA
ACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGT
CCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATGGAT
CTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTCTCTGCTGA
TGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGTGGTACAGGGGTGTTCTGTCTATA
ACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCTCCCCGTAGATTGGCAGCA
45 GCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAACAT
CATGTGGAGATCAGTAGAAGGGGAGCTTAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGG
TCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTGAAC
GAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAAATAA
CAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCT
50 TTCTTGTGGAGGATCATGGGTTCTGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATT
ATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGT
GATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGAT
CGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGT
GATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAG
55 GACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAAGGAATGCCAGGCA

CTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGC
 GGAAGGGTGATCGAGGAATGGTGTGTCAGGGAGTGCACAATGCCCCACTGTCGTTCCGGGCTAA
 AGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACAGAAAGCAACTTAGTAAGG
 TCAATGGTGAAGTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTG
 5 CTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGC
 AGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGAT
 GGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCAT
 TCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCA
 TGCTGCTGGCCTTGGCCTCGTGTTTTTTGCAAACCTGCGATCTCCGCCTTGGAAAGGCGACCTGATGGT
 10 TCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAA
 CATCACCTTGGCAATCCTGGCTGCTCTGACCACTGGCCCGGGGCACACTGCTTGTGGCGTGAG
 AGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAAGGCAGTGTGAAGA
 AGAACTTACCATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTTCGACCCCATCAACGTGG
 TGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCT
 15 GTTGGCCTGATATGCGCATTTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCCAT
 GGCCGCGTCTGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGA
 AAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGAT
 GTGGCGCTAGATGAGAGTGGTGACTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGAT
 CATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCTGG
 20 AGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGTCTATGGGATGTGCCTGCTCCCA
 AGGAAGTAAAAAAGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGG
 TTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAA
 AAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGAT
 CTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCCTGGGACGGGCACAGCGAGGTGCAGCT
 25 CTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGACAA
 AGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATCCTA
 GACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTGATAAAAAATGGGAGTTATGT
 TAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGC
 TGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCTT
 30 CCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTAAGTGTGATCTTAGCTCCAACCAGGGTT
 GTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTCAA
 TGTACCCACTCTGGAACAGAAATCGTCACTTAATGTGCCATGCCACCTTCACTTCAGTCTCAAT
 ACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTC
 AAGCATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCA
 35 TGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCG
 AAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGA AAA
 ACAGTTTGGTTTGTTCAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGG
 AAAACGGGTCTACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAG
 AGTGGGACTTTGTCTGTGACAACTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTCA
 40 TAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCC
 ATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACC
 TGGAGATGAGTACCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTG
 AAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTG
 AGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTT
 45 TGTGGAACATCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAAT
 AACCTACACAGATAGAAGATGGTGTCTTGATGGCACGACCAACAACACCATAATGGAAGACAGTG
 TGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGACGC
 CAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAG
 CGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAA
 50 GCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGC
 GGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGG
 AATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGAAGTCTTGG
 GGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCTATTGT
 TGTGTTCTATTGCTGGTGGTGTGCTACCTGAGCCAGAAAGCAAAGATCTCCCCAGGACAACCA
 55 TATGGCAATCATCATCATGGTAGCAGTAGGTTCTTCTGGGCTTGATTACCGCCAATGAACCTCGGATG
 GTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATA
 GGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACT

TTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGCGATG
 GCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGA
 GTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCATT
 5 TTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCTGCCAG
 AAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGA
 CACAATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCG
 TCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCC
 GCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTTACAGCCACTTCACTG
 10 TGTAACATTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCT
 GGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCCTGGGAGAGAAATGGAAGGCCCGCT
 TGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGA
 GAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAG
 TGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAAGTCAATTGATCTTG
 15 GATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGA
 TACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAAGCTATGGGTGGAACATAGT
 CCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGA
 CATAGGTGAGTCATCATCTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGT
 GGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGCATAAAAGTGTGTGCCCATACACCAGCA
 20 CTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTC
 TCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGT
 GTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGG
 AGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAG
 ATCATTGGTAACCGCATTGAAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAAAA
 25 CCACCCATATAGGACATGGGCTTACCATGGAAGCTATGTGGCCCCCACACAAGGGTCAGCGTCCTC
 TCTAATAAACGGGGTTGTGAGGCTCCTGTCAAAACCCCTGGGATGTGGTGACTGGAGTCACAGGAA
 TAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGG
 GTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAGAG
 CTAGGCAAACACAAACGACCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTTCGTAGCAA
 30 TGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAAC
 GATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGA
 GTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAAGGGGAATTTGGAAGGCCAAGGG
 CAGCCGCGCCATCTGGTATATGTGGCTAGGGCTAGATTTCTAGAGTTCAAGCCCTTGGATTCTT
 GAACGAGGATCACTGGATGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAA
 35 AGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACAC
 TGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAAAA
 TGGAGAAAGGGCACAGGGCCTTGGCATTTGGCCATAATCAAGTACACATACCAAAAACAAAGTGGTA
 AAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTGAGACAAAGACCAAAAG
 GGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTG
 40 GAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAG
 TGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGAT
 TGC GTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAAA
 GTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCGGTT
 TTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCA
 45 CCAAGATGAACTGATTGGCCGGGCCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTG
 CTGTCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGAC
 TGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGGT
 CAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGG
 ATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTCCTATTT
 50 GGGAAAAAGGGAAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTG
 AGAACATTAAAAATACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGAC
 TACCTATCCACCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTGAGCACC
 ATCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCT
 CCAGGAGAAGCTGGGTAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCA
 55 TGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
 GGGAAAAGAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGG
 ATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATTGACG

CTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATA
GCGGCGGCCGGTGTGGGGAAATCCA

KU501215.1 Zika virus strain PRVABC59, Puerto Rico, complete genome (SEQ ID NO: 4)

5 GTTGTGTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
ACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCG
GAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGA
AGAGGCTGCCAGCCGGACTTCTGCTGGGTTCATGGGCCATCAGGATGGTCTTGGCGATTCTAGCCT
TTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAA
10 AAGAGGCTATGGAAACAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTCGGAATTGTTGGCCTCCTGCTGAC
CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
15 CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTGTGTACGGAACCTGCCATCAC
AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCCATTCCACCAGGAAGCT
GCAAACGCGGTGCAAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
ATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGT
20 GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTGATGTTGTCT
TGGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
GGCTTCTGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
ATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGG
25 AGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
GAATCTGGAGTACCGGATAATGCTGTCACTTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGA
CACAGGACATGAACTGATGAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCGAGAGCC
GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
TCAGATTTGTATTACTTGAATTAACAAGCACTGGTTGGTTTCAACAAGGAGTGGTTCCACGAC
30 ATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAATCCACACTGGAACAACAAAGAAGCACT
GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAG
CAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
TCTGGCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTG
TGTACTGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGG
35 GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAA
CTCTGACCCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
AGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAAAGCATTTGAAGCCACTGTGAG
AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
40 TCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAA
TGTCCTGGTTCTCACAAATTTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTCTCTGC
TGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
45 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAA
CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
CGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTATTTCTGTCAGAGCAGCAAAAGACAAA
TAACAGCTTTGTCTGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
50 GCTTTCTTGTGGAGGATCATGGGTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACA
GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTG
ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
GTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACA
55 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGGAGGAATGCCAGGC

ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCTGTTCCGGGGCTA
 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAAGGAAAGCAACTTAGTAAG
 5 GTCAATGGTGACTGCAGGATCAACTGATCACATGGACCACTTCTCCCTTGGAGTGCTTGTGATCCT
 GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCCTTGGAAGGCGACCTGAT
 10 GGTTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGGCGGGGGTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAACTTACCATTGTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 15 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTGCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCCTGATGACCATCTGTGGCATGAACCAATAGCCATACCTTTGCAGCT
 20 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCCTGGGATGGGCACAGCGAGGTGCA
 25 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAACGGGAGTTA
 TGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCCTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTT
 30 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 GTTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 35 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTTATGGACAC
 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAA
 AAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCA
 AGAGTGGGACTTTGTCGTGACAACTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGTGT
 40 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGAC
 CCATGCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 TGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 45 TTTGTGGAACATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCCGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGG
 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 50 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGGAGACCCTAGAGACCATAATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTCTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATT
 GTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 55 CAAATGGCAATCATCATCTGGTAGCAGTAGGTTCTTCTGGGCTTGATTACCGCCAATGAACCTCGGA
 TGGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCCTGACAA

CTTTCATTACCCCAGCCGTCCAACATGCAGTGACCACCTCATACAACAACACTACTCCTTAATGGCGA
 TGGCCACGCAAGCTGGAGTGTGTTTGGCATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCTGCC
 5 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGC
 CGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCTCTGATCACAG
 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTTACAGCCACTTCAC
 TGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 10 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTGCGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 AGAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGTCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 15 ATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCAG
 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 20 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAAACGTGGTTCTTTGACGAG
 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCCACACAAGGGTCAGCGTC
 25 CTCTCTAATAAACGGGGTTGTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAG
 AGCTAGGCAAACACAAACGGCCACGAGTCTGCACCAAAGAAGAGTTCATCAACAAGGTTTCGTAGC
 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGA
 30 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 GAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATT
 TTGAACGAGGATCACTGGATGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGTATACCAGGAGGAAGGATGTATGCAGATGACA
 35 CTGCTGGCTGGGACACCCGCATTAGCAGGTTTGATCTGGAGAATGAAGCTCTAATACCAACCAA
 ATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAACAGTTATGGACATTATTTTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAA
 40 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGA
 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCG
 TTTTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 CACCAAGATGAACTGATTGGCCGGGCCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGAC
 45 TGCTTGCTAGCAAAATCATATGCGCAAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTG
 GTCATCCATGGAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGT
 GGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTCCCTAT
 TTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGC
 50 TGAGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGG
 ACTACCTATCCACCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
 CAATCTTAATGTTGTGAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
 CATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
 55 ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
 GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGA

KU509998.1 Zika virus strain Haiti/1225/2014, Haiti, complete genome (SEQ ID NO: 5)

GTTGTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
 ACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGG
 AGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAA
 5 GAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCCTT
 TTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAA
 AAGAGGCTATGGAAATAATAAAGAAAGTTCAAGAAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
 GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGAC
 CACAGCTATGGCAGCGGAGGTCAGTACGCTGGGAGTGCATACTATATGTACTTGGACAGAAACG
 10 ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGG
 ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
 CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
 AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCCATTCCACTAGGAAGCT
 GCAAACGCGGTCGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
 15 ATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
 CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGT
 GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCT
 TGGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
 ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
 20 GGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
 ATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
 AGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
 GAATCTGGAGTACCGGATAATGCTGTCACTTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGA
 CACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
 25 GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCCTTGACTTT
 TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTCAAGGAGTGGTTCCACGAC
 ATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAATCCACACTGGAACAACAAGAAAGCACT
 GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCTGTTCTAGGGAGTCAAGAAGGAG
 CAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
 30 TCTGGCCACTTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCCTTG
 TGTACCGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGG
 GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAA
 CTCTGACCCCACTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
 AGATGATGCTGGAACCTGATCCACCATTGTTGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
 35 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGTAAGCCACTGTGAG
 AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
 TCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAA
 TGTCTGTTCTCACAATTTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
 GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTCTCTGC
 40 TGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
 ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAA
 CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
 CGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
 45 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTGAGAGCAGCAAAGACAAA
 TAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
 GCTTTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACA
 GTGATCTAGGCTACTGGATTGAGAGTGAGAGAAGATGACACATGGAGGCTGAAGAGGGCCCATCTG
 50 ATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGACAGATGGAATAGAAGAGA
 GTGATCTGATCATAACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACA
 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGGAGGAATGCCCAGGC
 ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 CGGAAGGGTGTGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTGCTTCCGGGCTA
 55 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAG
 GTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCT

GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 5 CATGCTGCTGGCCTTGCCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGAT
 GGTTCCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAAGTTACCAATTTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGT
 10 GGTGGGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGTTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 15 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCTTTGTCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 20 GATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 25 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAAACCAGGAGAGTT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 GTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTTCACGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 30 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACACCAATTATGGACAC
 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGAATTATTTGGA
 AAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAAACGGTTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAAACAAACATCA
 35 AGAGTGGGACTTTGTCGTGACAACTGACATTTTCAGAGATGGGCGCCAACTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGAC
 CCATGCCTGTCACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 40 TGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 TTTGTGGAAGTCAATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 ATAACCTACACAGATAGAAGATGGTGTCTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGG
 45 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCTATT
 50 GTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 CTTTCATTACCCAGCCGTCCAACATGCAAGTACCCTCATACAACAACACTACTCCTTAATGGCGA
 55 TGGCCACGCAAGCTGGAGTGTGTTGGTATGGGCAAAAGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCC

AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGC
 CGTCTCCAGCGCCATACTGTGCGGACCGCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAG
 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTTACAGCCACTTCAC
 5 TGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 AGAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 10 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 ATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAG
 15 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAG
 20 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAACCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAG
 AGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGC
 25 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 GAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTC
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACA
 30 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAA
 ATGGAGAAAGGGCAGAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAAAAGTGGT
 AAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCTGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 35 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGA
 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACTGGGAAGAAGTTCCG
 TTTTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 40 CACCAAGATGAACTGATTGGCCGGGCCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGAC
 TGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTG
 GTCAATCCATGGAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGT
 GGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTAT
 45 TTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGC
 TGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGG
 ACTACCTATCCACCCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
 CAATCTTAATGTTGTGAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
 50 CATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
 ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
 GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGA

KU527068.1 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, complete

55 genome (SEQ ID NO: 6)

AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATC
 AACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCC
 GGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTG
 AAGAGGCTGCCAGCCGACTTCTGCTGGGTCTATGGGCCCATCAGGATGGTCTTGGAATTCTAGCC
 5 TTTTGTAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAGTGGGGAAA
 AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAA
 TGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGA
 CCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAAC
 GATGCTGGGGAGGCCATATCTTTTCCAACACATTGGGGATGAATAAGTGTTATATACAGATCATG
 10 GATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGA
 ACCAGATGACGTGATTTGTTGGTGCAACACGACGTCAACTTGGGTGTGTACGGAACCTGCCATCA
 CAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCCTCCATTCCACTAGGAAGC
 TGCAAACGCGGTGCGAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAA
 AATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGC
 15 TCAACGAGCCAAAAAGTCATATACTTGGTTCATGATACTGCTGATTGCCCGGCATACAGCATCAGG
 TGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTGATGTTGTC
 TTGGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGT
 TACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACA
 TGGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAA
 20 TATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGG
 GAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGAAGAGCATCCAGCCAG
 AGAATCTGGAGTACCGGATAATGCTGTACAGTTCATGGCTCCAGCACAGTGGGATGATCGTTAATG
 ACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGC
 CGAAGCCACCCTGGGGGGTTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACT
 25 TTTCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTCCACAAGGAGTGGTTCCACG
 ACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAATCCACACTGGAACAACAAAGAAGCA
 CTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTGCTGGTTCTAGGGAGTCAAGAAGG
 AGCAGTTCACACGGCCCTTGTGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGT
 CCTCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCT
 30 TGTGTACCGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTG
 GAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCA
 AACTCTGACCCCACTTGGGAGGTTGATAACCCGTAACCCGTAATCACTGAAAGCACTGAGAAT
 CTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTTTACATTGTTCATAGGAGTCGGGGAGA
 AGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAGGCAATTTGAAGCCACTGTG
 35 AGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGC
 TCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGG
 AATGTCCTGGTTCTCACAAATCCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAA
 TGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTCTCT
 GCTGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTGCT
 40 CTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGG
 CAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAG
 AACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCTTGGAAGAGAATGGAGTTCAACT
 GACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTG
 TGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCAGCAAAGACA
 45 AATAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCGAACATAGAGCATGGAA
 CAGCTTTCTTGTGGAGGATCATGGGTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGA
 AGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGGAAGGAGGCTGTAC
 ACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCAT
 CTAATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGGCAGATGGAATAGAAGA
 50 GAGTGATCTGATCATTTCCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTA
 CAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTTCGTTTGAAGAAATGCCCGG
 GCACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCA
 AGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTGCTTCCGGGC
 TAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAACTAGTATGTA
 55 AGGTCAGTGGTGACTGTCAGGATCAACTGATGATGATGATGATGATGATGATGATGATGATGATGAT
 CTGCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAAT
 GGCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTT

GATGGGCGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGG
 CATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAA
 GCATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACCTGCGATCTCCGCCTTGGAAGGCGACCTGA
 TGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGA
 5 TAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTG
 GAGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGA
 AGAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACG
 TGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACA
 GCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTTCGCCAAGGCAGATATAGAGATGGCTGGGCC
 10 CATGGCCCGCGGTTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTC
 GATGTGGCGCTAGATGAGAGTGGTGATTCTCCTGGTGGAGGATGACGGTCCCCCATGAGAGA
 GATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGC
 TGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTC
 15 CCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCT
 AGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCA
 CAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCA
 GGATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCCTGGGACGGGCACAGCGAGGTGC
 AGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAATATTTAAG
 20 ACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAAT
 CCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTT
 ATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGTTCGAGCCTTCG
 ATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGT
 TCTTCCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAG
 25 GGTGTGCTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGGCTTCAGTGCGTTATATGACAACAGCAG
 TCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTTCACGTC
 TACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATC
 CCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATC
 TTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGAC
 30 ACCGAAGTGGAAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGG
 AAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAG
 CTGGA AAAACGGGTATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACAT
 CAAGAGTGGGACTTTGTCTGTGACAACCTGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGT
 GTCATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTTTGGCTGGA
 35 CCCATGCCTGTCTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAA
 ACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGC
 TTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGAC
 CTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGAC
 CTTTGTGGAACCTCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGG
 40 AATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACA
 GTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGA
 CGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAG
 GAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAG
 GAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCCTTACAAAGCCGC
 45 GGCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCT
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCT
 TGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCAT
 TGTTGTGTTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAA
 CCAAATGGCAATCATCATGTTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGG
 50 ATGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGAGCAACC
 ATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACA
 ACTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTTAATGGCG
 ATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTT
 GGAGTCCCCTGCTAATGATAGTTGCTACTACAATTAACACCCCTGACCCTAATAGTGGCCATC
 55 ATTTTGTCTCGTGGCGCACTACATGTACTGATCCCAAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCC
 CAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACAT
 TGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAG

CAGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACA
 GCCGCAACTTCCACTTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCA
 CTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACATAGTAACAAGAAAC
 GCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCC
 5 GCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCA
 GAGAAGAGGCCCCGCCGCGCCCTCAAGGATGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGA
 AGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCT
 TGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAG
 10 GATACACAAAAGGAGGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATA
 GTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGT
 GACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCAT
 GGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAAGTGTTGTGCCCATACACCA
 GCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCA
 15 CTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAG
 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATG
 AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATG
 AAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGA
 GAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGT
 20 CCTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGAAGTGCAG
 GAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAA
 GAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTTCGTAG
 CAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTG
 AACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCC
 25 AGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAA
 GGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTCGAAGCCCTTGGATT
 CTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTAC
 AAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGAC
 ACTGCTGGCTGGGACACCCGCATCAGCAGGTTTCGATCTGGAGAATGAAGCTCTAATCACCAACCA
 30 AATGGAGAAAAGGGCATAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGG
 TAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTTCGAGACAAGACCAA
 AGGGGAGCGGACAAGTTGTCACCTTACGCTCTTAACACATTTACCAACCTTGGTGCAACTCAT
 CGGAATATGGAGGTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAA
 AGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATG
 35 ATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAA
 AAGTTAGGAAGGACACACAAGAGTGGA AACCTCAACTGGATGGGACA ACTGGGAAGAAGTTCC
 GTTTTGTCTCCACCACCTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 CCACCAAGATGAACTGATTGGCCGGGCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGA
 CTGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCC
 40 GACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCTCAACTGGGAGAACTACCT
 GGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTG
 TGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTA
 TTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGG
 45 CTGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATG
 GACTACCTATCCACCCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCA
 CCAATCTTAATGTTGTGAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACC
 CCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
 CCATGCTGCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCATGCGCTTGGAGGCGCAG
 50 GATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTG
 TGGATCTCCAGAAGAGGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATTG
 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
 ATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCTT

KU681081.3 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand,

55 complete genome (SEQ ID NO: 7)

AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATC
 AACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCC
 GGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTG
 AAGAGGCTGCCAGCCGACTTCTGCTGGGTCTATGGGCCATCAGGATGGTCTTGGCGATTCTAGCC
 5 TTTTGTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAGTGGGAAAA
 AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAA
 TGCTAGGAAGGAGAAGAAGAGACGAGGCACAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGA
 CCACAGCTATGGCAGCGGAGGTCCTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAGC
 GATGCTGGGAGGCCATATCTTTTCCAACCACTGGGGATGAATAAGTGTTATATACAGATCATG
 10 GATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTAGA
 ACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCA
 CAAAAAAGGTGAAGCACGGAGATCCAGAAGAGCTGTGACGCTCCCCCTCCCATTTCCACTAGGAAGC
 TGCAAACGCGGTTCGACAGCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAA
 AATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGC
 15 TCAACGAGCCAAAAAGTCATATACTTGGTTCATGATACTGCTGATTGCCCGGCATACAGCATCAGG
 TGCATAGGAGTCAGTAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTC
 TTGGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGT
 TACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACA
 TGGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAA
 20 TATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGG
 GAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGAAGAGCATCCAGCCAG
 AGAATCTGGAGTACCGGATAATGCTGTACGTTTCATGGCTCCAGCACAGTGGGATGATCGTTAATG
 ACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGC
 CGAAGCCACCCTGGGGGGTTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACT
 25 TTTCAGATTTGTATTACTTGACTATGAACAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACG
 ACATTCCATTACCTTGGCACACTGGGGCAGACACCGGAACTCCACACTGGAACAACAAGAAGCA
 CTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCTGGTTCTAGGGAGTCAAGAAGG
 AGCAGTTCACACGGCCCTTGTGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGT
 CCTCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCT
 30 TGTGTACCGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTG
 GAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCA
 AACTCTGACCCAGTTGGGAGGTTGATAACCCGTAACCCGTAATCACTGAAGGCATGAGAATG
 CTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTTCATAGGAGTCGGGGAGA
 AGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAAAGCATTGGAAGCCACTGTG
 35 AGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGT
 TCTTAACCTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGG
 AATGTCCTGGTTCTCACAAATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAATACAAAGAA
 TGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGTCTCC
 GCTGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTCTG
 40 CTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCTCGTAGATTGGC
 AGCAGTAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAGAATGGAAA
 ACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTG
 ACGGTCTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGT
 GAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAA
 45 ATAACAGCTTTGTCTGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAAC
 AGCTTTCTTGTGGAGGATCATGGGTTTCGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAA
 GATTATTCACTAGAGTGTGATCCAGCCGTCATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACA
 CAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAACGACACATGGAGGCTGAGGAGGGCCACC
 TGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGACAGATGGAATAGAAGAG
 50 AGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAGGGCTAC
 AGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGG
 CACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAA
 GCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCTGTTCCGGGCT
 AAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAAAGTAACCTAGTAA
 55 GGTCAATGGTGACTGCAGGATCAACTGATACATGGATCACTTTTCCCTTGGAGTGCTTGTGATTC
 TGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGATCTGGCTAAGCTTGCAATTTTG

ATGGGTGCCACCTTTGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGGTAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAG
 CATGCTGCTGGCCTTGCCCTCGTGTCTTTTGCAAACTGCGATCTCCGCTTGGAAGGCGACCTGAT
 5 GGTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAC
 AATATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCGGGGGGTTTCATGCTCCTCTCTCTGAAGGGGAAAGGCAGTGTGAA
 GAAGAACTTACCATTGTGCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 10 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGCCCC
 ATGGCCCGGTCGGTCTGCTAATTGTTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTTACTGGAAACAGTCCCCGGCTCG
 ATGTGGCACTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAAGTGGTCCTGATGACCATCTGTGGCATGAACCAATAGCCATACCTTTGACAGCT
 15 GGAGCGTGGTACGTATACGTGAAAACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCATGTCAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 20 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGACTATCCAGCAGGAACCTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGTATAGGACTCTATGGCAATGGGGTCTGTATCAAGAATGGGAGTTA
 TGTCAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAAACCAGGAGAGTT
 25 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACGAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 GTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTACCCATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCCACCTTCACCTTCACGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCAGCTGCCATCTT
 30 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTCCCGGACTCCAACCTACCAATTATGGACA
 CCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGA
 AAAACAGTTTGGTTTTGTCCCAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAGGC
 TGGAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATC
 AAGAGTGGGACTTCGTGCTGACAACTGACATTTAGAGATGGGCGCCAACCTTTAAAGCTGACCGT
 35 GTCATAGATTCCAGGAGATGCCATAAGCCGGTCATACTTGATGGCGAGAGAGTCACTTCTGGCTGG
 ACCCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACA
 AACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGATGAAGACCATGCACACTGG
 CTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGA
 CCTGAGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGA
 40 CCTTTGTGGAACCTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCG
 GAATAACCTACACAGATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGAC
 AGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGG
 ACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGA
 GGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACGGAGAGATTCCA
 45 GGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCG
 CGGCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGC
 TGGGAATCTTTTTCGTCTTGATGCGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTC
 TTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGCGTCCTCA
 TTGTTGTGTTCTTATGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCCCCCAGGACA
 50 ACCAAATGGCAATCATCATATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCG
 GATGGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAAC
 CATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCGGCCTGGGCCATCTATGCTGCCCTGAC
 AACTTTCAATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACTACTCCTAATGGC
 GATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTT
 55 TGAGATCCCCTGCTAATGATAGTTGCTATCACAATTAACACCCCTGACCCTAATAGTGGCTAT
 CATTTTGCTCGTGGCGCACTACATGTACTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGC
 CCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACA
 TTGACACAATGACTATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTA

GCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGGGAAGCTGGGGCCCTGATCAC
 AGCTGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTC
 ACTGTGCAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAA
 5 CGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCTGGGAGAGAAATGGAAGGCC
 CGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGC
 AGAGAAGAGGCCCCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGG
 AAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATC
 TTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAA
 10 GGATACACAAAAAGGAGGCCCTGGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACAT
 AGTCCGCTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTG
 TGACATAGGTGAGTCATCATCTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCAT
 GGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTGTAAAAAGTGTGTGCCCATACACCA
 GCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCA
 15 CTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAG
 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCAGGAGGCCAGTGAAATATG
 AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATG
 AAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGA
 GAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCTACACAAGGGTCAGCGT
 20 CCTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGAAGTGCAG
 GAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGACACC
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAA
 GAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTTCGTAG
 CAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACCGCAGTGGAAGCTGTG
 AACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCC
 25 AGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAA
 GGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTCGAAGCCCTTGGATT
 CTTAAATGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTAC
 AAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGAC
 ACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTTTAATCACCAACCA
 30 AATGGAGAAAAGGGCACAGGGCCTTAGCATTGGCCATAATCAAGTACACATAACCAAAACAAAGTGG
 TAAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAAGACCAA
 AGGGGAGCGGACAGTTGTCACTTACGCTCTTAACACATTACCAACCTTGGTGCAACTCATT
 CGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAA
 AGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATG
 35 ATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAA
 AAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCC
 GTTTTGTTCACCACCTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 CCACCAAGATGAACTGATTGGCCGGGCGGCTGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGA
 CTGCTTGCTAGCAAAGTCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCC
 40 GACTGATGGCCAATGCCATCTGTTTCATCTGTGCCAGTTGACTGGGTCCAAGTGGGAGAACTACCT
 GGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTG
 TGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTCCCTA
 TCTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGG
 45 CTGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATG
 GACTACCTATCCACCCAAGTTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTATAAGCA
 CCAATCTTAGTGTTGTGAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACC
 CCCCCAGGAGAGGCTGGGAAACCAAGCCCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
 CCATGCTGCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAG
 GATGGGAAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTG
 50 TGGATCTCCAGAAGAGGGGACTAGTGGTTAGAGGAGACCCCCGGAAACGCAAAACAGCATATTG
 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
 ATAGCGGCGCCGGTGTGGGGAAATCCATGGGTCT

KU681082.3 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines,

55 complete genome (SEQ ID NO: 8)

AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATC
 AACAGGTTTTATTTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCC
 GGAGGATTCCGGATTGTCAATATGCTAAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTG
 AAGAGGCTGCCAGCCGACTTCTGCTGGGCCATGGGCCCATCAGGATGGTCTTGGCGATACTAGC
 5 CTTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAA
 AAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCA
 ATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGCGTCGGAATTGTTGGCCTCCTCCTG
 ACCACAGCCATGGCAGTAGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAG
 CGATGCTGGGGAGGCCATATCTTTTCCAACCACACTGGGGATGAATAAGTGTACATACAAATCAT
 10 GGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGTTGGATGAGGGGGTAG
 AACCAGATGACGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTATGGAACCTGCCACC
 AAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCCATTCCACTAGGAAG
 CTGCAAACGCGGTCGCAGACCTGGTTGGAATCAAGAGAATACACAAAGCACCTGATTAGAGTTGA
 AAATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGTCATCGCTTGGCTTTTGGGAAG
 15 TTCAACGAGCCAAAAAGTCATATATCTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAG
 GTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGT
 CTTGGAACATGGAGGTTGTGTTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGG
 TTACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGAT
 ATGGCTTCGGACAGCCGCTGCCAACACAAGGTGAGGCCTACCTTGACAAGCAGTCAGACACTCA
 20 ATATGTCTGCAAAAGAACGTTAGTGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAG
 GGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCA
 GAGAATCTGGAGTACCGGATAATGCTGTGAGTTTCATGGCTCCCAGCACAGTGGGATGATCGTTAAT
 GACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAG
 CCGAAGCCACCCTGGGGGGTTTTGGGAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCCTTGAC
 25 TTTTCAGATTTGTATTACCTGACTATGAATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCAC
 GACATTCCATTACCTTGGCATGCTGGGGCAGACACTGGAACCTCCACATTGGAACAACAAAGAAGC
 ACTGGTAGAGTTCAAGGACGCACATGCAAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAG
 GAGCAGTTCACACGGCCCTTGTCTGGAGCTCTGGAGGCTGAGATGGATGGAGCCAAGGGAAGGCTG
 TCCTCTGGCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCC
 30 TTGTGCACTGCAGCGTTCACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTG
 GAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGATATGCA
 AACTCTGACCCGAGTTGGGAGGTTGATAACCCGTAACCCCTGTAATCACTGAAAGCACCAGAACT
 CTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTTTACATTGTTCATAGGAGTCGGGGAGA
 AGAAGATCACCCATCACTGGCACAGGAGTGGCAGCACCATTTGGAAGAGCATTGAAAGCCACTGTG
 35 AGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGGGGTGC
 TCTCAACTCATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTCGGAGG
 AATGTCCTGGTTCTCACAATTTCTCATTGGAACGTTGCTGGTGTGGTTGGGTCTGAATACAAAGAA
 TGGATCTATTTCCCTTACGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTTTCT
 GCTGATGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTTCGT
 40 CTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCTCGTAGATTGGC
 AGCAGCAGTCAAGCAAGCCTGGGAAGATGGGATCTGTGGGATCTCCTCTGTCTCAAGAATGGAAG
 ACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTG
 ACGGTTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCGTGCCTGT
 GAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAA
 45 ATAACAGCTTTGTCTGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAAC
 AGCTTTCTTGTGGAGGATCATGGGTTTGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAA
 GATTATTATTAGAGTGTGATCCAGCCGTCATTGGAACAGCTGCTAAGGGAAAGGAGGCTGTGCA
 CAGCGATCTAGGCTACTGGATTGAGAGTGAGAAGAACGACACATGGAGGCTGAAGAGGGGCCAC
 CTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAGTAGAAGA
 50 AAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAGGGCT
 ACAGGACTCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGGAGGAATGCCCA
 GGCATAAGGTCCACGTGGAGGAAACATGTGGGACAAGAGGACCATCCCTGAGATCAACCACTGC
 AAGCGGAAGGTTGATCGAGGAATGGTGCTGCAGGGAATGCACAATGCCCCACTGTCTGTTCCGAG
 CTAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACCAAGTAAGTAAGTAAGTA
 55 AAGTCAATGGTGACTGCAGGATCAACTGATCAGATGGATCACTTCTCTCTTGGAGTGCTTGTGATT
 TTGCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAAT
 GGCAGTGCTGGTAGCCATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTT

GATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATTTGGCGCTGATAGCGG
 CATTCAAAAGTCAGACCTGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAGA
 GCATGCTGCTGGCCTTGGCCTCGTGTCTTCTGCAAACCTGCGATCTCCGCCTTGGAAAGGCGACCTGA
 TGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGA
 5 CAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGACACTGCTTGTGGCGTG
 GAGAGCAGGCCTTGCTACTTGCGGGGGGTTTCATGCTCCTCTCTCTGAAGGGGAAAGGCAGTGTGA
 AGAAGAACCTACCATTTGTCATGGCCTTGGGACTAACTGCTGTGAGGCTGGTCGACCCCATCAACG
 TGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTACTCACA
 GCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTTCGCCAAGGCGGATATAGAGATGGCTGGGCC
 10 CATGGCCGCGGTTCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAATCACTGGAAACAGTCCCCGGCTC
 GATGTGGCACTAGATGAGAGTGGTGATTCTCCCTAGTGGAGGATGATGGTCCACCCATGAGAGA
 GATCATACTCAAAGTGGTCTGATGACCATCTGCGGCATGAACCCAATAGCCATACCCCTTTCGAGC
 TGGAGCGTGGTACGTGTATGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCGTGCTC
 15 CCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCT
 TGGTTCAACACAAGTTGGAGTGGGAGTCATGCAAGAGGGGGTCTTCCACACTATGTGGCACGTCA
 CAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCA
 GGATCTGGTGTCTACTGTGGTCCGTGGAAGCTAGACGCCGCTGGGACGGGCACAGCGAGGTGC
 AGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAACATTTAAG
 20 ACAAAGGATGGGGACATTGGAGCAGTTGCGCTGGACTACCCAGCAGGAACCTTCAGGATCTCCAAT
 CCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGTAATGGGGTCGTGATAAAAAATGGGAGTT
 ATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCCTTCGAGCCTTCG
 ATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACCTGCATCCTGGAGCCGGGAAAACAGGAGAGT
 TCTTCCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAG
 25 GGTGCTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGGCTTCAGTTTCGTTATATGACAACAGCAGT
 CAATGTCACCCAATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCTACCTTCACTTCACGCCT
 ACTACAACCAATCAGAGTCCCCAACTATAATTTGTATATTATGGATGAGGCCCACTTCACAGATCC
 CTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCT
 30 TCATGACCGCCACGCCACCAGGAACCCGTGACGCATTCGCCGACTCCAACCTACCAATTATGGACA
 CCGAGGTGGAAGTCCCAGAGAGAGCCTGGAGCACAGGCTTTGATTGGGTGACGGATCATTCTGGG
 AAAACAGTCTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAGGC
 TGGAAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAACGAAAAATC
 AAGAGTGGGACTTCGTGCTGACAACCGACATTTTCAGAGATGGGCGCCAACCTTTAAAGCTGACCGT
 GTCATAGATTCCAGGAGATGCTTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTTTGGCTGGA
 35 CCCATGCCTGTCTACACATGCCAGCGCTGCTCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAA
 ACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGATGAAGATCACGCACACTGGC
 TTGAAGCAAGAATGCTTCTTGACAACATTTACCTCCAAGATGGCCTCATAGCTTCGCTCTATCGAC
 CTGAGGCCGACAAAGTAGCAGCTATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGAC
 CTTTGTGGAACCTCATGAAAAGAGGAGATCTTCCGGTTTGGTTGGCCTATCAGGTTGCATCTGCCGG
 40 AATAACCTACACAGATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGACA
 GTGTGCCGGCAGAGGTGTGGACCAGATACGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGA
 CGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAAGAGTTTGCCGCTGGGAAAAGAG
 GAGCGGCCTTTGGAGTGATAGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAG
 GAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCCTTACAAAGCCGC
 45 GGCGGCCCAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCT
 GGAATCTTTTTCGTCTTGATGCGGAACAAGGGCATGGGGAAGATGGGCTTTGGAATGGTGACTCT
 TGGGGCCAGCGCATGGCTTATGTGGCTCTCGGAAATTGAGCCAGCCAGAAATTGCATGTGTCTCAT
 TGTCGTGTTCTTATTTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCTCAGGACAA
 CCAAATGGCAATCATCATCATGGTAGCAGTGGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGG
 50 ATGGTTGGAGAGAAACAAAAAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACC
 ACAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCTATCTATGCTGCTCTGACA
 ACTTTCATCACCCAGCCGTCCAACATGCGGTGACCACTTCATACAACAACACTACTCCTTAATGGCG
 ATGGCCACGCAAGCTGGGGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTT
 GGAGTCCCCTGCTAATGATGGGTGCTACTACAATTAACACCTCTGACCCCTAATAGTGGCCATC
 55 ATTTTGCTCGTGGCGCACTACATGTACTGTATCCCAGGGCTGCAGGCAGCAGCTGCGGGGTGCC
 CAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACAT
 TGACACAATGACAATTGACCCCCAAGTGGAAAAAAGATGGGGCAGGTGCTACTCATAGCAGTAG

CCGTCTCCAGCGCCATACTGTTCGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGGCCCTGATCACA
 GCTGCAACTTCCACCTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCCACAGCCACTTCA
 CTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAAC
 GCTGGCTTGGTCAAGAGACGTGGGGGTGGAACGGGAGAGACCCTGGGAGAGAAATGGAAGGCC
 5 GCCTGAACCAGATGTCGGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGC
 AGAGAAGAGGCCCCGCGTGGCCTCAAGGACGGTGTGGCAACAGGAGGCCATGCTGTGTCCCGAGG
 AAGTGCAAAGCTTAGATGGCTGGTGGAGAGAGGATACCTGCAGCCCTATGGAAAGGTCATTGATC
 TTGGATGTGGCAGAGGGGGCTGGAGTTACTATGCCGCCACCATCCGCAAAGTTCAGGAAGTGAAA
 GGATACACAAAAAGAGGGCCCTGGTCATGAAGAACCCTATGTTGGTGCAAAGCTATGGGTGGAACAT
 10 AGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCACATGGCGGGCTGAGCCGTGTGACACTTTGTGTG
 TGATATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCAT
 GGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAAGTGTTGTGCCCATACACCA
 GCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGGGTGCCA
 CTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAG
 15 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCAGGAGGCCAGTGAAATATG
 AGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATG
 AAGATCATTGGTAACCGCATTGAGAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGA
 GAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCTACACAAGGGTCAGCGT
 CCTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGAAGTGCAGC
 20 GAATAGCCATGACTGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTATGGAAG
 GAGCTAGGCAAAACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTTCGTAG
 CAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTG
 AATGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCATCACCTGAGAGGAGAGTGTCA
 25 GAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTTAGAGTTCGAAGCCCTTGGATTC
 TTGAATGAGGATCATTGGATGGGGAGAGAGAATTCAGGAGGTGGTGTGAAGGACTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGATA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAA
 30 ATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGT
 AAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAAGACCAAA
 GGGGAGCGGAAAGTTGTCACTTACGCTCTTAATACATTACCAACCTGGTGGTGCAGCTCATTC
 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGTGCGGAGGCCAGAGAAA
 GTGACCAACTGGTTGCAAAGCAACGGATGGGATAGGCTCAAAAGAATGGCAGTCAGTGGAGATG
 35 ATTGCGTTGTGAAACCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAA
 AAGTTAGGAAGGACACACAAGAGTGGAAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCC
 GTTTTGCTCCCACTTCAACAACTCCATCTTAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 CCACCAAGATGAACTGATTGGCCGAGCCCGGTATCACCAGGGGCGGGATGGAGCATCCGGGAGA
 CTGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCC
 40 GACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGATTGGGTTCCAACCTGGGAGAACTACCT
 GGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTATGGAACAGAGTG
 TGGATTGAGGAAAACGACCACATGGAAGACAAGACCCAGTTACAAAATGGACAGACATTCCCTA
 TTTGGGAAAAAGAGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGTACTACCTGGG
 CTGAGAACATCAAAAATACAGTCAACATGATGCGCAGGATCATAGGTGATGAAGAAAAGTACATG
 45 GACTACCTATCCACCCAGGTTTCGCTACTTGGGTGAAGAAGGGTCCACACCTGGAGTGCTGTAAGCA
 CCAATCTTAGTGTTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACC
 CCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAG
 CCATGCTGCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAG
 GATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTG
 50 TGGATCTCCAGAAGAGGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATTG
 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
 ATAGCGGCGCCGGTGTGGGGAAATCCATGGGTCT

KU707826.1 Zika virus isolate SSABR1, Brazil, complete genome (SEQ ID NO: 9)

GACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGGATTTGGAAACG
 AGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAA
 AACCGGAGTAGCCCCGTGTGAGCCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGACTTCTGCTG
 5 GGTTCATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTTGAGATTACGGCAATCAAGCCA
 TCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAAGAGGCTATGGAAATAATAAAGAA
 GTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGA
 GGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCCT
 AGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCA
 10 ACCAATTGGGGATGAATAAGTGTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACC
 ATGAGCTATGAATGCCCTATGCTGGATGAGGGGTGGAACCAGATGACGTCGATTGTTGGTGCAA
 CACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCACAAAAAAGGTGAAGCACGGAGATCTA
 GAAGAGCTGTGACGCTCCCTCCCATTCCTAGGAAGCTGCAAACCGGGTCGCAAACCTGGTTG
 GAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTT
 CGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTT
 15 GGTTCATGATACTGCTGATTGCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACT
 TTGTGGAAGGTATGTCAGGTGGGACCTGGGTTGATGTTGTCTTGGAAACATGGAGGTTGTGTCACCG
 TAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCG
 GAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCAAC
 ACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGG
 20 ACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTT
 GCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCT
 GTCAGTTCATGGCTCCCAGCACAGTGGGATGATTGTTAATGACACAGGACATGAAACTGATGAGA
 ATAGAGCGAAAAGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGA
 AGCCTAGGACTTGATTGTGAACCGAGGACAGGCCCTTGACTTTTCAGATTTGTATTACTTGACTATG
 25 AATAACAAGCACTGGTTGGTTTCAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGG
 GCAGACACCGGAACTCCACACTGGAACAACAAAGAAAGCACTGGTAGAGTTCAAGGACGCACATG
 CCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTACACAGGCCCTTGCTGGA
 GCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTGGCCACTTGAATGTCGCCT
 GAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTCCTTGTGTACTGCAGCGTTCACATTAC
 30 CAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGAT
 GGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCCACTTGGGAGGTT
 GATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAAGCTTAAGATGATGCTGGAACCTGATC
 CACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAGAAGATCACCCACCACTGGCAC
 AGGAGTGGCAGCACCATTTGAAAAGCATTGGAAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGT
 35 CTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCA
 TCCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCACAAATTCT
 CATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTT
 GGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCGCTCTGCTGATGTGGGGTGCTCGGTGGA
 40 CTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTTCGTCTATAACGACGTTGAAGCCTGGA
 GGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGG
 GAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGA
 AGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAA
 AAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGG
 AAGGCTTGGGGGAAATCGTACTTCGTACAGAGCAGCAAAGACAAATAACAGCTTTGTCTGGATGG
 45 TGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATG
 GGTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAAGATTATTCATTAGAGTGTGATC
 CAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATT
 GAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTG
 AATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAG
 50 TCTTTAGCTGGGCCACTCAGCCATCACAAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCC
 ATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAAGGAATGCCCAGGCACTAAGGTCCACGTGGAGG
 AAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGA
 ATGGTGCTGCAGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGG
 AATGGAGATAAGGCCCCAGGAAGAAACCAAGCAACTTAGTAAGGTCAATGGTGATGACAGGA
 55 TCAACTGATCATTGGACCACTTCCCTTGGAGTGCTGTGATTCTGCTCATGGTGAGGAAGGG
 CTGAAGAAGAGAATGACCACAAAGATCATCATAAGCATCAATGGCAGTGCTGGTAGCTATGAT
 CCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGA

AATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGT
 TGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTC
 GTGTCTTTTGCAAACCTGCGATCTCCGCCCTTGGAAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCT
 TTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGGCAATCCTG
 5 GCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCCTTGCTACTTGC
 GGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTTGTCATG
 GCCCTGGGACTAACCCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACA
 AGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATT
 GGCTGGAGGGTTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCATGGCCGCGGTCTGGTCTGCTAA
 10 TTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCACA
 TGGGAAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGG
 TGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGAT
 GACCATCTGTGGCATGAACCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAA
 GACTGGAAAAAGGAGTGGTGTCTATGGGATGTGCCTGCTCCCAAGGAAGTAAAAAAGGGGGAG
 15 ACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGTTGGAGTGGG
 AGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGATCCGCGCTGAGAAGCG
 GTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCA
 TGGAAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGA
 GAGAGCGAGGAACATCCAGACTCTGCCCCGAATATTTAAGACAAAGGATGGGGACATTGGAGCG
 20 GTTGCCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGT
 AGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAGGGA
 GGAGGGAGGAAGAGACTCCTGTTGAGTGTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACT
 GTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCCTGAAATAGTCCGTGAAGCC
 ATAAAAACAAGACTCCGTAAGTGTGATCTTAGCTCCAACCAGGGTTGTGCTGCTGAAATGGAGGA
 25 GGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTCAATGTCACCCACTCTGGAACAGA
 AATCGTCGACTTAATGTGCCATGCCACCTTCACTTTCAGTCTACTACAGCCAATCAGAGTCCCCAA
 CTATAATCTGTATATTATGGATGAGGCCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATA
 CATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAA
 CCCGTGACGCATTTCCGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGA
 30 GCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTTCGAAGC
 GTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAGGCTGGAAAACGGGTCATACAGCTCAG
 CAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAACATCAAGAGTGGGACTTTGTCTGTGACAA
 CTGACATTTACAGAGATGGGCGCCAACTTTAAAGCTGACCGTGTGCATAGATTCCAGGAGATGCCTAA
 AGCCGGTCATACTTGATGGCGAGAGAGTCAATTCTGGCTGGACCCATGCCTGTACACATGCCAGCG
 35 CTGCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGA
 GGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAA
 TATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCCAT
 TGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAACCTCATGAAAAGAGGA
 GATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAGATGG
 40 TGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAG
 ACACGGAGAGAAAAGAGTGTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGG
 CCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCC
 CTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGCTGTGCT
 CATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCGGAGACCCTAG
 45 AGACCATATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTCTTCGTCTTGATGAGGA
 ACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGGCCAGCGCATGGCTCATGTGG
 CTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTTCTATTGCTGGTGGTGC
 TCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCAAAATGGCAATCATCATGGTA
 GCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAAACAAAGAGTGA
 50 CCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACC
 TGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACTTTCATTACCCAGCCGTCCAAC
 ATGCAGTGACCACTTCATACAACAACACTCTCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTT
 TTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTT
 GCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCATTTTGTCTGCTGGCGCACTACATGT
 55 ACTTGATCCCAGGGCTGCAGGCAGCTATGCGCGTGTGCCCAGAAAGAGAACGGCAGCTGGCATC
 ATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
 AGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCG

GGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAA
 GGCTCTCCGAACAAGTACTGGAACCTCTTACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGT
 TACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGG
 5 GGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGG
 AGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCCCTC
 AAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGT
 GGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGA
 GTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGT
 10 CATGAAGAACCCTGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGA
 CGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAG
 TCCTGAAGTGGAAGAAGCACGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTGAAAAAA
 GACCAGGAGCCTTTTGTATAAAGGTGTTGTGCCCATACACCAGCACTATGATGGAAACCCTGGAGC
 GACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAG
 15 ATGTATTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGCTCCT
 CTTGGGGCGCATGGACGGCCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGGCTCTG
 GCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAA
 AGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGC
 TTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTTGTGAG
 20 GCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACAC
 CGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCCAAGAAGGC
 ACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCCAAACACAAACGGCC
 ACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTAGCAATGCAGCATTAGGGGCAATAT
 TTGAAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTA
 25 GTGGATAAGGAAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGG
 GAAAAAGAGAAAAGAAACAAGGGGAATTTGGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATAT
 GTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGGATCACTGGATGGG
 GAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAG
 AGATGAGTCGTATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATC
 30 AGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCACCAAAATGGAAAAAGGGCACAGGGCCTT
 GGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAA
 AAGGGAAAACAGTTATGGACATTATTTGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCACT
 TACGCTCTTAACACATTACCAACCTGAGTGGTGCAACTCATTGGAATATGGAGGCTGAGGAAGTT
 CTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAAGTGACCAACTGGTTGCAGAGCAA
 35 CGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGATTGCGTTGTGAAGCCAATTGATG
 ATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAG
 TGGAAACCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTTGCTCCCACTTCAACAAG
 CTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAAGTATTGGCCGG
 GCCCCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGC
 40 GCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTC
 ATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAT
 GGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATG
 GAAGACAAGACCCAGTTACGAAATGGACAGACATCCCCTATTTGGGAAAAAGGGGAAGACTTGTG
 GTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTAAAAACACAGTCA
 45 ACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTTCGC
 TACTTGGGTGAAGAAGGTCTACACCTGGAGTGCTGTAAGCACCACTTAAATGTTGTGAGGCCTG
 CTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACC
 AAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCCTGTGAGCCCCTCAG
 AGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGGTGGCGACC
 50 TTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGGACTAGT
 GGTTAGAGGAG

KU744693.1 Zika virus isolate VE_Ganxian, China, complete genome (SEQ ID NO: 10)

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
 55 ACAGGTTTTATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGG
 AGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAA

GAGGCTGCCAGCCGGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCAATTCTAGCCTT
 TTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAGTGGGGAAAA
 AAGATGCTATGGAAATAATAAAGAAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
 5 GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTCGGAATTGTTGGCCTCCTGCTGAC
 CACAGCTATGGCAGCGGAGGTCCTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
 ATGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTTATATACAGATCATGG
 ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
 CCAGATGACGTGATTTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
 10 AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTTCCCATTCCACTAGGAAGCT
 GCAAACGCGGTTCGCAAACCTGGTTGGAATCAAGAGAATAACAAAGCACTTGATTAGAGTCGAAA
 ATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
 CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGT
 GCATAGGAGTCAGCAATAGGGACTTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCT
 15 TGGAACATGGAGGTTGTGTACCGCAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
 ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACAT
 GGCTTCGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
 ATGTTTGCAAAAAGAACGTTAGTGACAGAGGCTGGGGAAATGGATGTGGACTTTTTTGGCAAAGGG
 AGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
 20 GAATCTGGAGTACCGGATAATGCTGTGAGTTCATGGCTCCCAGCACAGTGGGATGCTCGTTAATGA
 CACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
 GAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
 TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGCTCACAAGGAGTGGTTCCACGAC
 ATTCCATTACCTTGGCACGCTGGGGCAGCCACCGGAACCTCCACACTGGAACAACAAAGAAGCACT
 25 GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAAAGTGTGCTGGTTCTAGGGAGTCAAGAAGGAG
 CAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGGAAGGCTGTCC
 TCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCCTTG
 TGTACCGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACAGTGGACGGGACAGTCACAGTGGG
 GGGACAGTACGGAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAGA
 30 CTCTGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
 AGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAG
 AGGTGCCAAGAGAAATGGCAGTCTTGGGAGACACAGCTGGGACTTTGGATCAGTTGGAGGCGCTC
 TCAACTCATTGGGCAAGGGCATCCATCAAATTATTGGAGCAGCTTTCAAATCATTGTTTGGAGGAA
 35 TGTCCTGGTTCTCACAATTTCTCATTGGGACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATG
 GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGCTCTCAGG
 TGGTGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
 ATAACGATGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAAA
 40 CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
 CGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCTGTG
 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAAA
 TAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
 GCTTTCTTGTGGAGGATCATGGGTTCCGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 45 ACTATTGGTTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACAC
 AGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGTGGCTGAAGAGGGGCCATCT
 GATCGAGATGAAAACATGTGAATGGCCAAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAG
 AGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATGCCAGAGAGGGCTAC
 AGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGG
 50 CACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAA
 GCGGAAGGGTGATCGAGGAATGGTGCTCCAGGGAGTGCACAATGCCCCCACTGTCTTCCAGGCT
 AAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAA
 GGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTG
 TGCTCATGGTGACAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCAAGCACATCAATG
 55 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGC
 ATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAACTGCGATCTCCGCTTGGGAAGGCGACCTGAT

GGTTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTAGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGACACTGCTTGTGGCGTGG
 AGAGCAGGCCTTGCTACTTGCAGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGT
 5 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 ATGGCCGCGGTGCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 10 ATCATACTCAAGGTGGTCCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCCTTTCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGCAGACTGCTA
 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 15 GATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 CAAAGGATGGGGACATTGGAGCGGTTGCACTGGATTACCCAGCAGGAACCTTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGTAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGA
 20 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTGGCTCCAACCAGG
 GTTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTC
 AATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTTACGTCTA
 CTACAGCCAATTAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 25 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 CGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGAGTATTCTGGAA
 AAACAGTTTGGTTTGTTCACGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCA
 30 AGAGTGGGACTTTGTCTGTGACAACTGACATTTTCAGAGATGGGCGCAACTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGGTGGCGAGAGAGTCATTCTGGCTGGAC
 CCATGCCTGTACACATGCCAGCGCTGCCAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 35 TGAGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 TTTGTGGAACCTCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCGCGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGTCTAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGG
 40 AGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 GCGGCCCAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATT
 45 GTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCCATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 TGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TGGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATCCTGCCTTGACAT
 CTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAATACTCCTTAATGGCGA
 50 TGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCCTGACCCTAATAGTGGCCATCA
 TTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCC
 AGAAGAGAACCGCAAGTGGCATCATGAAGAACCCTGTTGTGGAGGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCAAGTGAGAGAAAAGATGGGACAGGTGCTACTACTGACGATAGC
 55 CGTCTCCAGCGCCATACTGTCTGAGGACCGCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAG
 CCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTCTACAGCCACCTCAC
 TGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACG

CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG
 AGAAGAGGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 5 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAGAAGTGAAAGG
 ATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCCTTTGTATAAAAAGTGTGTGCCCATACACCAG
 10 CACTATGATGGAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCTAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTGGTAACCGCATTGAAAGGATCCGCGCTGAGAAAAGCGGAAACGTGGTTCTTTGACGAG
 15 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGATGCCGCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTGGAGTCACAGG
 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAG
 AGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGC
 20 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 GAGTTGTGTGTACATCACAATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTC
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGTAAGGGCTGGGATTACA
 25 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAA
 ATGGAGAAAGGGCACAGGGCCCTTGGCATTGGCCATAATCAAGTACACATAACCAAAACAAAGTGGT
 AAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTGAGACAAGACCAAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTCAACACATTTACCAACCTAGTGGTGCAACTCATTC
 30 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCGGTCACTGGAGATGA
 TTGCGTTGTGAAACCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCCT
 TCTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCC
 35 ACCAAGATGAACTGATTGGCCGGGGCCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACT
 GCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGA
 CTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTGG
 TCAATCCATGGAAGGGGAGAATGGATGACCACTGAAGACATGCTTGTGGCGTGGAACAGAGTGTG
 GATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTCACGAAATGGACAGACATTCCCTATT
 40 TGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCT
 GAGAACATTAAAAACACAGTCAACATGGTGCAGCAGGATCATAGGTGATGAAGAAAAGTACATGG
 ACTACCTATCCACCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
 CAATCTTAATGTTGTGAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
 45 CATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
 ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
 GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGA

LC002520.1 Zika virus genomic RNA, strain: MR766-NIID, Uganda, complete genome

50 (SEQ ID NO: 11)

AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACAACAGTATC
 AACAGGTTTAATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAGAAGAAATCCG
 GAGGATTCCGGATTGTCAATATGCTAAAAACGCGGAGTAGCCCGTGTAAACCCCTTGGGAGGTTTG
 AAGAGGTTGCCAGCCGACTTCTGCTGGGTCATGGACCCATCAGAATGGTTTTTGGCGATACTAGCC
 55 TTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTTCCGTGGGGAAA

AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAA
 TGCTAGGAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGA
 CTACAGCCATGGCAGCAGAGATCACTAGACGCGGGAGTGCATACTACATGTACTTGGATAGGAGC
 5 GATGCCGGAAGGCCATTTTCGTTTGCTACCACATTGGGAGTGAACAAGTGCCACGTACAGATCAT
 GGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGCCCTATGCTGGATGAGGGAGTGG
 AACCAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTGTGTACGGAACCTGTCATC
 AAAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAG
 TTGCAAACGCGGTGCGCAGACCTGGTTAGAATCAAGAGAATACACGAAGCACTTGATCAAGGTTGA
 10 AAACCTGGATATTACAGGAACCCCGGGTTTGCGCTAGTGGCCGTTGCCATTGCCTGGCTTTTGGAAG
 CTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATACAGTATCAG
 GTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTACAGGTGGGACCTGGGTTGATGTTG
 TCTTGGAAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTTGACATAGAGTTG
 GTCACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGA
 CATGGCTTCGGACAGTCGTTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTC
 15 AATATGTCTGCAAAAGAACATTAGTGGACAGAGGTTGGGGAAACGGTTGTGGACTTTTTGGCAAA
 GGGAGCTTGGTGACATGTGCCAAGTTTACGTGTTCTAAGAAGATGACCGGGAAGAGCATTCAACC
 GGAAATCTGGAGTATCGGATAATGCTATCAGTGCATGGCTCCCAGCATAGCGGGATGACTGTCA
 ATGATATAGGATATGAACTGACGAAAATAGAGCGAAAGTCGAGGTTACGCCTAATTCACCAAGA
 GCGGAAGCAACCTTGGGAGGCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGA
 20 CTTTTCAGATCTGTATTACCTGACCATGAACAATAAGCATTGGTTGGTGCACAAAGAGTGGTTTCA
 TGACATCCCATTGCCTTGGCATGCTGGGGCAGACACTGGAACCTCCACACTGGAACAACAAAGAGG
 CATTGGTAGAATTCAGGATGCCCACGCCAAGAGGCAAAACCGTCGTCGTTCTGGGGAGCCAGGAA
 GGAGCCGTTACACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAAGGGAAAGCT
 GTTCTCTGGCCATTTGAAATGCCGCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTCATATTC
 25 CTTGTGCACTGCGGCATTCACATTCACCAAGGTCCCAGCTGAAACACTGCATGGAACAGTCACAGT
 GGAGGTGCAGTATGCAGGGACAGATGGACCCTGCAAGATCCCAGTCCAGATGGCGGTGGACATGC
 AGACCCTGACCCCACTTGGAAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGCACTGAGAAC
 TCAAAGATGATGTTGGAGCTTGACCCACCATTTGGGGATTCTTACATTGTCTATAGGAGTTGGGGAC
 AAGAAAATCACCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCACTGT
 30 GAGAGGCGCCAAGAGAATGGCAGTCCTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTG
 TGTTCAACTCACTGGGTAAGGGCATTACACAGATTTTGGAGCAGCCTTCAAATCACTGTTTGGAG
 GAATGTCTTGTTCTCACAGATCCTCATAGGCACGCTGTAGTGTGGTTAGGTTTGAACACAAAGA
 ATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGAGTGATGATCTTCTCTCCACGGCTGTTTC
 TGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAAGGAAACGAGATGTGGCACGGGGGTATTCA
 35 TCTATAATGATGTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGG
 CAGCAGCAGTCAAGCAGGCCCTGGGAAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAA
 AACATCATGTGGAATCAGTAGAAGGGGAGCTCAATGCTATCCTAGAGGAGAATGGAGTTCAACT
 GACAGTTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAAAGATTGCCAGTGCCTG
 TGAATGAGCTGCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGCGGCAAAAGACC
 40 AACACAGTTTTTGTGTCGACGGTGACACACTGAAGGAATGTCCGCTTGAGCACAGAGCATGGAA
 TAGTTTTCTTGTGGAGGATCACGGGTTTGGAGTCTTCCACACCAGTGTCTGGCTTAAGGTCAGAGA
 AGATTACTCATTAGAATGTGACCCAGCCGTCATAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGC
 ACAGTGATCTGGGCTATTGGATTGAAAGTGAAGAAGATGACACATGGAGGCTGAAGAGGGCCAC
 CTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTGTGGACAGATGGAGTAGAAGA
 45 AAGTGATCTTATCATACCCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGGTTA
 CAGAACCCAAGTGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATCCGGTTTGAGGAATGTCCAG
 GCACCAAGGTTTACGTGGAGGAGACATGCGGAACTAGAGGACCATCTCTGAGATCAACTACTGCA
 AGTGGAAGGGTCATTGAGGAATGGTGCTGTAGGGAATGCACAATGCCCCCACTATCGTTTCGAGC
 AAAAGACGGCTGCTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAGAGCAACTTAGTG
 50 AGGTCAATGGTGACAGCGGGTCAACCGATCATATGGACCACTTCTCTCTTGGAGTGCTTGTGATT
 CTACTCATGGTGCAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAAT
 GGCAGTGCTGGTAGTCATGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCT
 GATGGGTGCTACTTTCGCAGAAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGG
 CATTTAAAGTCAGACCAGCCTTGCTGGTCTCTCTCAATTTTCAGAGCCAATTGGACACCCCGTGAGA
 55 GCATGCTGTAGCCCTGGCTTCGTCTTCTGCAAACTGCGATCTCTGCTCTTGAAGGTGACTTGAT
 GGTCTCATTAATGGATTTGCTTTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGA
 CAACATCGCTCTACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATG

GAGAGCGGGCCTGGCTACTTGTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGA
 AGAAGAACCTGCCATTTGTCATGGCCCTGGGATTGACAGCTGTGAGGGTAGTAGACCCTATTAATG
 TGGTAGGACTACTGTTACTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTTCTCACA
 5 GCCGTTGGCCTGATATGTGCACTGGCCGGAGGGTTTGCCAAGGCAGACATTGAGATGGCTGGACC
 CATGGCTGCAGTAGGCTTGCTAATTGTGCTAGCTATGTGGTCTCGGGAAGAGTGTGGACATGTACAT
 TGAAAGAGCAGGTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCCTCGGCTTG
 ACGTGGCACTGGATGAGAGTGGTGATTTCTCCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAG
 10 ATCATACTTAAGGTGGTCCTGATGGCCATCTGTGGCATGAACCCAATAGCTATACCTTTTGCTGCA
 GGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGGGACGTGCCTGCTCC
 CAAAGAAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGATGACTCGCAGACTGCTA
 GGTTC AACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTAC
 AAAAGGAGCCGCACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAG
 GACTTGGTGTCTACTGTGGGCCTTGGAAGTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACA
 15 GCTTTTGGCCGTACCTCCCGGAGAGAGGGCCAGAAACATTCAGACCCTGCCTGGAATATTCAAGA
 CAAAGGACGGGGACATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGACCTCAGGATCTCCGATC
 CTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAATGGAAGCTA
 TGTTAGTGTCTATAACCCAGGGAAAGAGGGAGGAGGAGACTCCGGTTGAATGTTTCGAACCCCTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTGGATCTGCATCCAGGAGCCGGAAAAACCAGGAGAGTT
 20 CTTCTGAAATAGTCCGTGAAGCCATAAAAAAGAGACTCCGGACAGTGATCTTGGCACCAACTAG
 GGTGTGCTGCTGCTGAGATGGAGGAGGCCTTGAGAGGACTTCCGGTGCCTTACATGACAACAGCAG
 TCAACGTCACCCATTCTGGGACAGAAATCGTTGATTGATGTGCCATGCCACTTTCACCTCACGCTT
 ACTACAACCCATCAGAGTCCCTAATTACAATCTCTACATCATGGATGAAGCCCACTTCACAGACCC
 CTCAAGTATAGCTGCAAGAGGATATATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTT
 25 TTATGACTGCCACACCACCAGGAACCCGTGATGCGTTTCCTGACTCTAACTACCAATCATGGACA
 CAGAAGTGGAAGTCCCAGAGAGAGCCCTGGAGCTCAGGCTTTGATTGGGTGACAGACCATTCTGGG
 AAAACAGTTTGGTTTCGTTCCAAGCGTGAGAAACGGAAATGAAATCGCAGCCTGTCTGACAAAGGC
 TGGAAGCGGGTCATACAGCTCAGCAGGAAGACTTTTGAGACAGAATTCAGAAAACAAAAATC
 AAGAGTGGGACTTTGTCTATAACAACTGACATCTCAGAGATGGGCGCCAACCTCAAGGCTGACCGG
 30 GTCATAGACTCTAGGAGATGCCTAAAACCAGTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGG
 CCCATGCCTGTCACGCATGCTAGTGCTGCTCAGAGGAGAGGACGTATAGGCAGGAACCCCTAACAA
 ACCTGGAGATGAGTACATGTATGGAGGTGGGTGTGCAGAGACTGATGAAGGCCATGCACACTGGC
 TTGAAGCAAGAATGCTTCTTGACAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGGC
 CTGAGGCCGATAAGGTAGCCGCCATTGAGGGAGAGTTTAAGCTGAGGACAGAGCAAAGGAAGAC
 35 CTTCTGTGAACCTCATGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGG
 AATAACTTACACAGACAGAAAGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACA
 GCGTACCAGCAGAGGTGTGGACAAAGTATGGAGAGAAGAGAGTGCTCAAACCGAGATGGATGGA
 TGCTAGGGTCTGTTTCAGACCATGCGGCCCTGAAGTCGTTCAAAGAATTCGCCGCTGGAAAAAGAG
 GAGCGGCTTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAG
 40 GAAGCCATTGACAACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGC
 GGCAGCCCAACTGCCGGAGACCCTAGAGACCATTATGCTCTTAGGTTTGCTGGGAACAGTTTCACT
 GGGGATCTTCTTCGTCTTGATGCGGAATAAGGGCATCGGGAAGATGGGCTTTGGAATGGTAACCCT
 TGGGGCCAGTGCATGGCTCATGTGGCTTTCGGAAATTGAACCAGCCAGAATTGCATGTGTCTCAT
 TGTTGTGTTTTTATTACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAGATCTCCCCAAGATAA
 45 CCAGATGGCAATTATCATCATGGTGGCAGTGGGCCTTCTAGGTTTGATAACTGCAAACGAACCTGG
 ATGGCTGGAAAGAACAAAAATGACATAGCTCATTAATGGGAAGGAGAGAAGAAGGAGCAACC
 ATGGGATTCTCAATGGACATTGATCTGCGGCCAGCCTCCGCCTGGGCTATCTATGCCGCATTGACA
 ACTCTCATCACCCAGCTGTCCAACATGCGGTAACCACTTCATACAACAACACTACTCCTTAATGGCG
 ATGGCCACACAAGCTGGAGTGCTGTTTGGCATGGGCAAAGGGATGCCATTTTATGCATGGGACCTT
 50 GGAGTCCCGCTGCTAATGATGGGTTGCTATTCACAATTAACACCCCTGACTCTGATAGTAGCTATC
 ATTCTGCTTGTGGCGCACTACATGTACTTGATCCCAGGCCTACAAGCGGCAGCAGCGCTGCTGCC
 CAGAAAAGGACAGCAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAACCTGACAT
 TGACACAATGACAATAGACCCCAAGGTGGAGAAGAAGATGGGACAAGTGTTACTCATAGCAGTAG
 CCATCTCCAGTGTCTGTGCTGCTGCGGACCGCCTGGGGATGGGGGGAGGCTGGAGCTCTGATCACA
 GCAGCGACCTCCACCTTGTGGGAAGGCTCTCCAAACAATACTGGAACCTCTACAGCCACCTCA
 55 CTGTGCAACATCTTCAGAGGAAGCTATCTGCAAGAGAGCTTCCCTTATCTATACAGTGACGAGAAAC
 GCTGGCCTGGTTAAGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTC
 GTCTGAATCAGATGTCGGCCCTGGAGTTCTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTA

GAGAGGAGGCTCGCCGTGCCCTCAAGGATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGA
 AGTGCAAAGCTCAGATGGTTGGTGGAGAGAGGATATCTGCAGCCCTATGGGAAGGTTGTTGACCT
 CGGATGTGGCAGAGGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGCAGGAGGTGAGAG
 5 GATACACAAAGGGAGGTCCCGGTCATGAAGAACCCATGCTGGTGCAAAGCTATGGGTGGAACATA
 GTTCGTCTCAAGAGTGGAGTGGACGTCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGT
 GACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAAGAGACACGAACACTCAGAGTGCTCTCTAT
 GGTGGGGGACTGGCTTGAAAAAAGACCAGGGGCCTTCTGTATAAAGGTGCTGTGCCCATACACCA
 GCACTATGATGGAAACCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATTAGTCAGAGTGCCA
 10 TTGTCTCGCAACTCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAAG
 TGTGTCCACCACAAGTCAGCTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATG
 AGGAGGATGTGAACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATG
 AAAATCATCGGCAGGCGCATTGAGAGAATCCGCAATGAACATGCAGAAACATGGTTTCTTGATGA
 AAACCACCATAACAGGACATGGGCCTACCATGGGAGCTACGAAGCCCCACGCAAGGATCAGCGT
 15 CTTCCCTCGTGAACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGAGTTACAG
 GAATAGCCATGACTGACACCACACCATAACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACC
 AGGGTGCCAGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTCTTCTGCTGTGGAA
 GGAGCTGGGGAAACGCAAGCGGCCACGCGTCTGCACCAAAGAAGAGTTTATCAACAAGGTGCGC
 AGCAATGCAGCACTGGGAGCAATATTTGAAGAGGAAAAAGAATGGAAGACGGCTGTGGAAGCTG
 20 TGAATGATCCAAGGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACACCACCTGAGAGGAGAGTGT
 CACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAGCAAGGAGAGTTCCGGGAAAGCAA
 AAGGTAGCCGCGCCATCTGGTACATGTGGTTGGGAGCCAGATTCTTGGAGTTTGAAGCCCTTGGAT
 TCTTGAACGAGGACCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTCCAAGGGTTAGGATTG
 CAAAGACTTGGATACATTCTAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATG
 25 AACTGCTGGCTGGGACACCCGCATTAGTAAGTTTGATCTGGAGAATGAAGCTCTGATTACCAACC
 AAATGGAGGAAGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATACACATACCAAAAACAAAGTG
 GTGAAGGTTCTCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAGACCA
 GAGAGGGAGTGGACAAGTTGTCACTTATGCTCTCAACACATTCACCAACTTGGTGGTGCAGCTTAT
 CCGGAACATGGAAGCTGAGGAAGTGTTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGA
 AAGTGACCAGATGGTTGCAGAGCAATGGATGGGATAGACTCAAACGAATGGCGGTCAGTGGAGAT
 30 GACTGCGTTGTGAAGCCAATCGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGACATGGGA
 AAAGTTAGGAAAGACACACAGGAGTGGAAACCCCTCAGACTGGATGGAGCAATTGGGAAGAAGTCC
 CGTTCTGCTCCCACCACCTTCAACAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCC
 GCCACCAAGATGAAGTGAATGATTGGCCGAGCTCGCTCTCACCAGGGGCAGGATGGAGCATCCGGGAG
 ACTGCCTGTCTTGCAAAATCATATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTT
 35 CGACTGATGGCTAATGCCATTTGCTCGGCTGTGCCAGTTGACTGGGTACCAACTGGGAGAACCACC
 TGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAGGACATGCTCATGGTGTGGAATAGAGT
 GTGGATTGAGGAGAACGACCATATGGAGGACAAGACTCCTGTAAACAAAATGGACAGACATTCCCT
 ATCTAGGAAAAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCCTTGG
 GCTGAAAACATCAAAGACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACAT
 40 GGACTATCTATCCACCCAAGTCCGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTGTAAGC
 ACCAATTTTAGTGTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAGCTGTGCAGCCTGTAAC
 CCCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAA
 GCCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAAGCGCA
 GGATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGACTAGCT
 45 GTGAATCTCCAGCAGAGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATT
 GACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCG
 AACAGCGGCGGCCGGTGTGGGGAAATCCATGGTTTCT

AY632535.2 NC_012532.1 Zika virus strain MR 766, Uganda, complete genome (SEQ ID

50 NO: 12)

AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTTCGAGTCTGAAGCGAGAGCTAACAACAGTATC
 AACAGGTTTAATTTGGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCCAAGAAGAAATCC
 GGAGGATCCGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTAACCCCTTGGGAGGTTTG
 AAGAGGTTGCCAGCCGACTTCTGCTGGGTCATGGACCATCAGAATGGTTTTGGCGATACTAGCC
 55 TTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTTCCGTGGGGAAA

AAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAA
 TGCTAGGAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGA
 CTACAGCCATGGCAGCAGAGATCACTAGACGCGGGAGTGCATACTACATGTACTTGGATAGGAGC
 5 GATGCCGGAAGGCCATTTTCGTTTGCTACCACATTGGGAGTGAACAAGTGCCACGTACAGATCAT
 GGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGCCCTATGCTGGATGAGGGAGTGG
 AACCAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTACGGAACCTGTCATC
 AAAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAG
 10 TTGCAAACGCGGTCGCAGACCTGGTTAGAATCAAGAGAAATACACGAAGCACTTGATCAAGGTTGA
 AAACCTGGATATTCAGGAACCCCGGGTTTGCGCTAGTGGCCGTTGCCATTGCCTGGCTTTTGGAAG
 CTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATACAGTATCAG
 GTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTGAGGTGGGACCTGGGTTGATGTTG
 TCTTGGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTCGACATAGAGTTG
 GTCACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGA
 15 CATGGCTTCGGACAGTCGTTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTC
 AATATGTCTGCAAAAAGAACATTAGTGGACAGAGGTTGGGGAAACGGTTGTGGACTTTTTGGCAAA
 GGGAGCTTGGTGACATGTGCCAAGTTTACGTGTTCTAAGAAGATGACCGGGAAGAGCATTCAACC
 GGAAATCTGGAGTATCGGATAATGCTATCAGTGCATGGCTCCCAGCATAGCGGGATGATTGGAT
 ATGAACTGACGAAGATAGAGCGAAAGTCGAGGTTACGCCTAATTCACCAAGAGCGGAAGCAAC
 20 CTTGGGAGGCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCTTGACTTTTCAGATCT
 GTATTACCTGACCATGAACAATAAGCATTGGTTGGTGACAAAAGAGTGGTTTCATGACATCCCAT
 GCCTTGGCATGCTGGGGCAGACACCGGAACTCCACACTGGAACAACAAAGAGGCATTGGTAGAAT
 TCAAGGATGCCACGCCAAGAGGCAAACCGTCGTCTGTTGTTGGGGAGCCAGGAAGGAGCCGTTTAC
 ACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTTCTCTGGCCA
 25 TTTGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTCATATTCCTTGTGCACTGC
 GGCATTCACATTCACCAAGGTCCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGGTGCAGT
 ATGCAGGGACAGATGGACCTGCAAGATCCCAGTCCAGATGGCGGTGGACATGCAGACCCTGACC
 CCAGTTGGAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGCACTGAGAACTCAAAGATGAT
 GTTGGAGCTTGACCCACCATTGTTGGGATTCTTACATTGTCATAGGAGTTGGGGACAAGAAAATCAC
 30 CCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCACTGTGAGAGGGGCCA
 AGAGAATGGCAGTCTTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCAACTCA
 CTGGGTAAGGGCATTACACAGATTTTTGGAGCAGCCTTCAAATCACTGTTTGGAGGAATGTCCTGG
 TTCTCACAGTCTCATAGGCACGCTAGTGTGGTTGAGTTTGAACACAAAGAATGGATGATCTATC
 35 TCCCTCACATGCTTGGCCCTGGGGGAGTGATGATCTTCCCTCTCCACGGCTGTTCTGCTGACGTGG
 GGTGCTCAGTGGACTTCTCAAAAAGGAAACGAGATGTGGCACGGGGGTATTTCATCTATAATGAT
 GTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGGCAGCAGCAGT
 CAAGCAGGCCTGGGAAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAAAACATCATGT
 GGAAATCAGTAGAAGGGGAGCTCAATGCTATCCTAGAGGAGAATGGAGTTCAACTGACAGTTGTT
 GTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAAAGATTGCCAGTGCTGTGAATGAGCT
 40 GCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGCGGCAAGACCAACAACAGTT
 TTGTTGTGACGGTGACACACTGAAGGAATGTCCGCTTGAGCACAGAGCATGGAATAGTTTCTTG
 TGGAGGATCACGGGTTTGGAGTCTTCCACACCAGTGTCTGGCTTAAGGTCAGAGAAGATTACTCAT
 TAGAATGTGACCCAGCCGTCATAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGCACAGTGATCTG
 GGCTATTGGATTGAAAGTGAAAAGAATGACACATGGAGGCTGAAGAGGGCCCACCTGATTGAGAT
 45 GAAAACATGTGAATGGCCAAAGTCTCACACATTGTGGACAGATGGAGTAGAAGAAAGTGATCTTA
 TCATACCCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGGTTACAGAACCCAA
 GTGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATCCGGTTTGAGGAATGTCCAGGCACCAAGGT
 TTACGTGGAGGAGACATGCGGAACTAGAGGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGG
 TCATTGAGGAATGGTGCTGTAGGGAATGCACAATGCCCCACTATCGTTTCGAGCAAAAAGACGGC
 50 TGCTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAGAGCAACTTAGTGAGGTCAATGGT
 GACAGCGGGGTCAACCGATCATATGGACCACTTCTCTTGGAGTGCTTGTGATTCTACTCATGGT
 GCAGGAGGGGTGAAGAAGAGAATGACCACAAAGATCATCATGAGCATCAATGGCAGTGCTG
 GTAGTCATGATCTTGGGAGGATTTCAATGAGTGACCTGGCCAAGCTTGTGATCCTGATGGGTGCT
 ACTTTCGCAGAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTTAAAGTC
 55 AGACAGCCCTTGCTGGTCTCCTTCAATTTTCAGAGCCAATTTGGACACCCCGTGAGAGCATGCTGCTA
 GCCCTGGCTTCGTGTCTCTGCAAACTGCGATCTCTGCTCTTGAAGGTGACTTGATGGTCTCTCATT
 ATGGATTTGCTTTGGCTTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGACAACATCGCTC
 TACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAGCGGGCC

TGGCTACTTGTGGAGGGATCATGCTCCTCTCCCTGAAAAGGAAAGGTAGTGTGAAGAAGAACCTG
 CCATTTGTTCATGGCCCTGGGATTGACAGCTGTGAGGGTAGTAGACCCTATTAATGTGGTAGGACTA
 CTGTTACTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGTGAAGTTCTCACAGCCGTTGGCCTG
 5 ATATGTGCACTGGCCGGAGGGTTTGCCAAGGCAGACATTGAGATGGCTGGACCCATGGCTGCAGT
 AGGCTTGCTAATTGTCAGCTATGTGGTCTCGGAAAGAGTGTGGACATGTACATTGAAAGAGCAG
 GTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCCTCGGCTTGACGTGGCACTG
 GATGAGAGTGGTGACTTCTCCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAGATCATACTCAA
 GGTGGTCTGATGGCCATCTGTGGCATGAACCCAATAGCTATACCTTTTGTCTGCAGGAGCGTGGTA
 10 TGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGGGACGTGCCTGCTCCCAAAGAAGTGA
 AGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGATGACTCGCAGACTGCTAGGTTCAACACA
 GGTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTACAAAAGGAGCCG
 CACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAGGACTTGGTGTCA
 TACTGTGGGCCCTTGGAAGTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACAGCTTTTGGCCGTA
 15 CCTCCCGGAGAGAGGGCCAGAAACATTACAGACCCTGCCTGGAATATTCAAGACAAAGGACGGGGA
 CATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGACCTCAGGATCTCCGATCCTAGACAAATGTGG
 AAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAATGGAAGCTATGTTAGTGCTATAA
 CCCAGGGAAAGAGGGAGGAGGAGACTCCGGTTGAATGTTTCGAACCCTCGATGCTGAAGAAGAA
 GCAGCTAACTGTCTTGGATCTGCATCCAGGAGCCGAAAAACCAGGAGAGTCTTCTGAAATAG
 20 TCCGTGAAGCCATAAAAAAGAGACTCCGGACAGTGATCTTGGCACCAACTAGGGTTGTGCTGCT
 GAGATGGAGGAGGCCTTGAGAGGACTTCCGGTGCCTTACATGACAACAGCAGTCAACGTCACCCA
 TTCTGGGACAGAAATCGTTGATTTGATGTGCCATGCCACTTTCACCTTCACGCTTACTACAACCCATC
 AGAGTCCCTAATTACAATCTCAACATCATGGATGAAGCCCACTTCACAGACCCCTCAAGTATAGCT
 GCAAGAGGATACATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTTTTATGACTGCCAC
 25 ACCACCAGGAACCCGTGATGCGTTTCTGACTCTAACTCACCAATCATGGACACAGAAGTGGAAAG
 TCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACAGACCATTCTGGGAAAACAGTTTGG
 TTCGTTCCAAGCGTGAGAAACGGAAATGAAATCGCAGCCTGTCTGACAAAGGCTGGAAAGCGGGT
 CATAAGCTCAGCAGGAAGACTTTTGAGACAGAAATTCAGAAAACAAAAATCAAGAGTGGGACT
 TTGTCATAAACAAGTACATCTCAGAGATGGGCGCCAACCTCAAGGCTGACCGGGTCATAGACTCTA
 30 GGAGATGCCTAAAACCAGTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGGCCCATGCCTGTCA
 CGCATGCTAGTGCTGCTCAGAGGAGAGGACGTATAGGCAGGAACCCTAACAAACCTGGAGATGAG
 TACATATTGAGAGGTGGGTGTGCAGAGACTGATGAAGGCCATGCACACTGGCTTGAAGCAAGAAT
 GCTTCTTGACAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGGCTGAGGCCGATAA
 GGTAGCCGCCATTGAGGGAGAGTTTAAGCTGAGGACAGAGCAAGGAAGACCTTCGTGGAACCTCA
 35 TGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGGAATAACTTACACAG
 ACAGAAGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACAGTGTACCAGCAGAG
 GTTTGGACAAAGTATGGAGAGAAGAGAGTGCTCAAACCGAGATGGATGGATGCTAGGGTCTGTTC
 AGACCATGCGGCCCTGAAGTCGTTCAAAGAATTCGCCGCTGGAAAAAGAGGAGCGGCTTTGGGAG
 TAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAGGAAGCCATTGACAAC
 40 CTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGCGGCAGCCCAACTGCC
 GGAGACCCTAGAGACCATTATGCTCTTAGGTTTGTCTGGGAACAGTTTCACTGGGGATCTTCTTCGT
 CTTGATGCGGAATAAAGGCATCGGGAAGATGGGCTTTGGAATGGTAACCCCTGGGGCCAGTGCAT
 GGCTCATGTGGCTTTTCGGAATTTGAACCAGCCAGAATTGCATGTGTCCTCATTGTTGTGTTTTATT
 ACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAGATCTCCCCAAGATAACCAGATGGCAATTA
 45 TCATCATGGTGGCAGTGGGCCTTCTAGGTTTGATAACTGCAAACGAACTTGGATGGCTGGAAAGA
 ACAAAAAATGACATAGCTCATCTAATGGGAAGGAGAGAAGAAGGAGCAACCATGGGATTCTCAA
 TGGACATTGATCTGCGGCCAGCCTCCGCTGGGCTATCTATGCCGCATTGACAACTCTCATCACCC
 CAGCTGTCCAACATGCGGTAACCACTTCATACAACAACACTACTCCTTAATGGCGATGGCCACACAAG
 CTGGAGTGCTGTTTGGCATGGGCAAAGGGATGCCATTTATGCATGGGGACCTTGGAGTCCCGCTGC
 50 TAATGATGGGTTGCTATTACAATTAACACCCCTGACTCTGATAGTAGCTATCATTCTGCTTGTGGC
 GCACTACATGTACTTGATCCCAGGCCTACAAGCGGCAGCAGCGCGTGCTGCCAGAAAAGGACAG
 CAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAAGTACATTGACACAATGACA
 ATAGACCCCCAGGTGGAGAAGAAGATGGGACAAGTGTTACTCATAGCAGTAGCCATCTCCAGTGC
 TGTGCTGCTGCGGACCGCCTGGGGATGGGGGAGGCTGGAGCTCTGATCACAGCAGCGACCTCCA
 CCTTGTGGGAAGGCTCTCCAAACAATACTGGAACCTCTACAGCCACCTCACTGTGACACATCT
 55 TCAGAGGAAGCTATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAGAACCGCTGGCCTGGTTA
 AGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTCGTCTGAATCAGAT
 GTCGGCCCTGGAGTTCTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCG

CCGTGCCCTCAAGGATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAAGATCA
 GATGGTTGGAGGAGAGAGGATATCTGCAGCCCTATGGGAAGGTTGTTGACCTCGGATGTGGCAGA
 GGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGCAAGGAGGTGAGAGGATACACAAAGG
 GAGGTCCCGGTCAATGAAGAACCCATGCTGGTGCAAAGCTATGGGTGGAACATAGTTCGTCTCAAG
 5 AGTGGAGTGGACGTCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAG
 TCATCATCTAGTCCTGAAGTGAAGAGACACGAACACTCAGAGTGCTCTCTATGGTGGGGGACTG
 GCTTGAAAAAAGACCAGGGGCCTTCTGTATAAAGGTGCTGTGCCCATACACCAGCACTATGATGG
 AAACCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATTAGTCAGAGTGCCATTGTGTGCGCAAC
 10 TCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAAGTGTGTCCACCAC
 AAGTCAGTCTCCTCGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGAGGAGGATGTGA
 ACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAAATCATCGGC
 AGGCGCATTGAGAGAATCCGCAATGAACATGCAGAAACATGGTTTCTTGATGAAAACACCCATA
 CAGGACATGGGCCCTACCATGGGAGCTACGAAGCCCCACGCAAGGATCAGCGTCTTCCCTCGTGA
 ACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGAGTTACAGGAATAGCCATG
 15 ACTGACACCACACCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACCAGGGTGCCAG
 ATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTCTTCTGCTGTGGAAGGAGCTGGGG
 AAACGCAAGCGGCCACGCGTCTGCACCAAGAAGAGTTTATCAACAAGGTGCGCAGCAATGCAGC
 ACTGGGAGCAATATTTGAAGAGGAAAAAGAATGGAAGACGGCTGTGGAAGCTGTGAATGATCCA
 AGGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACACCACCTGAGAGGAGAGTGTACAGCTGTGT
 20 GTACAACATGATGGGAAAAAGAGAAAAAGCAAGGAGAGTTTCGGGAAAGCAAAAGGTAGCCGC
 GCCATCTGGTACATGTGGTTGGGAGCCAGATTCTTGGAGTTTGAAGCCCTTGGATTCTTGAACGAG
 GACCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTCGAAGGGTTAGGATTGCAAAGACTTG
 GATACATTCTAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATGACACTGCTGGC
 TGGGACACCCGCATTAGTAAGTTTGATCTGGAGAATGAAGCTCTGATTACCAACCAAATGGAGGA
 25 AGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATACACATACCAAAAACAAAGTGGTGAAGGTTT
 TCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAGACCAGAGAGGGAG
 TGGACAAGTTGTCACTTATGCTCTCAACACATTCACCAACTTGGTGGTGCAGCTTATCCGGAACAT
 GGAAGCTGAGGAAGTGTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGAAAGTGACCA
 GATGGTTGCAGAGCAATGGATGGGATAGACTCAAACGAATGGCGGTCACTGGAGATGACTGCGTT
 30 GTGAAGCCAATCGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGACATGGGAAAAGTTAG
 GAAAGACACACAGGAGTGGAACCCCTCGACTGGATGGAGCAATTGGGAAGAAGTCCCCTTCTGCT
 CCCACCACTTCAACAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTCCCGCCACCAAG
 ATGAAGTATTGGCCGAGCTCGCGTCTCACCAGGGGCAGGATGGAGCATCCGGGAGACTGCCTGT
 CTTGCAAAATCATATGCGCAGATGTGGCAGCTCCTTTATTTCACAGAAGAGACCTTCGACTGATG
 35 GCTAATGCCATTTGCTCGGCTGTGCCAGTTGACTGGGTACCAACTGGGAGAACCACCTGGTCAATC
 CATGGAAAGGGAGAATGGATGACCACTGAGGACATGCTCATGGTGTGGAATAGAGTGTGGATTGA
 GGAGAACGACCATATGGAGGACAAGACTCCTGTAAACAAAATGGACAGACATTCCCTATCTAGGAA
 AAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCCTTGGGCTGAAAAC
 ATCAAAGACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCT
 40 ATCCACCCAAGTCCGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTGTAAGCACCATTCTT
 AGTGTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAGCTGTGCAGCCTGTAACCCCCCAGG
 AGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTG
 CCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGGAAGCGCAGGATGGGAA
 AAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGACTAGCTGTGAATCTCC
 45 AGCAGAGGGGACTAGTGGTTAGAGGAGACCCCCGGAAAACGCAAAACAGCATATTGACGTGGGA
 AAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAACCTCGGGC
 GCCGGTGTGGGGAAATCCATGGTTTCT

>Chimeric Asian ZIKV Sequence H/PF/2013 polyprotein flanked with consensus sequence

50 from other strains (SEQ ID NO: 13)

GTTGTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCA
 ACAGGTTTTATTTTGGATTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCG
 GAGGATTCCGGATTGTCAATATGCTAAAAACGCGGAGTAGCCCGTGTGAGCCCCCTTTGGGGGCTTGA
 AGAGGCTGCCAGCCGACTTCTGCTGGGTGATGGGCCCATCAGGATGGTCTTGGCGATTCTAGCCT
 55 TTTTGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCACTGGGGAAAA

AAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAAGATCTGGCTGCCATGCTGAGAATAATCAAT
 GCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTCGGAATTGTTGGCCTCCTGCTGAC
 CACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACG
 ACGCTGGGGAGGCCATATCTTTTCCAACCACATTGGGGATGAATAAGTGTTATATACAGATCATGG
 5 ATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA
 CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAC
 AAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCCATTCCACTAGGAAGCT
 GCAAACGCGGTGCAAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAA
 ATTGGATATTCAGGAACCCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCT
 10 CAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGT
 GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCT
 TGGAAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTT
 ACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACAT
 GGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAAT
 15 ATGTCTGCAAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTGGCAAAGGG
 AGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGA
 GAATCTGGAGTACCGGATAATGCTGTGAGTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGA
 CACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCC
 GAAGCCACCCTGGGGGGTTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTT
 20 TCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGAC
 ATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAACTCCACACTGGAACAACAAAGAAGCACT
 GGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTTCGTGGTTCTAGGGAGTCAAGAAGGAG
 CAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCC
 TCTGGCCACTTGAAATGTGCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTG
 25 TGTACCGCAGCGTTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGGA
 GGTACAGTACGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAAA
 CTCTGACCCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTA
 AGATGATGCTGGAACCTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAG
 30 AGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTC
 TCAACTCATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAA
 TGTCTGGTTCTCACAATTTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGTATG
 GATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGTGTCTCTGC
 TGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTTCGTCT
 35 ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCA
 GCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAAGAATGGAAAA
 CATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGA
 CGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTG
 AACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTCAGAGCAGCAAAGACAAA
 40 TAACAGCTTTGTGCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACA
 GCTTTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAG
 ATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACA
 GTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGGCCATCTG
 ATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGA
 45 GTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACA
 GGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGC
 ACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAG
 CGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAATGCCCCACTGTGCTTCCGGGGCTA
 AAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGTAACCTTAGTAAG
 50 GTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCT
 GCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCGATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTG
 ATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGTGATAGCGGC
 ATTCAAAGTCAGACGAGCGTTGCTGGTATCTTTACATCTTCAGAGCTAATTGGACACCCCGTGAAAG
 55 CATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAAATCGGATCTCCGCTTGGAAGGCGACCTGAT
 GGTCTCATCAATGGTTTGTCTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGAT
 AACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGG

AGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAA
 GAAGAACTTACCATTTGTTCATGGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGT
 GGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAG
 CTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCC
 5 ATGGCCGCGTTCGGTCTGCTAATTGTTCAGTTACGTGGTCTCAGGAAAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCG
 ATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAG
 ATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATACCCCTTTCAGCT
 GGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCC
 10 CAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTC AACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTAC
 AAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAG
 GATCTGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCA
 GCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAATATTTAAGA
 15 CAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTTCAGGATCTCCAATC
 CTAGACAAGTGTGGGAGAGTGTAGGACTTTATGGCAATGGGGTCTGATCAAAAATGGGAGTTA
 TGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGTCTTCGAGCCTTCGA
 TGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTT
 CTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGG
 20 GTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCCTTATATGACAACAGCAGTC
 AATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACCTCACGTCTA
 CTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCC
 TCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTT
 CATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACAC
 25 CGAAGTGGAAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAA
 AAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCT
 GGAAAACGGGTCATACAGCTCAGCAGAAAAGACTTTTGGAGACAGAGTTCCAGAAAACAAAACATCA
 AGAGTGGGACTTTGTCTGACAACCTGACATTTTCAGAGATGGGCGCAACTTTAAAGCTGACCGTGT
 CATAGATTCCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGAC
 30 CCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAA
 CCTGGAGATGAGTATCTGTATGGAGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCT
 TGAAGACAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACC
 TGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 TTTGTGGAACCTCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGA
 35 ATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAG
 TGTGCCGCGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGTCTCAAACCGAGGTGGATGGAC
 GCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGAGG
 AGCGGCTTTTGGAGTGTGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGG
 AAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCG
 40 GCGGCCCAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTG
 GGAATCTTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTT
 GGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATT
 GTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAAC
 CAAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGA
 45 TGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCA
 TAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAA
 CTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACCTACTCCTTAATGGCGA
 TGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTG
 GAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCATCA
 50 TTTTGTCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCTGCC
 AGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATT
 GACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGC
 CGTCTCCAGCGCCATACTGTGCGGAGCCGCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAG
 CGGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCAC
 55 TGTGTAACATTTTATGGGGAAGTTACTTGGCTGGAGTTCTCTAATCTACACAGTAACAAGAAACG
 CTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCG
 CTTGAACCAGATGTGCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAG

AGAAGAGGCCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAA
 GTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTT
 GGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGG
 5 ATACACAAAAGGAGGGCCCTGGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACATAG
 TCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATG
 GTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCAG
 CACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCAC
 10 TCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAAAAGT
 GTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCCAGGAGGCCAGTGAAATATGA
 GGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGA
 AGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAG
 AACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTC
 CTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCCTGGGATGTGGTGACTGGAGTCACAGG
 15 AATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTA
 GGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAG
 AGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGC
 AATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGAAGACTGCAGTGGAAGCTGTGA
 ACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCA
 20 GAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAAGGCCAAG
 GGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCT
 TTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACA
 CTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAA
 25 ATGGAGAAAGGGCACAGGGCCCTTGGCATTGGCCATAATCAAGTACACATACCAAAAACAAAGTGGT
 AAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACCTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTC
 GGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAA
 GTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGA
 30 TTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGAAA
 AGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCG
 TTTTGCTCCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 CACCAAGATGAACTGATTGGCCGGGCCCCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGAC
 TGCTTGCTAGCAAAATCATATGCGCAAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCG
 35 ACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAACCTGGGAGAACTACCTG
 GTCATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAAACAGAGTGT
 GGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTCCCTAT
 TTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGC
 TGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGG
 40 ACTACCTATCCACCCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCAC
 CAATCTTAGTGTGTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCC
 CCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGC
 CATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGG
 ATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGT
 45 GGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCCCCCGGAAAACGCAAAACAGCATATTG
 ACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGA
 ATAGCGGCGGCCGGTGTGGGGAAATCC

50 In some embodiments, the Zika virus has a RNA genome corresponding to the DNA
 sequence provided by the nucleic acid sequence of any one of SEQ ID NOs: 2-13. In some
 embodiments, the Zika virus has a variant genome that is at least 80%, 81%, 82%, 83%, 84%,

85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-13.

Provided below are amino acid sequences of the E-proteins of Zika strains that may
5 be used in the methods, compositions, and/or vaccines described herein.

isol-ARB15076.AHF49784.1.Central_African_Republic/291-788 Flavivirus envelope glycoprotein E. (SEQ ID NO: 14)

10 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLYYLTMMN
KHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGAL
EAEMDGAKGRLFSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCK
15 VPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSTIGK
AFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGL
NTKNGSISLTCLALGGVMIFLSTAVSA

isol-IbH_30656.AEN75265.1.Nigeria/291-788 Flavivirus envelope glycoprotein E. (SEQ ID NO: 15)

20 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDENRAKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLYYLTMMN
KHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGAL
EAEMDGAKGRLSSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGRDGPCK
25 VPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSIIGK
AFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGL
NTKNGSISLTCLALGGVMIFLSTAVSA

ArB1362.AHL43500.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 16)

30 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDXXXXXXNRAEVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLFSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
GTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWH
35 RSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIG
TLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD128000.AHL43502.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 17)

40 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMXXXXXGHETDENRAKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMMNKHRLVRKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLFSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
GTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWL
45 KKGSSIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKVHQIFGAAFKSLFGGMSWFSQILIG
TLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD158095.AHL43505.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 18)

50 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSGMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLY
YLTMMNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAKGRLFSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
DGPCCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS

GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD158084.AHL43504.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 19)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSQMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAKGRLFSGHLKCRCLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
DGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-ARB13565.AHF49783.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 20)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSQMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAKGRLFSGHLKCRCLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
DGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-ARB7701.AHF49785.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 21)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSQMIVNDIGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYY
LTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
LAGALEAEMDGAKGRLFSGHLKCRCLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGT
DGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRS
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-ArD_41519.AEN75266.1.Senegal/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 22)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGRLFSGHLKCRCLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
GTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWH
RSGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIG
TLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

MR766-NIID.BAP47441.1.Uganda/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 23)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
LEYRIMLSVHGSQHSQMIVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAKGKLFSGHLKCRCLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
GTDGPCKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWH
SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

LC002520.1/326-829 Zika virus genomic RNA, strain: MR766-NIID, Uganda, Flavivirus envelope glycoprotein E. (SEQ ID NO: 24)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 5 ALAGALEAEMDGAAGKGLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
 GTDGPCKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHR
 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

isol-MR_766.AEN75263.1.Uganda/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 25)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 10 ALAGALEAEMDGAAGKGLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYA
 GTDGPCKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHR
 15 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

ArD7117.AHL43501.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 26)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 20 LTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTA
 LAGALEAEMDGAAGKGLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHR
 25 SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
 LVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

AY632535.2/326-825 NC_012532.1 Zika virus strain MR 766, Uganda, Flavivirus envelope glycoprotein E. (SEQ ID NO: 27)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 30 NTKHNLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAG
 ALEAEMDGAAGKGLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGP
 CKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSTI
 35 GKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLVW
 LGLNTKNGSISLTCLALGGVMIFLSTAVSA

MR_766.AAV34151.1.Uganda/291-790 Flavivirus envelope glycoprotein E.

IQ32ZE1|Q32ZE1_9FL (SEQ ID NO: 28)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 40 NTKHNLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAG
 ALEAEMDGAAGKGLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGP
 CKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSTI
 45 GKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLVW
 LGLNTKNGSISLTCLALGGVMIFLSTAVSA

MR_766.YP_009227198.1.Uganda/1-500 envelope protein E [Zika virus] (SEQ ID NO: 29)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSGMTVNDIGYETDENRAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 50 NTKHNLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAG
 ALEAEMDGAAGKGLFSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGP
 CKIPVQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSTI
 55 GKAFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLVW
 LGLNTKNGSISLTCLALGGVMIFLSTAVSA

KU681081.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand, Flavivirus envelope glycoprotein E. (SEQ ID NO: 30)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHTGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITEGTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 SGSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGVLNSLKGKIHQIFGA AFKSLFGGMSWFSQILIGT
 LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Zika_virus% H.sapiens-tc% THA% 2014% SV0127- _14.AMD61710.1.Thailand/291-794
 Flavivirus envelope glycoprotein E. (SEQ ID NO: 31)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHTGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITEGTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 SGSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGVLNSLKGKIHQIFGA AFKSLFGGMSWFSQILIGT
 LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

CK-ISL_2014.AIC06934.1.Cook_Islands/1-504 Flavivirus envelope glycoprotein E. (Fragment)
 OS=Zika virus GN=E PE=4 SV=1 (SEQ ID NO: 32)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHTGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITEGTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLKGKIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

Natal_RGN.AMB18850.1.Brazil:_Rio_Grande_do_Norte,_Natal/291-794 Flavivirus envelope
 glycoprotein E.] (SEQ ID NO: 33)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHTGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITEGTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLKGKIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Si323.AMC37200.1.Colombia/1-504 Flavivirus envelope glycoprotein E. (SEQ ID NO: 34)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHTGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAKGRLSSGHLKCRKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITEGTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLKGKIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

KU707826.1/317-820 Zika virus isolate SSABR1, Brazil, Flavivirus envelope glycoprotein E.
 (SEQ ID NO: 35)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHTGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT

ALAGALEAEMDGA KGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- 5 KU509998.1/326-829 Zika virus strain Haiti/1225/2014, Haiti, Flavivirus envelope glycoprotein E. (SEQ ID NO: 36)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 10 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQT VVVVLGSQEGAVHT
 ALAGALEAEMDGA KGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- 15 isol-GDZ16001.AML82110.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 37)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 20 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQT VVVVLGSQEGAVHT
 ALAGALEAEMDGA KGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- 25 BeH819015.AMA12085.1.Brazil/291-794 Flavivirus envelope glycoprotein E.] (SEQ ID NO: 38)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 30 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQT VVVVLGSQEGAVHT
 ALAGALEAEMDGA KGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- 35 MRS_OPY_Martinique_PaRi_2015.AMC33116.1.Martinique/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 39)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 40 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQT VVVVLGSQEGAVHT
 ALAGALEAEMDGA KGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- 45 KU501215.1/308-811 Zika virus strain PRVABC59, Puerto Rico, Flavivirus envelope glycoprotein E. (SEQ ID NO: 40)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTG HETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 50 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQT VVVVLGSQEGAVHT
 ALAGALEAEMDGA KGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

- 55 Haiti%1225%2014.AMB37295.1.Haiti/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 41)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 5 ALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

KU527068.1/308-811 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal,

10 Flavivirus envelope glycoprotein E. (SEQ ID NO: 42)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 15 ALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Z1106027.ALX35662.1.Suriname/5-508 Flavivirus envelope glycoprotein E. (SEQ ID NO: 43)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 20 ALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-FLR.AMM39804.1.Colombia:_Barranquilla/291-794 Flavivirus envelope glycoprotein E.
 (SEQ ID NO: 44)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 30 ALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

PLCal_ZV_isol-From_Vero_E6_cells.AHL37808.1.Canada/254-757 Flavivirus envelope
 glycoprotein E. (SEQ ID NO: 45)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 40 ALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSVGGALNSLKGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

BeH818995.AMA12084.1.Brazil/291-794 Flavivirus envelope glycoprotein E. [Zika virus].

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNCGFLFGKGS�VTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 50 ALAGALEAEMDGAKGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR

GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

H/PP/2013.AHZ13508.1.French_Polynesia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 47)

5 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
10 ALAGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

PRVABC59.AMC13911.1.Puerto_Rico/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 48)

15 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
20 ALAGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

KU321639.1/326-829 Zika virus strain ZikaSPH2015, Brazil, Flavivirus envelope glycoprotein E. (SEQ ID NO: 49)

25 IRCIGVSNRDFVEGMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDM
ASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPENL
EYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYL
TMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTAL
AGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD
30 GPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGS
TIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLM
WLGLNTKNGSISLMCLALGGVLIFLSTAVSA

ZikaSPH2015.ALU33341.1.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 50)

35 IRCIGVSNRDFVEGMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDM
ASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPENL
EYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYL
TMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTAL
AGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD
40 GPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGS
TIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLM
WLGLNTKNGSISLMCLALGGVLIFLSTAVSA

103344.AMC13912.1.Guatemala/291-794 polyprotein [Zika virus].

103344.AMC13912.1.Guatemala Flavivirus envelope glycoprotein E. (SEQ ID NO: 51)

45 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEIRSYCYEASISDM
ASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPENL
EYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYL
TMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTAL
AGALEAEMDGAKGRLSSGHLKRLKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD
50 GPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGS
TIGKAFEATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLM
WLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Brazil-ZKV2015.AMD16557.1.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 52)

55 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE

NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGTQEGAVHT
 ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 5 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

KU497555.1/308-811 Zika virus isolate Brazil-ZKV2015, Flavivirus envelope glycoprotein E.
 (SEQ ID NO: 53)

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISD
 10 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGTQEGAVHT
 ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 15 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-ZJ03.AMM39806.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 54)

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 20 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGARRMAVLGDTAWDFGSGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 25 LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-FSS13025.AFD30972.1.Cambodia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 55)

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 30 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 35 LVWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Z1106032.ALX35660.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]
 (SEQ ID NO: 56)

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 40 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 45 LMWLGLNAKNGSISLMCLALGGVLIFLSTAVSA

isol-Z1106033.ALX35659.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]
 (SEQ ID NO: 57)

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPE
 50 NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
 YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTTPHWNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
 ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAE TLHGTVTVEVQYAG
 TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
 GSTIGKA FEATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTL
 55 LMWLGLNAKNGSISLMCLALGGVLIFLSTAVSA

isol-BeH828305.AMK49165.1.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 58)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDTQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-GD01.AMK79468.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 59)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNGTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-Z1106031.ALX35661.1.Suriname/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 60)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVLAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
SGSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

ACD75819.1.Micronesia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 61)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPAVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

KU681082.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, Flavivirus envelope glycoprotein E. (SEQ ID NO: 62)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
GSTIGKAFAEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTL
LVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

isol-Zika_virus%*H.sapiens-tc*%PHL%2012%CPC-0740.AMD61711.1.Philippines/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 63)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
MASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPE
NLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLY
YLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHT
ALAGALEAEMDGAAGRLSSGHLKCRLLKMDKRLRLKGVSYSLCTAAFTFTKIPAEHLHGTVTVEVQYAG

TDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHHWHRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLVWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

isol-BeH823339.AMK49164.2.Brazil/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 64)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVSTTVSNMAEVRSYCYEATISDIASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTAVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHHWHRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSA

isol-P6-740.AEN75264.1.Malaysia/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 65)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE NLEYRIMLSVHGSQHSGMIVNDXGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGD K KITHHHWXRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLTCLALGGVLIFLSTAVSA

KU744693.1/326-829 Zika virus isolate VE_Ganxian, China, Flavivirus envelope glycoprotein E. (SEQ ID NO: 66)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE NLEYRIMLSVHGSQHSGMLVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLAHKEWFHDIPLPWHAGAAATGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLRLKGVSYSLCTAAFTFTKIPAETVDGTVTVEGQYGTGDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHHWHRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIIGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSG

isol-VE_Ganxian.AMK79469.1.China/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 67)

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFACSKKMTGKSIQPE NLEYRIMLSVHGSQHSGMLVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLAHKEWFHDIPLPWHAGAAATGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLRLKGVSYSLCTAAFTFTKIPAETVDGTVTVEGQYGTGDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHHWHRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIIGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSG

ArD157995.AHL43503.1.-/291-794 Flavivirus envelope glycoprotein E. (SEQ ID NO: 68)

ISCIGVSNRDLVEGMSGGTWVDVVLEHGGCVTEMAQDKPTVDIELVTMTVSNMAEVRSYCYEASISDMASASRCPTQGEPSLDKQSDTQSVCKRTLGDGRWGNGCGIFGKGS�VTC SKFTCKCKMPGKSIQPENLEYRIMLPVHGSQHSGMIVNDIGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLFSGHLKCR LKMDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQSAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKMMLELDPPFGDSYIVIGVGD K KITHHHWHRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTAVSA

MR_766.ABI54475.1.Uganda/291-788 Flavivirus envelope glycoprotein E. (SEQ ID NO: 69)
 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISD
 MASDSRCPTQGEAYLDKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPEN
 LEYRIMLSVHGSQHSQMIVNDENRAKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLYYLTMMN
 5 KHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGAL
 EAEMDGAKGRLFSGHLKCRLKMDKRLRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCK
 VPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSRGSTIGK
 AFEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGL
 NTKNGSISLTCLALGGVMIFLSTAVSA

In some embodiments, the Zika virus has polyprotein, including an envelope (E) protein, with an amino acid sequence provided by any one of SEQ ID NO: 14-69. In some embodiments, the polyprotein or E protein sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-69.

The terms "identical" or percent "identity" in the context of two or more nucleic acids or amino acid sequences refer to two or more sequences or subsequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*e.g.*, at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity) over a specified region or over the entire sequence, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. In some embodiments, the identity exists over the length of a protein, such as the E protein.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. Methods of alignment of sequences for comparison are well known in the art. See, *e.g.*, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443, 1970, by the search for similarity method of Pearson and Lipman. Proc. Natl. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, Jalview and TFASTA in the Wisconsin Genetics

Software Package, Genetics Computer Group. 575 Science Or., Madison. WI), by multi sequence alignment implementation using e.g. CLUSTALW (Larkin et al., (2007).

Bioinformatics, 23, 2947-2948.) or MAFFT (Kato & Toh 2008 Briefings in Bioinformatics 9:286-298), or by manual alignment and visual inspection (see. e.g., Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (Ringbou ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively.

EXAMPLES

Example 1: Production of a Zika drug substance suitable for application as a vaccine in humans and animals

Materials and Methods:

For the production of ZikaV the JEV process platform (Srivastava et al., Vaccine 19 (2001) 4557-4565; US 6,309,650B1) was used as a basis. Small changes of certain process steps were applied to adapt on ZikaV properties and to improve purity. A short summary of the process steps is outlined below (see also Figure 8a+b).

Upstream:

- Roller Bottle based Vero cell expansion (25x850cm² CellBind):
- 5% CO₂, 35°C, MEM+2mM L-Glutamine+10% FBS
- Infection with ZikaV research Master Seed Bank (rMSB) at MOI 0.01
- Virus Production without serum
- 5% CO₂, 35°C, MEM+2mM L-Glutamine
- Multiple harvests (days 2, 3, 5 and 7) with re-feed
- Sterile filtration of harvests and storage at 2-8°C until further processing

Downstream:

- Pooling of harvests and concentration by ultrafiltration (100kDa)

PAT018/EP/PR1

- Stabilization of concentrated harvest (Tris/10% sucrose) for storage if required (-80°C)
 - Removal of hcDNA by Protamine Sulphate (2 mg/mL)
 - Sucrose Gradient Purification (optimized three layered gradient)
 - 5 • Formaldehyde Inactivation (0.02%, 22°C, 10 days), neutralization with Na-metabisulfite
 - Dilution to DS antigen target content and formulation with Aluminium hydroxide (0.5mg Al/mL)
- 10 Definitions & Abbreviations
- BSA Bovine serum albumin
- HPLC High performance liquid chromatography
- JEV Japanese Encephalitis Virus
- MALS Multi angle light scattering
- 15 NIV Neutralized inactivated virus
- PBS Phosphate buffered saline
- rms radius Root mean square radius
- RSD Relative standard deviation
- SEC Size exclusion chromatography
- 20 SGP Sucrose gradient purified
- ZikaV Zika Virus
- rMSB research master seed bank
- p.i. Post infection
- SGC Sucrose gradient chromatography
- 25 PS Protamine sulfate

Zika Virus Strain H/PF/2013 was originally isolated from a 51-year-old woman (SEQ ID NO: 13). A sample was obtained from European Virus Archive EVAg. Based on this material, a research master seed bank (rMSB) was prepared on vero cells as the cell substrate.

30

Virus growth on Vero Cells

Vero cells were grown in Eagle's minimal essential medium (EMEM) containing 10% fetal bovine serum (FBS). Roller bottle cultures of Vero cell monolayers were infected with Zika Virus Strain H/PF/2013 at a multiplicity of infection (moi) of 0.01 plaque forming units (pfu) per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM without FBS and incubated at +35°C with 5% CO₂. Infected Vero cell cultures were incubated until the virus titer reaches a desired level.

The culture medium was harvested at days 2, 3, 5 and 7 and were pooled from those harvest days and then centrifuged in standard centrifuge. The supernatants were then filtered. Virus culture supernatants were concentrated by TFF ultrafiltration to remove cell culture media components and reduce batch volume.

Evaluation of harvest Procedure

The current JEV harvest process has scheduled harvests on days 3, 5, 7 and 9 post infection. To mimic the JEV process roller bottles infected with ZIKV bank P4-FBS at an MOI of 0.01 in infection medium (MEM with 2% FBS + 2mM L-glutamine) for 2 hours. After removing the inoculum the cells were washed twice with PBS and 200mL production medium (MEM+ 2mM L-glutamine) was added.

After taking a sample on day 2 the first virus harvest was conducted on day 3 after infection. At this point significant higher CPE could be observed compared to cells where virus was removed on day 2. Plaque assay analysis showed that the viral titers on day 2 were in the same range as for the standard harvesting schedule. However, starting with day 3 harvest the observed titers were significantly lower correlating with the increased CPE observed compared to the standard harvest schedule. On day 5 post infection no more living cells could be observed at all and the experiment was terminated with a final day 5 harvest.

The calculated titers per plaque assay are summarized in the list below:

Log 10 PFU/mL

sample day2 7.02

harvest day 3 6.66

harvest day 5 6.26

This finding led to an optimized harvest schedule to better control of CPE and allow additional harvest day 5 and 7, see Figure 19. For both harvest days the optimized ZikaV

protocol yield significant higher virus titers compared to the modified protocol showing that the time of the first harvest is crucial for production yields. Additionally first harvesting at day 3 results in maximum 2 harvest points whereas first harvesting at day 2 allows for 4 harvest points further increasing the yield gain.

5

Downstream Purification of Zika virus

The purification process was carried out at room temperature (18-22 °C) unless stated otherwise. Virus purification started with concentration of filtered combined harvest using 100 kDa cut-off TFF ultrafiltration modules to remove cell culture media components and reduce batch volume. After concentration, the pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris pH 7.5 and 10% sucrose (w/w) using stock solution of both components (see Figure 9 for SEC_HPLC of different harvests prior to PS treatment). This allowed for freezing the concentrated harvest at <-65°C if required.

Host cell DNA and protein reduction as well reduction of non-infectious virus aggregates in the concentrated material was achieved by precipitation with protamine sulphate (2 mg/mL) followed by sucrose density centrifugation (2-8°C) as final polishing step (see Figure 10 for SEC_HPLC of different harvests post PS treatment). The purification process was designed to be completed within 2 working days with SGC starting on end of day 1 followed by fractionation and SDS-PAGE analysis on day 2. The sucrose gradient fractions were stored at 2-8 °C during the SDS-PAGE analysis (Silver staining) to identify the pure fractions containing ZikaV (see Figure 12). After pooling the relevant fractions, the pool was diluted and inactivated by Formalin. After pooling the relevant fractions of sucrose gradient centrifugation, the pool was diluted 1:3 in PBS and inactivated by Formalin (0.02% v/v, 200ppm). Fractions were subjected to analysis by SDS-PAGE.

25

Effect of PS treatment on virus recovery

Samples of individual 30x concentrated harvests day 2, 3, 5 and 7 were analysed before and after PS treatment by SEC-HPLC and plaque assay. SEC-HPLC was used for determination of relative total ZikaV content (active + inactive) expressed as peak area, whereas the rel. ZikaV peak purity is given as relative content of virus monomer population to total virus peak. Plaque assay states the content of total active virus particles in each sample. Experimental results are summarized in Table 1. The virus peak recovery by SEC.

HPLC was only between 12 to 36% with peak purity after PS treatment in the range of >90% (no virus aggregates detected). The recovery of active virus particles by plaque assay was all > 100% (130-700%, range within the variability of the assay) showing that no active virus particles were lost during PS treatment. These results show that during PS treatment only non-infective (immature and/or aggregated virus) particles were removed.

Table 1: ZikaV Recovery by SEC-HPLC and Plaque assay before and after PS treatment.

SEC-HPLC

	Peak area mAU*min			
Harvest day	30x conc	30x +PS	SEC Recovery (%)	rel. virus monomer content after PS (%)
Day 2	101.36	18.63	18	89%
Day 3	144.51	17.48	12	90%
Day 5	19.97	5.92	30	96%
Day 7	68.80	24.43	36	99%

Plaque Assay

	PFU/mL		
Harvest day	30x conc	30x +PS	Plaque Recovery (%)
Day 2	3E+08	5E+08	179
Day 3	2E+08	4E+08	193
Day 5	1E+08	9E+08	700
Day 7	3E+08	4E+08	132

Sucrose gradient centrifugation

The PS treated harvest was split in two parts and loaded on two centrifuge bottles.

Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ZikaV material. The ZikaV PS treated concentrated harvest was loaded on top of a solution consisting of three layers of sucrose with different density. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose gradient and complete separation of the virus particles from residual contaminants as demonstrated for ChikV, see Figure 13. The optimal volumes of the sucrose solutions were

determined empirically. The volumes of individual layers for a centrifugation in 100 mL bottle scale are shown in Table 2.

Table 2: Individual layers/volumes for a centrifugation in bottle

5	~40 mL PS treated harvest load Load
	15 mL 15 % Sucrose solution J
	15 mL 35 % Sucrose solution I
	20 mL 50 % Sucrose solution H
	90 mL total volume

10

The sucrose gradient bottles were prepared by stratifying the individual sucrose layers. A plastic tube was attached to peristaltic pump tubing. The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle (see Figure 11). Using a peristaltic pump the ZikaV material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as feed vessel. The first solution pumped was the ZikaV material as it represented the solution of lowest density (10 % sucrose (w/w)). After the ZikaV material the sucrose solutions were pumped in ascending order starting with the 15 % (w/w) solution J, followed by 35 % sucrose solution I and finishing with the highest density sucrose solution H (50 % (w/w)). The described setup is shown in Figure 11. After all sucrose solutions were transferred the plastic tubing was carefully removed in order not to disturb the layers.

Prior to centrifugation the centrifuge was pre-cooled to 4 °C. The prepared SG bottles were carefully transferred into the pre-cooled rotor (Note: Sudden movement of the bottles during transfer to the rotor must be avoided in order not to disturb the sucrose layers). The bottles were centrifuged at ~11.000 RCF max at 4 °C for at least 20 hours, no break/deceleration activated. In case a different centrifuge system with a different rotor is used the necessary speed and centrifugation times need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.

Harvesting of the sucrose gradient was done manually using a peristaltic pump. A plastic tube attached to peristaltic pump tubing was used for harvesting the sucrose gradient. The bottle containing the gradient was mounted onto a laboratory stand in a tilted position

(~12°) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle.

Using a peristaltic pump set to a flow rate of 30 mL per minute the gradient was harvested and manually split into 2 mL fractions. A total number of 32 fractions per bottle were harvested (~ 64 mL) and the remaining volume was discarded. The fractions were immediately tested by SDS-PAGE / silver stain to identify the virus containing fractions with sufficient high purity. Representative SDS-PAGE is shown in Figure 12. Fraction 10-14 were pooled and further processed.

The purified viral solution was inactivated by incubation with 0.02% formaldehyde over a period of ten days in a 22°C controlled-temperature incubator. The formaldehyde is neutralized by addition of sodium metabisulphite on the tenth day.

The sucrose gradient pool (~17mL after sampling) was further diluted 3-fold with PBS to a final volume of 51mL in a PETG container. A volume of 1% formaldehyde (10,000ppm) solution equivalent to 1/50 of the final volume of the pre-formaldehyde pool was added to this pool resulting in an effective concentration of 200ppm. The formaldehyde-treated solution was mixed on a magnetic stirrer for 10 minutes. After sampling, the formaldehyde-treated viral solution was placed within a cooled incubator at 22°C ± 2°C. On Day 5 post addition of formaldehyde, the formaldehyde-treated viral solution was filtered through a 0.2 µm filter and then placed in the incubator at 22°C ± 2°C again. On Day 10, after removing the 10-Day inactivation final sample, a volume of 1 % (of the weight of the final formaldehyde-treated viral solution) of 200 mM-sodium metabisulphite solution (2mM final concentration) was aseptically transferred into the PETG container containing the formaldehyde-treated viral solution. After mixing for 5 minutes on a magnetic stirrer, the neutralized inactivated viral solution is held at room temperature (20 to 25°C) for a minimum of 30 minutes. After sampling, the neutralized inactivated viral solution is stored at 5°C ± 3°C until further processing.

Inactivation by formaldehyde

Critical parameters for this step are final formalin concentration, temperature, mixing and transfer into a new container. A preliminary acceptance criteria for maximum pfu/mL (determined by plaque assay) has been set on the diluted pool pre formaldehyde treatment.

The quality of the neutralized inactivated viral solution is monitored by the following parameters: Plaque assay on Day 10, SEC-HPLC, SDS-PAGE/Western Blot.

Interestingly, SEC-HPLC analysis of samples taken during the inactivation period followed by neutralization with bisulfite showed more or less constant peak area throughout the inactivation period. This is in contrast to JEV where losses of viral particles up to 60% are observed using the process disclosed by Srivastava et al. Vaccine 19 (2001) 4557-4565. In a scale-down model the viral losses were even much higher due to surface/area ratio at smaller scale and high losses due to unspecific adsorption. Differences of the ZikaV inactivation experiment and JEV inactivation were noticed as follows:

A) Much higher purity of ZikaV SGP pool with regard to residual PS ($<2\mu\text{g/mL}$) compared to JEV. The 3-fold ZikaV inactivated sample contained therefore $<<1\mu\text{g/mL}$ of residual PS. Commercial JEV SGP pool contains on average $\sim 120\mu\text{g/mL}$ (up to $152\mu\text{g/mL}$ possible). The average dilution to inactivation solution of ~ 14 -fold results in a residual PS content up to $\sim 11\mu\text{g/mL}$. It may be that higher amount of residual PS could cause virus precipitation due to cross-linking / reaction with formalin.

B) ZikaV inactivation sample contained $\sim 10\%$ sucrose (3-fold dilution of SGP pool containing ~ 30 - 35% sucrose). Sucrose might have stabilizing effect of viral ZikaV particles during treatment with formalin.

Dilution to DS and Formulation with Aluminium hydroxide (DP)

For preparation of ZikaV drug substance used in mouse potency assay an antigen content (expressed as total viral particles or SEC peak area) of 5 times higher compared to Ixiaro was targeted. The basis for determination of antigen content was SEC-HPLC. In short, a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25 °C, is used to detect ZikaV at 214 nm detection wavelength in harvest samples and throughout the downstream process. In the current JEV process the antigen content in NIV is determined by a specific ELISA. A good correlation was observed between antigen content determined by ELISA and SEC-HPLC. On average, the antigen content in commercial NIV samples is in the range of 33 AU/mL corresponding to $\sim 5.2\text{mAU}$ JEV peak area, see Figure 14.

ZikaV NIV day10 (Zika peak ~36 mAU, analysed on Waters HPLC/Superose6 Increase column) was diluted with PBS to a target of 6.3 (~5.7x dilution). Aluminium hydroxide was added to a final concentration of 0.5 mg/mL Aluminium (1/20 v/v Alum 2% stock solution added) to prepare ZikaV Drug Product (DP). The DP was gently mixed for 5 min. An aliquot of the DP was removed, Alum sedimented by centrifugation and the clear supernatant analysed by SEC-HPLC. No ZikaV peak was detected in the supernatant indicating complete adsorption (estimated as >95%) of viral particles on the mineral adjuvant. Formulated ZikaV DP was stored at 2-8°C.

The impurity profile of the inactivated Zika virus DS is comparable to the profile of JEV DS with the exception of a lower PS content (Table 3).

Table 3: Determination of impurity profile in Zika and JEV DS samples:

	Specification (JEV DS)	JEV	Zika
HCP (ng/mL)	<100 LOQ 12 ng/mL	<LOQ	<LOQ
DNA (pg/mL)	<200 LOQ 40 pg/mL	<40	<40
Aggregates by SEC-MALLS (%)	Not specified, part of characterization LOQ 5%	<LOQ	<LOQ
PS (µg/mL)	Specification only at SGP pool to demonstrate consistent process performance (19-152µg/mL), *PS content in DS calculated based on PS content in SGP pool (~100 µg/mL) and average dilution factor (~28x) to DS; LOQ 2µg/mL	~4*	<<LOQ

*Typical PS impurity in a JEV sample produced in accordance with protocol disclosed in Srivastava et al. Vaccine 19 (2001) 4557-4565

SEC-MALLS Results

A representative SEC-HPLC elution profile of ZikaV NIV at 214 nm detection wavelength is shown in Figure 20. Note that BSA (50µg/mL) was added to the sample to minimize

losses in HPLC glass vial due to unspecific surface adsorption. ZikaV monomer content was estimated as ~98% with a multimer content of ~2%.

SEC-MALLS analysis (Figure 21) of the sample confirmed the radius R_z of the monomer ZikaV population peak 1 as 21.6nm and ~49nm for the multimer peak 2.

- 5 Cumulative particle size distribution showed that 89% of all viral particles are within a radius range between 18 to 25nm (Figure 22).

Results confirm purity and homogeneity of ZikaV NIV.

Viral titer by plaque assay

- 10 Active ZikaV was analyzed by plaque assay throughout the process.

Sample	Pfu/mL
Harvest day 2 (filtered)	6.4×10^7
Harvest day 3 (filtered)	1.0×10^8
Harvest day 5 (filtered)	1.5×10^8
Harvest day 7 (filtered)	1.1×10^8
PS treated harvest 300x concentrate (=SGP load)	9.0×10^8
SGP pool	8.9×10^8
Inactivation start (SGP pool 1:3 diluted)	3.4×10^8
Inactivation day 5	<LOD
Inactivation day 10	<LOD

- 15 Comparison of PS and Benzonase on process performance

- A direct comparison of DNA removal method of concentrated ZikaV harvest pool was done. One aliquot was treated with PS (2mg/mL, 15min at room temperature), the other aliquot was treated with Benzonase (50 U/mL, 2 mM $MgCl_2$, 4h RT, 48h 2-8°C). Both samples were further purified by sucrose gradient as described in this report. Interestingly,
- 20 the Benzonase treated samples did not sure any pure fractions after sucrose gradient centrifugation of the treated ZikaV harvest. In those fractions where the specific virus bands were detected, a high amount of host cell proteins was detected throughout the collected fractions. The PS treated material resulted in pure ZikaV containing fractions as expected.
- This finding may suggest that PS is not only effective for DNA removal by precipitation; in
- 25 addition it improves the recovery of virus particles in the gradient by disrupting interaction of

DNA (fragments) and virus particles. Benzonase treatment does not remove DNA, it only results in its fragmentation. Residual DNA fragments might still interact with virus particles and residual HCPs resulting in cross-contamination and co-purification in the sucrose gradient. Pooled SGP fractions were also analysed by SEC-HPLC. Although a large peak was detected, SDS-PAGE confirmed that this sample was highly contaminated with HCPs. A large peak might be detected at UV214 and 280nm after SEC-HPLC analysis due to possible interaction of HCPs with large virus particles, changing the UV absorbance.

Immunogenicity of Vero grown Zika virus

The immunogenicity of inactivated Zika virus preparations is assessed using a mouse model of Zika infection. Groups of adult mice are immunized subcutaneously (s.c.) with 500, 50, or 5 ng of inactivated Zika virus with adjuvant (*e.g.* aluminium hydroxide with or without IC31®), or without adjuvant. An additional group of mice receive PBS as a negative control. Each group is administered the indicated inoculum at t=0 and in some cases also at three to four weeks later (t=3/4). Beginning approximately three weeks after administration of the last immunization, serum samples are obtained from each of the mice at regular intervals. The serum samples are tested for the presence of neutralizing antibodies using PRNT.

The *in vivo* protective efficacy of the inactivated Zika virus preparations is also assessed using a mouse model of Zika infection, *i.e.* IFN-alpha/beta receptor knock-out mice (A129) (see *e.g.* Dowall et al., 4. March 2016, <http://dx.doi.org/10.1101/042358>) or blocking of the IFN-alpha/beta receptor by administration of anti-IFN-alpha/beta receptor monoclonal antibodies to C57BL/6 or BALB/c mice (see *e.g.* Pinto et al., 7. December 2011, DOI: 10.1371/journal.ppat.1002407). For protection assays, groups of 10 three- to eight-weeks-old A129, C57BL/6 or BALB/c mice are inoculated subcutaneously in the hindquarters with inactivated Zika virus with adjuvant (aluminium hydroxide) or without adjuvant at t=0. Age-matched controls are inoculated with PBS or non-specific antigens in alum. Mice are optionally boosted with a second administration of the indicated inoculation three to four weeks later. The mice are then challenged subcutaneously at three to eight weeks post immunization by inoculation with a deadly dose of live Zika virus. One day prior to challenge of C57BL/6 and BALB/c mice, they are passively administered (intraperitoneally) with anti-IFN-alpha/beta receptor monoclonal antibodies. Challenged mice are monitored daily for

morbidity and mortality for up to twenty-one days. Another alternative is to challenge intracranially adult vaccinated/non-vaccinated adult mice and observe protection.

It is expected that the Zika virus produced by the process of the invention will provide very similar functional read-outs in *in vitro*, *in vivo* and finally human trials as the currently licensed JEV vaccine in the EU and US and elsewhere, IXIARO®. The dosage may alter but due to the very similar impurity profile and almost identical manufacture, a very similar efficacy and safety result will be expected as was determined for the currently licensed JEV vaccine (licensed in the EU and US and elsewhere).

Discussion & Conclusion

The existing manufacturing platform for production of inactivated JEV vaccine IXIARO® was used as a basis for a manufacturing feasibility study of inactivated ZikaV vaccine candidate (Asian strain H/PF/2013). The virus was produced on vero cells cultivated in roller bottles. The virus was purified by PS treatment followed by an optimized sucrose gradient. Inactivation was done by formalin treat (0.02 %, 10 days at 22 °C). For exploratory immunization studies in mice, a DP formulated with Alum was prepared with an estimated 5-fold higher virus particle content compared to IXIARO®, the commercial JEV Vaccine. The impurity profile of the DS met all criteria as defined in the specification for IXIARO®, the commercial JEV Vaccine.

Example 2: Development of a purification process for live attenuated Chikungunya virus vaccine produced in Vero cells

A downstream process was developed for the purification of infectious Chikungunya virus particles whereby non-infectious virus particles and aggregates are removed by the addition of protamine sulphate. The unexpected and novel purification properties of protamine sulphate (PS) were evaluated in purification processes for Chikungunya Virus (ChikV) as follows:

A downstream purification process for the attenuated Chikungunya virus mutant “Δ5nsP3” (as described by Hallengård et al., 2014, supra) produced under standard cell culture conditions in Vero cells was developed. Briefly, the downstream process consists of

crude harvest filtration followed by concentration and diafiltration on a tangential flow filtration (TFF) system. DNA and host cell proteins were reduced by precipitation with protamine sulphate and by batch adsorption, respectively. Sucrose density gradient centrifugation was done as a final polishing step. Out of 16 roller bottles 1 x 10¹² total PFU were purified with an overall DSP process yield of 10 - 15 % (~1 log₁₀ TCID₅₀ loss). Sucrose gradient pool samples were characterized with regard to product-related impurities, such as hcDNA, HCP and endotoxins and met safety criteria.

Harvest of Vero cell culture medium containing ChikV Δ5nsP3

ChikV Δ5nsP3 was grown on Vero cells in roller bottles. A first harvest was performed after 24 hours post infection (hpi; day 1 harvest) and stored at 2-8°C until further processing. After the first harvest, fresh medium was added and the roller bottles were returned to the incubator. A second harvest was done after 48 hours post infection (day 2 harvest) and stored at 2-8 °C.

Filtration of crude cell culture harvest

At both harvest timepoints the crude harvest was immediately filtered using a 0.2 µm filter capsule (GE ULTA™ CG, 2 inch). The filtered harvest after 48 hpi was pooled together with the 24 hpi harvest and the pooled filtered harvest material was immediately further processed by ultrafiltration.

Purification of ChikV Δ5nsP3 by tangential flow filtration (TFF)

The pooled filtered harvest material was further processed by tangential flow filtration (TFF) in order to concentrate the harvest, reduce host cell proteins and replace the depleted cell culture medium with a defined buffer system (buffer exchange). A Millipore TFF system (Millipore Pellicon II mini membrane holder) equipped with a 100 kDa cutoff PES membrane module (Pellicon2 Biomax, 1000 cm²) was used for concentration and buffer exchange. A Pellicon2 Biomax membrane module was mounted on the Pellicon II mini filter holder and the device was connected to a peristaltic pump. The system was first rinsed with ultra-pure water and then sanitized by recirculation of 0.1 M NaOH for 60 min. In case the system was not used immediately, it was stored in 0.1 M NaOH until use. Prior to use the

system was rinsed with 1 L of RO-water followed by buffer A until the permeate pH value was constant at $\text{pH } 7.4 \pm 0.2$.

Adjustment of the ChikV $\Delta 5\text{nsP3}$ harvest (pH, salt)

5 The pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris and 150 mM NaCl using stock solutions of both components (see Table 1). This adjustment was done to increase buffering capacity and to reduce unspecific adsorption to the membrane. The necessary volumes of stock solutions D (1 M Tris, pH 7.4) and E (4.5 M NaCl) were calculated as follows:

10 Volume of stock solution D (1 M Tris, pH 7.4) added to pooled harvest = Volume of pooled filtered harvest / 40

 Volume of stock solution E (4.5 M NaCl) added to pooled harvest = Volume of pooled filtered harvest / 30

15 4 L harvest obtained from 20 RB (850cm²) would require addition of 100 mL stock solution D (1 M Tris, pH 7.4) and 133 mL stock solution E (4.5 M NaCl).

 The calculated volumes of stock solution D and Buffer E were added to the pooled filtered harvest under gentle stirring. The adjusted harvest was then stirred using a magnetic stirrer for 5 minutes at room temperature.

20

Concentration and diafiltration of the ChikV $\Delta 5\text{nsP3}$ harvest by TFF

 In a first step the adjusted harvest material was concentrated approximately 10 fold. The feed flowrate was approximately 220 mL/min. The transmembrane flux at a transmembrane pressure of approximately 0.6 bar was in the range of 90 ± 5 mL/min per 25 1000 cm² membrane. After concentration, the cell culture medium was exchanged against 25 mM Tris, 150 mM NaCl, pH 7.5 by continuous diafiltration with 6 volume exchanges. The diafiltration buffer was supplied to the feed vessel from a measuring cylinder by a second peristaltic pump set to a flowrate of approximately 90 mL/min. Minor flowrate adjustments of the second peristaltic pump in the range of ± 10 mL/min were done manually to ensure a 30 constant volume of harvest in the feed vessel. After 6 volume exchanges, diafiltration was stopped. The liquid remaining in the membrane module was recovered by pumping the module empty with air.

Sucrose addition to diafiltrated ChikV Δ5nsP3 material

5 After diafiltration, sucrose stock solution H (50% (w/w) sucrose solution) was added to the diafiltrated material to achieve a final sucrose concentration of 10% (w/w). The volume of buffer H was calculated as follows:

Volume of stock solution H added (mL) = Volume (mL) of diafiltrated ChikV material x 0.25 (dilution factor = 1:4) (i.e., final sucrose concentration is 10%)

10 Example: 400mL diafiltrated ChikV solution would require addition of 100mL stock solution H (50% sucrose).

 The calculated volume of solution H was added to the diafiltrated ChikV Δ5nsP3 material under gentle stirring and the solution was then stirred using a magnetic stirrer for a further 5 minutes at room temperature. (At this stage of the process the material can be either
15 immediately further processed or stored frozen (< -65°C, hold step).)

DNA reduction by protamine sulphate precipitation

 A DNA precipitation step using protamine sulphate (PS) was performed to reduce hcDNA. Protamine sulphate stock solution L (50 mg/mL PS in PBS) was added to the
20 diafiltrated ChikV Δ5nsP3 material to a final nominal concentration of ~1.6 mg/mL. The necessary volume of stock solution L was calculated as follows:

Volume of stock solution L (50 mg/mL PS) added = Volume of diafiltrated ChikV Δ5nsP3 material in 10% sucrose / 31

 Example: 500 mL diafiltrated ChikV Δ5nsP3 solution in 10% sucrose would require
25 addition of 16 mL stock solution L (50 mg/mL PS in PBS).

The protamine sulphate stock solution was added while stirring the ChikV Δ5nsP3 material using a magnetic stirrer followed by incubation at 2-8°C for 30 minutes. After incubation, the DNA precipitate was not removed. The material was immediately further processed by batch adsorption with Capto™ Core 700 chromatography media.

30 Batch adsorption with Capto™ Core 700

 To reduce HCPs, a batch adsorption step with Capto™ Core 700 (CC700) chromatography medium was performed after DNA precipitation. CC700 slurry (50% slurry

in buffer A) was added directly to the protamine sulphate treated material. The required slurry volume was determined based on the volume of ChikV harvest material (d1+d2) and was calculated as follows:

Volume of CC700 slurry added to PS-treated concentrated harvest (mL) = Volume of
 5 ChikV Δ5nsP3 harvest material (mL) x 0.02 (dilution factor = 1:50) (i.e., final concentration of CC700 is 1%)

After slurry addition, the material was incubated at 4°C for 15 minutes under constant agitation using a magnetic stirrer. After incubation, the CC700 solid matter was allowed to settle by gravity for 10 minutes. The ChikV Δ5nsP3 material was then removed from the top
 10 of the solution in order to avoid blocking of the filter by the CaptoCore particles. The remaining CaptoCore particles and the DNA precipitate were then removed from the solution by filtration using a 0.2 μm Mini Kleenpak EKV filter capsule (Pall). The resulting filtrate was further processed by sucrose density gradient centrifugation.

15 Sucrose density gradient centrifugation

Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ChikV Δ5nsP3 material. The ChikV material was loaded on top of a solution consisting of three layers of sucrose with different densities. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose
 20 gradient and good separation of the virus particles from residual contaminants. The optimal volumes of the sucrose solutions were determined empirically. The volumes of individual layers for a centrifugation at 500 mL scale are shown in Table 3.

Table 3. Sucrose concentrations and volumes (500 mL scale).

25	Solution	Volume (mL)
	Harvest with 10% sucrose	360
	15% sucrose	40
	35% sucrose	40
	50% sucrose	60
30	Total volume	500

Preparation of the sucrose gradient

The sucrose gradient bottles (500 mL) were prepared by underlaying the individual sucrose layers. A 3.5 mm ID plastic tube was attached to 60 cm of peristaltic pump tubing. The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle. Using a peristaltic pump set to a flow rate of 25 mL per minute, the ChikV Δ5nsP3 material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as a feed vessel. The first solution pumped was the ChikV Δ5nsP3 material as it had the lowest density (10% sucrose (w/w)). Following the addition of the ChikV Δ5nsP3 material, the sucrose solutions were pumped in ascending order starting with the lowest (15%), followed by the 35% sucrose solution and finishing with the highest density sucrose solution (50%). After all sucrose solutions were transferred, the plastic tubing was carefully removed in order not to disturb the layers.

Centrifugation

Prior to centrifugation a Beckman Avanti JXN-26 centrifuge equipped with rotor Beckman 10.500 was pre-cooled to 4°C. The prepared SG bottles were carefully transferred into the pre-cooled (4°C) rotor so as to not to disturb the sucrose layers. The bottles were centrifuged at 10,000 rpm (~18,500 rcf) at 4°C for 17-20 hours. (In case a different centrifuge system with a different rotor would be used, the necessary speed and centrifugation times would need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.)

Sucrose gradient harvest

Harvesting of the sucrose gradient was done manually using a peristaltic pump. A 3.5 mm ID plastic tube attached to 60 cm of peristaltic pump tubing was used for harvesting the sucrose gradient. The 500 mL bottle containing the centrifuged gradient was mounted onto a laboratory stand in a tilted position (~12°) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle. Using a peristaltic pump set to a flow rate of 60 mL per minute, the gradient was harvested and manually split into 5 mL fractions. A third of the bottle volume was harvested

and the rest was discarded. The fractions were immediately tested by measuring UV absorbance in a plate reader as described below.

Analysis of fractions by UV absorbance and SEC-HPLC

UV absorbance measurement was used as primary method for analysis of the sucrose gradient fractions. Absorbance at 214, 280 and 260 nm was tested immediately after fractionation was completed. Briefly, a 100 μ L sample of each fraction was transferred into a 96 well plate and absorbance at 214, 260 and 280 nm was measured using a plate reader. The absorbance values were plotted against the fraction number. The presence of impurities was indicated by an increase of the UV214 signal after the main peak. The fractions comprising the main peak were pooled from the peak start to the valley of the 214 nm curve. This method can be used as single method for pooling ChikV Δ 5nsP3 fractions.

After identification of the virus containing fractions, the respective fractions were pooled. Pooling criteria for SGC fractions were based on UV 260 nm data, e.g. start of pooling at ~10% of peak maximum, end of pooling at ~30% of peak maximum. (Final pooling criteria at a manufacturing scale may need to be determined empirically.) The sucrose gradient pool was either stored at $< -65^{\circ}\text{C}$ or immediately further formulated to drug substance (DS).

Size exclusion chromatography

The final pooled SGC fractions containing purified infectious ChikV Δ 5nsP3 virus particles were analyzed for purity by SEC-HPLC. In brief, SEC was performed as follows: a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25°C , was used to detect ChikV particles at 214 nm detection wavelength in the pooled samples. SEC-HPLC is a semi-quantitative (relative yield) and qualitative (purity) method that separates intact virus particles from virus aggregates and host cell proteins (HCPs). The method cannot distinguish between infectious and non-infectious virus particles due to their identical retention time.

Two defined peaks were identified by SEC: the ChikV Δ 5nsP3 peak and a peak corresponding to buffer components. The SGC step yield based on SEC-HPLC data for pooled fractions F6-F11 was estimated at ~70 %. The final purity of the ChikV Δ 5nsP3 SGC pool, based on SEC-HPLC analysis, was estimated at $>95\%$.

SDS-PAGE and silver stain

SDS-PAGE silver stain was performed in order to qualitatively assess sample purity throughout the purification process from the first crude harvest through SGC. Briefly, ChikV process samples analyzed by SDS-PAGE/silver stain were diluted 1:1.33 with LDS buffer and were heated to 70°C for 5 minutes. The samples were loaded onto 4-12 % Bis-Tris Gels (NuPAGE). Silver staining was done using the Silver Express staining kit (Invitrogen).

A silver-stained gel of a representative ChikV Δ5nsP3 purification is shown in Figure 15. The viral proteins E1, E2 and C are marked on the right-hand side of the gel. The final SGC pool (fraction 7-fraction 11) is shown in lane 12. Note that a defined HCP band migrating between ChikV protein E2 and C still appears after CaptoCore700 treatment that has been identified as a single band in SDS-PAGE. This impurity is removed by sucrose gradient centrifugation, but can still be seen in fractions 13 and 14 (corresponding to lanes 14 and 15 of Figure 15).

Enrichment of infectious ChikV Δ5nsP3 particles by PS treatment

Although generally used as a method of removing contaminating hcDNA, it was observed in the course of the present invention that PS treatment also removes virus aggregates and HCPs. Size exclusion chromatography (SEC-HPLC, as described above) was used to throughout the purification process to determine the purity of the ChikV virus relative to impurities which also generate UV absorption.

As can be seen in Figure 16a, treatment with PS reduces not only host cell proteins and low molecular weight contaminants of the ChikV Δ5nsP3 preparation, but also reduces the SEC area corresponding to virus products, including aggregates as indicated. A surprising finding, however, was that even a reduction of the total SEC area by 86% (in a representative experiment shown in Fig. 16B, grey portion of bars) did not result in a concomitant reduction in infectious virus particles as measured by TCID₅₀ (left axis). Instead, even though a large percentage of virus particles were removed by PS treatment, the infectious particles were not. This observation indicates that PS treatment selectively enriches infectious virus particles from a larger pool of total virus particles present in the crude harvest.

TCID50 was performed to quantify infectious virus particles during the course of the purification process and to assign an active virus titer to final drug substance and drug product samples. Briefly, Vero cells were seeded at 2×10^4 cells per well in 100 μ L medium (EMEM with 2 mM L-Glutamine + 5 % FBS (+ 1 % antibiotic/antimycotic) in 96-well TC-treated flat-bottom plates and incubated overnight at 35°C / 5% CO₂. On day two, Vero cell monolayers were infected by adding 100 μ L of 1:10 serial dilutions of test samples to each of quintuplicate wells seeded with Vero cells and incubated at 35°C / 5% CO₂. On day seven, plaques were counted by visualization under a microscope. The TCID50 was calculated according to the Reed & Munch endpoint calculation method (Reed, L.J.; Muench, H. (1938) A simple method of estimating fifty percent endpoints" The American Journal of Hygiene 27: 493–497).

Furthermore, electron microscopy of ChikV samples before and after PS treatment showed that not only large aggregates but also smaller non-infectious virus-like particles (basically not fully assembled particles without RNA genome) are effectively removed by PS.

Furthermore, this enrichment of infectious virus particles could also be observed when analyzing day one and day two crude harvests separately. As presented in Table 4, the SEC area (total virus particles) of the day 1 harvest remains roughly the same after PS treatment; whereas a large decrease in virus peak area is seen for the day 2 harvest. This observation was confirmed by MALLS analysis of the virus preparation, wherein it was seen that a higher percentage of virus particles were of the correct size following PS treatment. Similarly to the results shown in Fig. 16, day 1 and day 2 harvests showed no reduction in infectious particles as measured by TCID50 following PS treatment, indicating that mainly non-infectious, immature and/or aggregated virus particles are removed during the PS treatment and infectious particles are enriched in the preparation.

Table 4. Overview of the process of ChikV $\Delta 5\text{nsP3}$ purification as described in Example 1. SEC-MALLS analysis of harvests before and after PS treatment shows the removal of larger virus particles (aggregates), an effect that is particularly pronounced for day 2 harvests.

	SEC	MALLS	Infectious particles		
	Area [mAU*min]		Total particles/mL	% correct size	
5	(20-40 nm)	TCID50 log 10			
	Harvest 1 (H1)	57	1.17E+11	49%	10.2
	Harvest 1 + PS	53	1.33E+11	81%	10.0
10	Harvest 2 (H2)	36	4.60E+09	3%	7.9
	H2 + protamine sulphate	2	8.80E+09	59%	7.9
	Combined Harvests (C)	67	2.60E+10	14%	9.9
	C + protamine sulphate	24	8.00E+10	72%	10.1

15

Finally, an overview of the relative amounts of ChikV particles and other components as measured by SEC-HPLC at various steps throughout the entire virus purification process from crude harvest (a) to the final SGC purified pool can be seen in Figure 17. In sum, not only are the vast majority of contaminants and undesired products removed by the process, ChikV particles are highly purified. As shown by the previously presented data, the final preparation is a highly enriched preparation of infectious ChikV particles.

20

Drug Substance (DS) Formulation

The pooled SGC fractions are diluted with DS formulation buffer M (10 mM Tris, 5% Sucrose, 1% (10 mg/mL) rHSA, pH 7.4 ± 0.2). The final target volume of DS should be in the range of approximately 2 L. Based on current data the estimated range of the dilution factor might be 1:20 to 1:50.

25

Final DS sterile filtration

The final DS was filtered under aseptic conditions in a laminar flow hood using a sterility grade 0.2 µm syringe filter (e.g. 0.2 µm Mini Kleenpak EKV filter capsule with 220 cm² filter surface, Pall).

- 5 Quantification of host cell DNA (hcDNA) host cell protein (HCP) and endotoxin
- The residual host cell DNA content of the sucrose gradient pool samples was determined by using the qPCR based assay. The DNA content in SGC pool was determined to be ≤ 0.002 ng/mL. The presence of residual host cell protein (HCP) from Vero cells was determined by ELISA. Residual host cell proteins present in the sucrose gradient pool samples were
- 10 quantified using the Vero Cell HCP ELISA kit (Cygnus, F500). The residual host cell protein content in SGC pool was determined to be ≤ 200 ng/mL.

- Endotoxin content of the SGC pool and DS was measured by Endosafe®-PTSTM system (Charles River). The system uses LAL reagents by a kinetic chromogenic methodology to measure color intensity directly related to the endotoxin content in a sample.
- 15 Each cartridge contains precise amounts of a licensed LAL reagent, chromogenic substrate and an endotoxin control standard. Samples were diluted 1:100 in WFI. The SGC Pool F7-F11 was determined to be < 5.00 EU/mL; likewise, the Drug Substance was also determined to have < 5.00 EU/mL.

- The following specifications for impurities in final Drug product were proposed:
- 20 hcDNA < 10 ng/dose; Endotoxins < 50 EU/dose; HCP < 200 ng/dose. These residual specifications would already be met in the highly concentrated SGC pool (~10 log TCID₅₀/mL), which provides a high margin of safety considering the high dilution factor of SGC pool to final DP of > 1:1000.

Further more detailed aspects of the invention:

A1. A Zika virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability.

A2. The Zika virus vaccine of claim A1, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability.

A3. The vaccine of claim A1 or A2, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 1-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 1-13 and able to pack a virulent Zika virus.

A4. The vaccine of any one of claims A1-A3, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

A5. The vaccine of any one of claims A1-A4, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

A6. The vaccine of claim A5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent to completely inactivate the Zika virus as measured by plaque assay.

A7. The vaccine of claim A6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

A8. The vaccine of claim A7, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

A9. The vaccine of any one of claims A5-A8, wherein the chemical activation is performed at about +4°C or about +22°C.

5 A10. The vaccine of any one of claims A1-A9, further comprising an adjuvant.

A11. The vaccine of claim A10, wherein the adjuvant is an aluminum salt adjuvant.

10 A12. The vaccine of claim A11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

A13. The vaccine of any one of A10-A12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).

15

A14. The vaccine of claim A13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 70) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 71).

20 A15. The vaccine of any one of claims A1-A14, further comprising one or more pharmaceutically acceptable excipient.

B1. A kit comprising a Zika virus vaccine of any one of claims A1-A15.

25 B2. The kit of claim B1, further comprising a second vaccine.

B3. The kit of claim B2, wherein the second vaccine is a West Nile virus vaccine, a Japanese Encephalitis virus vaccine, a Yellow Fever virus vaccine, a Dengue virus vaccine or a Chikungunya virus vaccine.

30

C1. A method, comprising

administering a first dose of a therapeutically effective amount of the Zika virus vaccine of any one of claims A1-A15 to a subject in need thereof.

5 C2. The method of claim C1, further comprising administering a second dose of a therapeutically effective amount of the Zika virus vaccine.

C3. The method of claim C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

10 C4. The method of claim C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

C5. The method of claim C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

15

C6. The method of any one of claims C1-C5, wherein the administering results in production of Zika virus neutralizing antibodies.

20 D1. A method of producing a Zika virus vaccine, comprising
(i) passaging a Zika virus on Vero cells, thereby producing a culture supernatant comprising the Zika virus;
(ii) harvesting the culture medium of (i);
(iii) precipitating the harvested culture medium of (ii), thereby producing a Zika virus
25 supernatant; and
(iv) optimally inactivating the Zika virus in the Zika virus supernatant of (iii) thereby producing an inactivated Zika virus.

30 D2. The method of claim D1, further comprising concentrating the culture medium of (ii) prior to step (iii).

D3. The method of claim D1 or D2, wherein the precipitating of (iii) comprises contacting the culture medium of (ii) with protamine sulfate or benzoate.

5 D4. The method of any one of claims D1-D3, further comprising (v) dialyzing the inactivated Zika virus of (iv), thereby producing a dialyzed Zika virus.

D5. The method of claim D4, further comprising (vi) filtering the dialyzed Zika virus of (v).

10 D6. The method of any one of claims D1-D5, wherein the inactivating is by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

D7. The method of claim D6, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for at least 4 days.

15

D8. The method of claim D6 or D7, wherein the chemical inactivation agent comprises formaldehyde.

20 D9. The method of any one of claims D6-D8, wherein the chemical activation is performed at about +4°C or about +22°C.

D10. The method of claim D8 or D9, further comprising neutralizing the formaldehyde.

25 D11. The method of claim D10, wherein the neutralizing is performed with sodium metabisulfite.

E1. The use of the optimally inactivated Zika virus vaccine of any one of claims A1-A15 for the treatment and prevention of a Zika virus infection.

30

E2. The use of claim E1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

E3. The use of claim E2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

5 E4. The use of claim E3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

E5. The use of claim E3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

10

E6. The use of claim E3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

15 E7. The use of any one of claims E1-E6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

F1. A pharmaceutical composition for use in the treatment and prevention of a Zika virus infection, wherein said pharmaceutical composition comprises the optimally inactivated Zika virus vaccine of any one of claims A1-A15.

20

F2. The pharmaceutical composition of claim F1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

25

F3. The use of claim F2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

30 F4. The use of claim F3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

F5. The use of claim F3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

F6. The use of claim F3, wherein the second dose of the Zika virus vaccine is
5 administered about 28 days after the first dose of the Zika virus vaccine.

F7. The use of any one of claims F1-F6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

CLAIMS

What is claimed is:

1. A process of purification of infectious virus particles, comprising the steps of:
 - 5 (a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
 - (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
 - 10 (c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably
 - 15 below 0.1 µg/mL, most preferably below 0.05µg/mL.
2. The process of claim 2, wherein the virus particles are selected from the group consisting of flaviviruses, e.g. yellow fever virus or Zika virus and alphaviruses, e.g. Chikungunya.
- 20 3. The process of claim 1 or claim 2, additionally comprising the step of:
 - (d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller
 - 25 than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.
4. The process of any of claims 1 to 3, wherein the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL and the residual host cell protein of the final virus
- 30 preparation (c) is less than 100 ng/mL.

5. The process of any of claims 1 to 4, wherein the crude harvest (a) comprising virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).

6. The process of claim 5, wherein the one or more pre-purification step(s) comprises

- 5 (a) filtration using a filter having a pore size equal to or less than 0.2 μm ; and/or
(b) digestion of host cell genomic DNA by enzymatic treatment; and/or
(c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

10 7. The process of any one of claims 1 to 6, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.

15 8. The process of any one of claims 1 to 7, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

20 9. The process of any one of claims 5 to 8, wherein the one or more pre-purification step(s) prior to step (b) of any of claims 5 to 8 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .

10. The process of any one of claims 1 to 9, wherein the residual impurity of the virus preparation (c) is less than 10%.

25 11. The process of any one of claims 1 to 10, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

12. The process of claim 11, wherein said cell line is a Vero cell line.

13. The process of any one of claims 1 to 12, wherein the infectious virus particles is an infectious Zika virus particle that is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

5

14. The process of any one of claims 1 to 13, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.

15. The process of any one of claims 1 to 14, wherein said process resulting in final virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

10

16. Use of the process according to any one of claims 1 to 15 for manufacturing a composition for immunization against a virus infection.

15

17. The use according to claim 16, wherein the composition for immunization against a virus infection is an infection caused by a group of viruses consisting of yellow fever virus, Chikungunya virus and Zika virus.

18. A composition comprising the virus particles obtainable or obtained by the process of any one of claims 1 to 17 for treating and/or preventing an infection, such as e.g. a Zika virus infection.

20

19. A Zika virus vaccine comprising an inactivated Zika virus particle grown on vero cells, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability and comprises minor amounts of protamine sulphate, preferably below the detection limit.

25

20. The Zika virus vaccine of claim 19, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability, preferably a 80% probability.

30

21. The vaccine of claim 19 or 20, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 and able to pack a virulent Zika virus.

5

22. The vaccine of any one of claims 19, 20 and 21, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

10

23. The vaccine of any one of claims 19, 20 to 22, wherein the Zika virus obtained by culturing on Vero cells is purified by protamine sulfate precipitation and sucrose gradient centrifugation.

15

24. The vaccine of claim 23, wherein the sucrose gradient centrifugation is an optimized sucrose gradient centrifugation.

20

25. The vaccine of claim 24, wherein the optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose solution, a second sucrose solution with 35% (w/w) sucrose solution, and a third sucrose solution with a 50% (w/w) sucrose solution.

25

26. The vaccine of any one of claims 19, 20 to 25, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

30

27. The vaccine of claim 26, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

28. The vaccine of claim 27, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

29. The vaccine of claim 28, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.
- 5 30. The vaccine of any one of claims 27-29, wherein the chemical activation is performed at about +4°C or about +22°C.
31. The vaccine of any one of claims 19 to 30, further comprising an adjuvant.
- 10 32. The vaccine of claim 31, wherein the adjuvant is an aluminum salt adjuvant.
33. The vaccine of claim 32, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.
- 15 34. The vaccine of claim 32, wherein the aluminum salt adjuvant is aluminium hydroxide with less than 1.25ppb Cu based on the final pharmaceutical composition comprising the Zika virus, preferably the inactivated Zika virus.
- 20 35. The vaccine of any one of claims 19 to 34, further comprising one or more pharmaceutically acceptable excipient.

ABSTRACT

Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering
5 said vaccines to subjects in need thereof.

Figure 1




Figure 2




Figure 3

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
DVV_1NC_001477.1	0	100.0	70.1	73.0	67.8	50.5	60.4	60.5	60.5	50.7	55.8	60.6	60.3	60.6	58.0	57.9	57.9	62.3	62.3	62.3	61.3
DVV_16681_NC_001474.2	1	70.1	100.0	70.8	68.6	60.5	60.5	60.5	60.6	60.7	54.9	60.9	60.3	60.4	58.3	58.3	58.3	58.3	62.7	62.8	62.2
DVV_3NC_001475.2	2	73.0	70.8	100.0	88.9	60.2	60.1	60.1	60.1	60.1	55.8	60.3	60.0	60.1	57.5	57.6	57.5	57.5	62.6	62.7	62.5
DVV_4NC_002640.1	3	67.8	68.6	68.9	100.0	60.5	60.6	60.6	60.6	60.4	55.4	60.8	60.3	60.5	58.0	57.9	57.9	62.1	62.0	62.0	62.1
JEV_SA14-14-2AF315119.1	4	60.5	60.5	60.2	60.5	100.0	99.8	99.4	99.5	99.1	56.5	70.6	70.3	70.3	57.9	58.0	58.0	61.9	61.8	61.8	61.4
JEV_SA14-14-2D90195.1	5	60.4	60.5	60.1	60.6	99.8	100.0	99.4	99.5	98.2	56.6	70.6	70.4	70.3	57.9	58.0	57.9	58.0	61.9	61.8	61.5
JEV_SA14D90194.1	6	60.5	60.5	60.1	60.6	99.4	99.4	100.0	99.8	98.6	56.6	70.8	70.5	70.4	58.0	58.0	58.0	58.0	61.9	61.8	61.6
JEV_virus_M55506.1	7	60.5	60.6	60.1	60.6	99.5	99.5	99.8	100.0	98.6	56.7	70.8	70.4	70.3	58.0	58.1	58.0	58.1	61.9	61.8	61.6
JEV_virus_NC_001437.1	8	60.7	60.7	60.1	60.4	98.1	98.2	98.6	98.6	100.0	56.6	70.6	70.5	70.6	58.3	58.3	58.4	58.3	62.1	62.0	61.7
TEV_virus_NC_001672.1	9	55.8	54.9	55.8	55.4	56.5	56.6	56.6	56.7	56.6	100.0	56.2	56.7	56.6	56.9	57.0	57.0	56.6	56.7	56.7	56.7
WNV_956_NC_001563.2	10	60.6	60.9	60.3	60.8	70.6	70.6	70.8	70.8	70.6	56.2	100.0	79.6	79.6	58.1	58.0	58.1	58.2	62.4	62.3	62.2
WNV_Chin-01.AY490240.2	11	80.3	60.3	60.0	60.3	70.4	70.4	70.5	70.4	70.5	56.7	79.6	100.0	95.3	58.2	58.2	58.2	58.2	62.1	62.1	62.7
WNV_NY99_Isol-385-99_NC_009942.1	12	60.6	60.4	60.1	60.5	70.3	70.3	70.4	70.3	70.6	56.6	79.6	95.3	100.0	57.8	57.8	57.8	62.0	62.0	62.0	62.4
YFV_17D_vaccine_strain_NC_002031.1	13	58.0	58.3	57.5	58.0	57.9	57.9	58.0	58.0	58.3	56.9	58.1	58.2	57.8	100.0	99.4	99.9	99.8	58.5	58.5	58.2
YFV_ASIBI.AY640589.1	14	57.9	58.3	57.6	57.9	58.0	58.0	58.0	58.1	58.3	57.0	58.0	58.2	57.8	99.4	100.0	99.4	99.4	58.4	58.4	58.1
YFV_Pasteur_17D-204.X15062.1	15	57.9	58.3	57.5	57.9	58.0	57.9	58.0	58.0	58.4	57.0	58.1	58.2	57.8	99.9	99.4	100.0	99.9	58.4	58.4	58.2
YFV_vaccine_strain_17D-213.U17067.1	16	58.0	58.3	57.5	57.9	58.0	58.0	58.0	58.1	58.3	57.0	58.2	58.2	57.8	99.9	99.4	99.9	100.0	58.4	58.4	58.1
ZVW_MR766-HIID.LC002520.1	17	62.3	62.7	62.6	62.1	61.9	61.9	61.9	61.9	62.1	56.6	62.4	62.0	62.0	58.5	58.4	58.4	58.4	100.0	99.7	88.9
ZVW_MR_766.AY632535.2	18	62.3	62.8	62.7	62.0	61.8	61.8	61.8	61.8	62.0	50.7	62.3	62.1	62.0	58.5	58.4	58.4	58.4	99.7	100.0	88.8
ZVW_MR_766_NC_012532.1	19	62.3	62.8	62.7	62.0	61.8	61.8	61.8	61.8	62.0	56.7	62.3	62.1	62.0	58.5	58.4	58.4	58.4	99.7	100.0	88.8
ZVW_ZikaSPH2015.KU321639.1	20	61.3	62.2	62.5	62.1	61.4	61.5	61.6	61.6	61.7	56.7	62.2	62.7	62.4	58.2	58.1	58.2	58.1	88.9	88.6	100.0

60 % Identity and higher
70 % Identity and higher
80 % Identity and higher

Figure 4




Figure 5




Figure 6

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
OVV_1 NC_001477.1	0	100.0	68.7	77.4	63.8	49.7	49.7	50.1	49.9	50.5	38.3	51.5	50.5	50.9	43.0	43.8	43.0	43.2	57.3	57.9	58.4	58.4	57.1
OVV_16681 NC_001474.2	1	68.7	100.0	68.7	64.0	46.7	46.7	47.1	46.9	47.5	38.9	48.4	47.5	47.6	43.6	44.4	43.6	43.6	53.6	53.8	54.2	54.2	53.8
OVV_3 NC_001475.2	2	77.4	68.7	100.0	62.8	48.0	48.0	48.2	48.6	48.2	38.2	46.8	46.7	46.3	41.6	42.2	41.6	41.7	57.3	57.7	58.2	58.2	57.1
OVV_4 NC_002640.1	3	63.8	64.0	62.8	100.0	47.5	47.5	47.7	47.5	48.1	39.7	49.6	49.6	49.8	40.0	40.6	40.0	40.0	55.8	56.4	56.4	56.4	55.8
JEV_SA14-14-2_AF315119.1	4	49.7	46.7	48.0	47.5	100.0	99.8	99.0	98.6	97.8	39.6	75.1	76.5	76.7	43.1	42.9	43.1	43.1	54.0	54.8	54.8	54.8	54.0
JEV_SA14-14-2_D90195.1	5	49.7	46.7	48.0	47.5	99.8	100.0	98.2	98.8	98.0	39.8	76.3	76.7	76.9	43.1	42.9	43.1	43.1	54.0	54.8	54.8	54.8	54.0
JEV_SA14_D90194.1	6	50.1	47.1	48.2	47.7	98.0	98.2	100.0	99.4	99.4	40.0	77.5	77.8	78.0	43.3	43.3	43.3	43.3	54.4	55.4	55.2	55.2	54.4
JEV_virus_M55506.1	7	49.9	46.9	48.2	47.5	98.6	98.8	99.4	100.0	99.2	40.0	77.3	77.6	77.8	43.3	43.3	43.3	43.3	54.2	55.2	55.0	55.0	54.2
JEV_virus_NC_001437.1	8	50.5	47.5	48.6	48.1	97.8	98.0	99.4	99.2	100.0	40.4	78.0	78.4	78.6	43.5	43.5	43.5	43.5	54.8	55.4	55.2	55.2	54.8
TEV_virus_NC_001672.1	9	38.3	38.9	38.2	39.7	39.6	39.8	40.0	40.0	40.4	100.0	41.3	41.6	41.0	42.3	41.9	42.3	42.3	39.9	39.9	39.6	39.6	39.9
WNV_956 NC_001563.2	10	51.5	48.4	46.8	49.6	76.1	76.3	77.5	77.3	78.0	41.3	100.0	94.6	94.0	43.8	43.6	43.8	43.8	55.0	54.8	54.8	54.8	55.0
WNV_Chin-01_AY490240.2	11	50.5	47.6	46.7	49.6	76.5	76.7	77.8	77.6	78.4	41.6	94.6	100.0	98.8	43.9	43.5	43.9	43.9	54.4	54.2	54.0	54.0	54.4
WNV_NY99_Isol-385-99_NC_009942.1	12	50.9	47.6	46.3	49.8	76.7	76.9	78.0	77.8	78.6	41.0	94.0	98.8	100.0	43.9	43.5	43.9	43.9	54.0	53.8	53.8	53.8	54.0
YFV_17D_vaccine_strain_NC_002031.1	13	43.0	43.6	41.6	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	100.0	97.6	100.0	99.8	42.0	43.4	43.5	43.5	42.0
YFV_ASIBI_AY640589.1	14	43.8	44.4	42.2	40.6	42.9	42.9	43.3	43.3	43.5	41.9	43.6	43.5	43.5	97.8	100.0	97.6	97.4	42.4	43.8	43.9	43.9	42.4
YFV_Isol-Pasteur_17D-204_X15062.1	15	43.0	43.6	41.6	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	100.0	97.6	100.0	99.8	42.0	43.4	43.5	43.5	42.0
YFV_vaccine_strain_17D-213_U17067.1	16	43.2	43.6	41.7	40.0	43.1	43.1	43.3	43.3	43.5	42.3	43.8	43.9	43.9	99.8	97.4	99.8	100.0	42.0	43.4	43.5	43.5	42.0
ZVW_BelH818995_KU365777.1	17	57.3	53.6	57.3	55.8	54.0	54.0	54.4	54.2	54.8	39.9	55.0	54.4	54.0	42.0	42.4	42.0	42.0	96.8	96.4	96.4	96.4	96.8
ZVW_MR766-MIND_LC002520.1	18	57.9	53.8	57.7	56.4	54.8	54.8	55.4	55.2	55.4	39.9	55.0	54.2	53.8	43.4	43.8	43.4	43.4	96.8	96.8	96.8	96.8	96.8
ZVW_MR_766_AY632535.2	19	58.4	54.2	58.2	56.4	54.8	54.8	55.2	55.0	55.2	39.6	54.8	54.0	53.8	43.5	43.9	43.5	43.5	96.4	98.8	100.0	100.0	96.2
ZVW_MR_766_NC_012532.1	20	58.4	54.2	58.2	56.4	54.8	54.8	55.2	55.0	55.2	39.6	54.8	54.0	53.8	43.5	43.9	43.5	43.5	96.4	98.8	100.0	100.0	96.2
ZVW_ZikaSPH2015_KU321639.1	21	57.1	53.8	57.1	55.8	54.0	54.0	54.4	54.2	54.8	39.9	55.0	54.4	54.0	42.0	42.4	42.0	42.0	99.8	96.6	96.2	96.2	100.0

50 % Identity and higher
60 % Identity and higher
70 % Identity and higher

Figure 7 (a)




Figure 7 (b)

[illegible][illegible]

Figure 8a




Figure 8b







Figure 9



- + Similar virus concentration in harvests Day 2, Day 3, Day 7; lower virus concentration in harvest Day 5
- + Day 2 and Day 3 harvests contain more HCP than Day 5 / 7 (correlates with observed CPE)
- + Minor amount of virus multimers observed

Figure 10



- + Protamine Sulfate removes virus aggregates and partially HCP
- + Infectious virus titer is not affected by PS treatment
- + Strong CPE on day 3, drop in productivity
- + Remaining cells seem to recover well and increase in Zika productivity

Figure 11





Figure 12



Lane	Sample
1	Molecular weight Marker
2	JEV Sucrose Gradient Pool (Reference)
3	Zika Harvest pool (day 2,3,5,7)
4	Zika Harvest pool (day 2,3,5,7) concentrated 300x
5	Zika Harvest pool (day 2,3,5,7) concentrated 300x + Protamine sulfate
6	Ultrafiltration Permeate
7	SGC Bottle1, Fraction 4
8	SGC Bottle1, Fraction 5
9	SGC Bottle1, Fraction 6
10	SGC Bottle1, Fraction 7
11	SGC Bottle1, Fraction 8
12	SGC Bottle1, Fraction 9
13	SGC Bottle1, Fraction 10
14	SGC Bottle1, Fraction 11
15	SGC Bottle1, Fraction 12
16	SGC Bottle1, Fraction 13
17	SGC Bottle1, Fraction 14
18	SGC Bottle1, Fraction 15
19	SGC Bottle1, Fraction 16
20	SGC Bottle1, Fraction 17
21	SGC Bottle1, Fraction 18
22	SGC Bottle1, Fraction 19
23	SGC Bottle1, Fraction 20
24	SGC Bottle1, Fraction 21
25	SGC Bottle1, Fraction 22
26	SGC Bottle1, Fraction 23

Pooled fractions F10-F14
(10mL total volume per bottle)

Figure 13

Baseline separation of Virus and PS/HCP




Figure 14





Figure 15



Lane	Sample
1	Marker Seebieplus2
2	CHIKV lot20150812_WVB2015-01_Filtered harvest 0.2µ_24hpi
3	CHIKV lot20150812_WVB2015-01_Filtered harvest 0.2µ_48hpi
4	20150813_CHIKV_DSP_DSP_UF/DF_Load
5	20150813_CHIKV_DSP_DSP_UF/DF_conc. 10x
6	20150813_CHIKV_DSP_DSP_UF/DF_conc.&dia. 11x
7	20150813_CHIKV_DSP_DSP_PStreatment
8	20150813_CHIKV_DSP_DSP_PS&CC700treatment
9	20150813_CHIKV_DSP_DSP_SGCFrac F5
10	20150813_CHIKV_DSP_DSP_SGCFrac F6
11	20150813_CHIKV_DSP_DSP_SGCPool F7-F10
12	20150813_CHIKV_DSP_DSP_SGCPool F7-F11 (final pool)
13	20150813_CHIKV_DSP_DSP_SGCPool F7-F12
14	20150813_CHIKV_DSP_DSP_SGCFrac F13
15	20150813_CHIKV_DSP_DSP_SGCFrac F14

Figure 16a




Figure 16b




Figure 17




Figure 18a




Figure 18b




Figure 18c




Figure 18d




Figure 19




Figure 20




Figure 21




Figure 22

